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ABSTRACT 
Elevated levels of homocysteine (HCy) are a known risk factor in several disease states (1). 
HCy has several other metabolites, homocysteine thiolactone (HCy-T) and homocysteic acid 
(HCA). Whilst HCy-mediated neurotoxicity has been extensively studied, the underlying 
mechanisms of HCy-T and HCA mediated neuronal damage remain largely unknown. This 
thesis aims to explore the underlying mechanisms, triggered by HCy and metabolites which 
result in neuronal cell death, and may be appropriate targets for future research on disease-
modifying interventions in neurodegenerative disorders. As ageing is the greatest risk factor 
for neurodegeneration, a novel model of human neuronal ageing was established, permitting 
investigation of the pathways triggered by HCy in ageing.  
Using SH-SY5Y cells, a novel differentiation protocol was established and categorised, once 
fully differentiated, these cells were shown to be fully functional neurons and could be 
maintained for a month in culture. Using a range of concentrations of HCy and HCy-T, the 
concentration cell death occurs at was determined using crystal violet and lactate 
dehydrogenase assays. Mechanisms of toxicity were determined using pharmacological 
intervention at the NMDA receptor, nitric oxide scavengers and antioxidants. Using a 
combination of immunocytochemistry, live cell imaging and ELISA, alterations in markers of 
cell damage could be examined.   
The results showed HCy and HCy-T have distinct mechanisms of toxicity. Whilst both are 
neurotoxic, HCy directly acts via the NMDA receptor, however HCy-T appears to be less 
potent. Additionally, HCy-T caused a greater increase in reactive oxygen species generation 
than HCy, and each metabolite also displayed distinct mitochondrial network abnormalities. 
Finally, using the long-term culture methods, the chronic effects of HCy, HCy-T and HCA 
were examined. However, extensive cell death was apparent at low doses in all metabolites 
xiii 
 
therefore no definitive mechanisms could be determined. This culture method was deemed not 
appropriate for toxicity experiments.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
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1.1 INTRODUCTION 
Elevated levels of homocysteine (HCy) are a known risk factor in several disease states; and it 
has been shown that HCy-reducing therapies may be beneficial to health (1). This thesis aims 
to explore the underlying mechanisms, triggered by HCy, which result in neuronal cell death. 
Specifically, this work aims to highlight pathways activated following metabolic conversion of 
HCy to the metabolite Homocysteine thiolactone (HCy-T), which may be appropriate targets 
for future research on disease-modifying interventions in neurodegenerative disorders. As 
ageing is the greatest risk factor for neurodegeneration, a novel model of human neuronal 
ageing was established, permitting investigation of the pathways triggered by HCy in ageing.  
1.1.1 Homocysteine metabolism 
HCy is a sulphur-containing non-protein amino acid that is a natural product of methionine 
metabolism (2).  Dietary consumption is considered the principle source of methionine, mainly 
derived from meat products , eggs and fish (2). 
The rate of generation and removal of HCy is controlled by two metabolic pathways; 
transsulferation and remethylation (figure 1.1). The formation of S-adenosyl methionine 
(SAM) from methionine and adenosine triphosphate (ATP) is catalysed by methionine 
adenosyltransferase (MAT) (3). SAM is the body’s primary methyl donor and is required for 
DNA methylation and protein synthesis. However, in the presence of elevated levels of 
methionine, SAM is converted to S-adenosyl homocysteine (SAH) with the aid of 
methyltransferase. SAH is then broken down to form HCy and adenosine, adenosine is the 
hydrolysed to for L-HCy, and as SAH can compete with SAM for binding sites, methylation 
reactions become impaired (4) (figure 1.1).  
To prevent the build-up of damaging levels of HCy, it is converted to either methionine or 
cysteine. In the remethylation pathway, HCy acquires a methyl group, which can be derived 
3 
 
from one of two sources. Firstly, betaine can be converted to N,N-dimethylglycine releasing a 
methyl group in a reaction that is vitamin B12 independent (4). Alternatively, in a vitamin B12-
dependant pathway, HCy is remethylated by the addition of a methyl group from the conversion 
of 5-methyltetrahydrofolate to tetrahydrofolate, which occurs as part of the folate cycle (figure 
1.1) (2). In the transsulfuration pathway, HCy is condensed with serine, catalysed by 
cystathione β synthase (CBS) using vitamin B6 as a cofactor, to form cystathione which is then 
cleaved to α-ketobutyrate and cysteine (5). Cysteine is a precursor of glutathione, the 
predominant redox buffer, meaning it is important with respect to oxidative stress (4).  
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Figure 1.1 Homocysteine Metabolism  
 
The above diagram illustrates the process by which homocysteine is metabolised and excreted from the body 
under normal circumstances. Methionine is derived from the diet; this is then catalysed by ATP to form S-
adenosylmethionine, which is the predominant methyl donor in the body and is responsible for most cellular repair 
systems. This can then be converted to s-adenosylhomocysteine which is responsible for incorporating 
homocysteine into proteins. This is then converted to homocysteine and can be condensed to cysteine in a vitamin 
B6 dependant manner and excreted in the urine. Alternatively, homocysteine can be converted back to methionine 
for usage by the means of entering the folate cycle. THF = tetrahydrofolate, SAM = S- adenosylmethionine, SAH 
= adenosylmethionine, B6 = vitamin B6, B12 = vitamin B12.   
1.1.2 Genetic Risk Factors for elevated homocysteine 
Physiologically normal levels of HCy range in the blood between 4 and 10µM, with mild 
elevation considered as 16-30 µM; intermediate elevation as 31-100µM; and severe elevation 
at over 100µM (6). Hyperhomocysteinemia (hHCy) is defined as the state wherein an 
individual presents with levels over 16µM in the blood. The state of homocysteinuria (wherein 
an individual presents with homocysteine in the urine) typically exists when levels exceed 100 
µM in the blood, and is most commonly due to homozygous mutation in the 1 carbon 
metabolism cycle genes such as methytetrahydrofolate reductase (MTHFR) (3,7). 
Heterozygosity for these mutations can lead to moderate HCy elevation, especially in 
individuals with a diet that is low in folate and/or vitamin B12 (8). Intermediate elevation of 
HCy has been linked with methionine adenosyltransferase (MAT) I/III deficiency, which 
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results in a reduction in the conversion in methionine to SAM (9). In addition, genetic 
mutations resulting in vitamin B12 or folate deficiency, thus impairing the conversion of HCy, 
are a genetic cause of hyperhomocysteinemia (10–12).  
1.2 NON-GENETIC FACTORS DETERMINING HOMOCYSTEINE ELEVATION 
A number of lifestyle factors can contribute to elevated HCy; including dietary vitamin B12 
and folate intake (13,14), coffee consumption (15), alcohol consumption and the use of certain 
medications. These will be discussed in more detail below.  
1.2.1 Influence of gender on homocysteine levels 
Males have higher levels of HCy than pre-menopausal females, although HCy in post-
menopausal females is higher; this is most likely due to hormonal differences between the 
genders (16). Although there is little research to date, it has been shown that testosterone levels 
have no effect on HCy (17,18). Therefore, it is more likely that the gender differences observed 
are due to oestrogen concentrations rather than testosterone. Oestrogen supplementation via 
hormone replacement therapy is effective in lowering HCy levels in post-menopausal women 
(19) supporting the hypothesis that HCy levels are hormonally modulated. This is thought to 
be due to oestrogens ability to enhance CBS, therefore increasing the conversion of HCy to 
cysteine. In addition, it has been demonstrated that 17β estradiol (levels of which are typically 
higher in females) directly applied to murine macrophage cells (RAW 264.7 cells) can 
attenuate the oxidative stress induced by direct application of HCy (20), suggesting that not 
only is oestrogen capable of lowering HCy levels, it can also attenuate the oxidative stress and 
damage generated by high levels of HCy (18).   
1.2.2 Influence of diabetes on homocysteine levels 
HCy concentrations have been found to be higher is those with certain endocrine disorders such 
as diabetes. The association between HCy and diabetes has been extensively studied, during 
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pregnancy high HCy has been associated with gestational diabetes which has been observed in 
many cohorts (21,22). Furthermore, high HCy has been identified as risk factor for the 
development of Type 2 Diabetes Mellitus (T2DM) in those with prior diagnosis of gestational 
diabetes (23). This has been suggested to be as result of the increased circulating levels of 
glucose influencing HCy metabolism and methylation. Although during pregnancy it is 
recommended that women commence taking folate supplementation it is also this that has been 
correlated with increased incidence of gestational diabetes, as has reduced vitamin B12 levels 
(24). Although much of the research has focussed on gestational diabetes the same has been 
investigated for type 1 and type 2 diabetes, although whether elevated HCy is associated with 
insulin resistance is debated. With tracking of HbA1c, a measure of how well the diabetes is 
being controlled, a positive correlation exists between poor long term glycaemic control and 
elevated HCy (25). However, in vivo, HCy has been shown to increase insulin resistance, one 
proposed mechanism for this is that HCy-T causes in increase in ROS, this in turn inhibits 
insulin receptor tyrosine kinase activity and therefore decreasing PI3K activity and inhibiting 
glycogen synthesis (26,27).   
1.2.3 Influence of pregnancy on homocysteine levels 
HCy levels have been shown to be lower in pregnant women than non-pregnant women (28), 
giving further credence to the hypothesis that hormonal factors are at play in determining HCy 
levels. HCy levels have been shown to be significantly decreased in the first trimester of 
pregnancy in particular (29), although the impact of certain public health measures advising 
women to make lifestyle changes at this time should be borne in mind.  
Guidance from the UK Department of Health encourages women to begin folate 
supplementation prior to conception and during early pregnancy to prevent neural tube defects 
(such as spina bifida) (30,31), and given the role of folate in HCy metabolism (figure 1.1), it is 
perhaps unsurprising that a reduction in HCy levels is observed in this population.  
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Similarly, other common lifestyle modifications during pregnancy may contribute to lower 
levels of HCy being observed. For example, guidance to reduce or abstain from alcohol and 
caffeine consumption (to be discussed in more detail below) as part of the current UK guidance 
(29) could also play a role. It is worth noting, however, that whilst pregnancy is generally 
associated with a reduction in HCy levels, elevated HCy during pregnancy has been associated 
with adverse outcomes such as the development of autism spectrum disorders and neural tube 
defects (32). Neural tube defects are the most common congenital defect which are caused by 
failure of neural tube closure in utero which can result in a range of outcomes from anencephaly 
to spina bifida (33). Furthermore, in women with gestational diabetes (34), HCy levels are often 
elevated (34). This, in turn, has been shown to increase the risk of miscarriage and low birth 
weight (30). Indeed, even in the absence of underlying metabolic aberrations such as diabetes, 
elevated levels of HCy have been correlated with low birth weight and slowed foetal growth 
(23). Finally, the risk of pre-eclampsia has also been positively correlated with elevated HCy 
and low folate levels (20). Together these data reinforce the detrimental effects of hHCy on 
pregnancy outcomes.  
1.2.4 Influence of ageing on homocysteine levels  
HCy levels have been shown to increase with advancing age (36), and the literature outlines 
several mechanisms by which this is thought to occur. These are further exacerbated in post-
menopausal females by hormonal factors, as previously discussed in section 1.2.1.  
Vitamin B deficiency is more common with advancing age (36), in part due to the increased 
incidence of atrophic gastritis, which results in reduced absorption of vitamin B12 from the 
diet (37). This lower vitamin B12 level contributes to elevation in HCy levels (figure 1.1). 
Similarly, a reduction in appetite (commonly associated with increasing age) (28) can result in 
increased HCy, due to reduced vitamin intake. This is due to various factors such as a reduction 
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in gastric emptying with age, resulting in earlier satiety, in turn resulting in reduced food intake 
overall. Age-related impairment of taste and smell are thought to make eating less appealing 
(28), thus reducing intake. In addition, the increased use of certain medications (such as proton 
pump inhibitors) can result in a reduction in taste and smell (38).   
1.2.5 Influence of caffeine intake on homocysteine levels 
Several authors have shown a strong positive association between caffeine consumption and 
elevated levels of HCy (36). Caffeine is an antagonist of vitamin B6, and can therefore down-
regulate the transsulfuration pathway, thereby inhibiting the breakdown and excretion of HCy, 
thus increasing its levels (39). Caffeine is also an antagonist at adenosine receptors however 
there is no evidence that this has an effect on HCy levels. Coffee consumption has been shown 
to significantly increase HCy levels in people with no pre-existing cardiovascular disease from 
11.2 ± 5 micromol/L for no consumption and 12.7 ± 4 micromol/L for >500 ml/day 
consumption (40). Similarly, it has been shown that caffeine consumption in capsule form, or 
through consumption of caffeinated beverages (such as coffee), can increase HCy levels, with 
coffee increasing HCy more than the equivalent caffeine concentration from the capsule (41). 
This is potentially due to other components in coffee which may also increase HCy levels. 
However, the precise relationship between caffeine intake and HCy is far from clear, with data 
from cohort studies highlighting benefits of moderate caffeine consumption in cognitive 
decline or impairment (34, 35), and in reducing systolic and diastolic blood pressure, as well 
as potentially reducing the likelihood of developing hyperhomocysteinemia (43) (as defined in 
section 1.1.2). These have been observed predominantly through studies examining coffee 
consumption either measured as cups per day or in milligrams. One postulation regarding the 
effects of  the consumption of caffeinated beverages and whether they lead to positive or 
negative effects on HCy levels is due to their content of phenolic acids (43,44). Phenolic acids, 
or polyphenols, are known to be the most abundant of the antioxidants that can be obtained 
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through the diet, and are widely found in caffeinated drinks (43). The exact interplay between 
polyphenol content of caffeinated drinks and HCy levels is unclear with some investigators 
reporting no effect and others reporting an increase due to the role of polyphenols as acceptors 
of methyl groups during the metabolism of methionine to HCy, which can lead to elevation of 
HCy levels (45–47). Conversely, the antioxidant activity of polyphenols has been linked to a 
decrease in total homocysteine (tHCy) in AD patients (48). Other potentially confounding 
factors are also apparent, with many authors examining the effects of caffeine on HCy using 
different beverages prepared in different ways (44). This could potentially explain the differing 
conclusions amongst studies, regarding the potential health benefits/risks of caffeine 
consumption. Ultimately, increased caffeine, in the majority of published studies, is associated 
with an increase in HCy levels (40,47,49).  
1.2.6 Influence of alcohol on homocysteine levels 
Many authors have studied the effects of alcohol consumption on HCy levels, and 
predominantly, strong positive correlations exist between alcohol consumption and HCy levels 
(50–52). For example, two weeks of consuming 24g of ethanol per day (either as vodka or red 
wine) was shown in one study to increase total homocysteine (tHCy) levels in healthy male 
participants by 3% and reduce B vitamin levels by 5%, suggesting a possible mechanism 
underpinning alcohol-mediated HCy elevation (51). A reduction in folate levels was also seen 
within the vodka intervention group as 4.81 to 4.36ng/ml and 4.94 to 4.63ng/ml in the red wine 
intervention group (51).  
However, just as with caffeinated beverages, the effects of alcohol on HCy levels have been 
reported to be either an increase or decrease, depending on the frequency, amount and type of 
alcohol consumed. It has been demonstrated that when all other lifestyle factors, such as 
smoking, were controlled, exclusive whisky drinkers had significantly increased tHCy levels 
by 2µM (53). In the case of  tequila, 30 days of daily administration of 30ml before a meal 
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revealed no acute increase in HCy but levels of HCy were increased after 30 days (51) 
suggesting a chronic effect. Therefore, it can be suggested that daily alcohol intake over a 
chronic period causes a decrease in either vitamin B12 and/or folate, or the ability of the body 
to absorb them, thus increasing HCy levels. Conversely, moderate and regular alcohol 
consumption (in the form of red or white wine) in obese participants lowered HCy levels, 
compared to obese subjects who drank no alcohol at all, or drank alcohol very infrequently 
(54,55). These individuals also had higher folate levels than those who did not drink (56). It 
has been well documented that there are beneficial effects of beer on HCy levels, thought to be 
due to many beers containing B vitamins and folate (53). Conversely, wine does not contain 
folate or any B vitamins essential to the HCy metabolism cycle. However some wines contain 
betaine which could serve as a methyl donor to convert HCy back to methionine (52).  
Taken together this shows that whilst excessive alcohol consumption, and purer forms (such 
as spirits) can increase HCy, moderate beer and wine consumption may be effective in reducing 
HCy, as they contain components such as antioxidants which are known to be effective in 
countering increases in HCy levels. Thus, alcohol consumption per se increases HCy levels but 
specific drinks may have a differential effect depending upon other components of the 
beverage.  
1.3 MALADAPTIVE EFFECTS OF HCy FOR HEALTH 
1.3.1 Evidence for a role of homocysteine in cardiovascular disease  
Moderately elevated HCy levels are associated with increased risk of developing 
cardiovascular disease (CVD) (57). Longitudinal experiments have attempted to determine if 
HCy is a true risk factor for CVD or a marker of disease presence (58). Several trials have 
shown that HCy-lowering treatments are ineffective at preventing the risk of a myocardial 
infarction (MI) in patients who have pre-existing hypertension (40). However data obtained 
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from hospital patients has shown that increases of 10µM HCy from the normal range increased 
the risk of a MI by 20% (60). In addition, individuals with moderate elevations of HCy are at 
a higher risk of atherosclerosis (42), a pathological process which commonly leads to CVD, 
MI and stroke (57). This is thought to be in part due to effects of HCy on the vasodilator, nitric 
oxide (NO), the mechanisms of which will be discussed in section 1.4.8. 
1.4 HCy IN NEURODEGENERATIVE DISORDERS 
1.4.1 Homocysteine increases the risk of developing psychiatric disorders  
Elevated levels of HCy have been associated with schizophrenia and other affective disorders 
(44) such as depression (63). Elevated HCy levels correlate positively with objective measures 
of low mood (a key clinical feature of depression) (64): the Profile of Mood States (POMS) 
and Perceived Stress Scale (PSS) (46), suggesting an association between elevated HCy and 
low mood. It was shown that in healthy young adults, vitamin B12 and folate supplementation 
can have a positive effect on mood as assessed by these measures, as a reduction in scores was 
noted after administration of a multivitamin and that HCy levels decreased (46). It should be 
noted however that in this trial a multivitamin was used therefore other compounds could have 
been responsible for the effect seen.  
Nutritional deficiencies are thought to play a role in the development of psychiatric disorders 
(66–69), as many nutrients obtained from the diet are crucial to the generation of 
neurotransmitters, deficiencies in which play a role in the neuropathology of a range of 
disorders, including obsessive compulsive disorder (OCD) and depression (68,69). Common 
nutritional deficiencies seen in those with psychiatric disorders include omega 3 fatty acids and 
B vitamins which act as precursors for key neurotransmitters such as dopamine, noradrenaline 
and serotonin (70,71).  
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This suggests, it is possible that dietary supplementation to reduce HCy by increasing B vitamin 
and folate concentrations could be used to elevate low mood and potentially treat psychiatric 
disorders, such as depression. This could be possible by changing the treatment process from 
using drugs or drugs alone, such as reuptake inhibitors, which are commonly used to treat a 
range of disorders (72,73), to instead harness the body’s own endogenous neurotransmitter 
production.  Furthermore, this has been shown to be an effective co-treatment for obsessive 
compulsive disorder (OCD) in mice assed using the marble burying test, although mood was 
not enhanced when dietary supplementation was given in combination with fluoxetine, a 
selective serotonin reuptake inhibitor (SSRI) (74). 
Whilst it has been shown that elevated HCy has been associated with deficiencies in 
neurotransmitters including serotonin, noradrenaline and dopamine (69), potentially suggesting 
a role of elevated HCy itself, some authors dispute this. It has been reported that reversing this 
effect was achieved by the consumption of a multivitamin containing B vitamins (65). To date, 
it has not been possible to ascertain to what degree HCy itself or other potentially confounding 
factors (such as the nutritional deficiencies outlined above) contribute to neurotransmitter 
deficiency in the pathology of psychiatric disorders.  
Many authors discussed the HCy hypothesis which states that HCy is capable of causing 
cerebral vascular disease and neurotransmitter deficiency, and this in turn causes the low mood 
associated with elevated HCy (75). Throughout the literature the hypothesis has been 
commonly reported, and whilst elevated HCy appears to be associated with low mood, the 
mechanism may not be entirely B vitamin-dependent. 
Several studies have also implicated elevated HCy in the pathology of schizophrenia  
(62,76,77), and the role of elevated HCy in schizophrenia is distinct from other mood disorders 
discussed above, as HCy is capable of activating the GABAergic and glutamatergic systems, 
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contributing to the pathology of the disorder (78).  HCy is a known partial agonist at the NMDA 
receptor (to be discussed in more depth in section 1.4.5) and impairment of NMDA receptor 
signalling is known to be common in schizophrenia (79) and is thought to play a key role in 
many of the symptoms of schizophrenia (79). This was suggested as a potential mechanism 
from a nested case-control study of a large birth cohort which showed that elevated maternal 
HCy levels in the third trimester were associated with a two-fold increase in the risk of the 
development of schizophrenia for the offspring (78).  
Genetic mutations within the MTHFR gene has been implicated in the pathology of 
schizophrenia. Higher levels of HCY have been found amongst first degree relatives within 
families with a history of schizophrenia, higher than in families without such a history (80). 
Furthermore, a positive correlation exists between elevation in HCy levels and the severity of 
negative symptoms of schizophrenia (negative symptoms include low mood and depression) 
(81).  
1.4.2 Mild cognitive impairment and Alzheimer’s disease 
Elevated HCy has been identified as an independent risk factor for several neurodegenerative 
disorders and has also been implicated in the development of mild cognitive impairment (MCI), 
a precursor to the development of dementia in some individuals (82). For instance, within the 
elderly African-Caribbean population increasing severity of MCI, as determined by a battery 
of 11 psychometric tests, was significantly associated with elevated HCy levels as gathered 
from unfasted venous samples (75). Further to this, a double blind randomised control trial 
showed that administration of B vitamins, folate or a multivitamin improved the memory of 
those with MCI, as determined by scores on the Mini Mental State Examination (MMSE), a 
quantitative measure of cognitive function (83). Indeed a number of small scale studies have 
suggested that in those with MCI, HCy-lowering therapies were effective in improving memory 
test performance scores  (56).  
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Cystathione beta synthase (CBS) mutant mice which have high levels of HCy mimicking that 
of hHCy in humans, develop severe mental retardation and premature death in homozygous 
mutants and heterozygous show impaired LTP and reduced cognitive abilities. The 
introduction of a high folate diet reduced the memory impairment by aiding the conversion of 
HCy back to methionine (85). Additionally, when wild type mice that were fed diets deficient 
in folate showed reduced performance in both spatial and cognitive tasks (86). Furthermore, it 
has been shown that the induction of elevated HCy through diet causes a reduction in the firing 
capacity in slice cultures in electrophysiological experiments as determined by analysing the 
input-output relationship in the CA1 region of the hippocampus. LTP was induced by a theta 
tetanus and this showed increased HCy impaired the mechanism of LTP, which is a crucial 
factor for memory formation (86). 
Alzheimer’s disease is a progressive neurodegenerative disease and the most common form of 
dementia which commonly affects those over the age of 65, the life expectancy post diagnosis 
is on average 7 years, at present there is no disease modifying treatments. The key hallmark 
pathologies of AD include neurofibrillary tangles and amyloid beta plaques within the brain 
causing progressive memory impairment (87–89). HCy is a risk factor for AD as concentrations 
above 14µM double the risk of developing AD and therefore a thorough and comprehensive 
understanding of the molecular mechanisms of HCy-mediated neurotoxicity offers the 
potential for novel drug developments for preventing or treating AD. There have been several 
trials examining the role of HCy-lowering therapies for  treating AD and for preventing the 
development of AD in those with mild cognitive impairment (MCI) (90). A combination of 
high dose vitamin B12, B6 and folic acid was successful in reducing the rate of brain atrophy 
by 30% (as measured by serial Magnetic Resonance Imaging (MRI) scans) coupled with a 
reduction in cognitive decline in those with MCI over a period of 2 years (measured using the 
MMSE) compared to a placebo group (90). However, other clinical trials using HCy-lowering 
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therapies were less successful when treatment had been commenced after the diagnosis of AD 
revealing that therapeutic interventions to modulate HCy levels may be most effective as 
preventative measure than a treatment (82, 83).  
HCy can also exacerbate amyloid β (A) and tau neurofibrillary tangle formation once the 
disease process has commenced. The toxicity of the soluble form of amyloid β (A) is 
enhanced in the presence of elevated HCy (92,93), demonstrating a role of HCy in accelerating 
the pathological processes driving AD. Additionally, HCy impairs the methylation of key 
promoter regions of the presenilin 1 gene, resulting in its overexpression (67). This leads to an 
increase in levels of the presenilin 1 enzyme which cleaves the amyloid precursor protein 
(APP) peptide alongside β-secretase (BACE) as part of the amyloidogenic pathway, which can 
result in accumulation of toxic Aβ1-42, a key pathology of AD (66). Furthermore, HCy can 
also downregulate protein phosphatase 2A (PP2A), due to impaired methylation, which results 
in hyper-phosphorylation of  tau leading to the formation of tau tangles (68, 69), another key 
hallmark pathology of AD (96). Thus, modulation of the key pathways linked to AD pathology 
may explain why elevated HCy is damaging to patients with symptomatic AD. However, these 
findings do not explain why HCy is a risk factor for the initiation of the disease, and this would 
benefit from being the focus of future research.  
1.4.3 Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurological disorder which is characterised by 
degeneration of the pars compacta region of the substantia nigra (70). The substantia nigra is a 
region of the brain predominantly comprised of dopaminergic neurons and as such, the 
commonest treatment for PD is with Levodopa (L- DOPA) therapy, a dopamine precursor to 
replace the loss of DA (98). This is an effective treatment but can provoke unwanted side 
effects such as dyskinesia which is characterised by uncontrollable movement (99). Although 
an effective treatment, L-DOPA increases HCy levels. The main metabolic fate of L-DOPA is 
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O-methylation leading to the formation of 3-O-methyldopa, in a reaction catalysed by catechol-
O-methyl-transferase (COMT) with SAM acting as a methyl donor (100). The donation of a 
methyl group from SAM leads to the formation of SAH, which in turn is hydrolysed to produce 
HCy. This leads to high levels of homocysteine in the plasma of L-DOPA-treated patients 
(100). A positive correlation exists between homocysteine levels and performance on the 
UPDRS (unified Parkinson’s Disease rating scale) revealing that hHCy can increase the rate of 
disease progression (100). In models of PD, administration of L-DOPA and the subsequent 
increase in HCy is associated with reduced neurogenesis within the subventricular zone (SVZ) 
of the adult brain (101) which is mediated via the NMDA receptor then activation of the ERK 
pathway (to be discussed in more depth in section 1.4.5). Furthermore, in empirical induction 
of PD symptoms in rodents using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and 6-hydroxydopamine (OHDA), dietary-induced hHCy exacerbated the neurotoxicity of 
both reagents although it was not neurotoxic in its own right (72). Thus, reducing HCy levels 
in PD patients (particularly those on L-DOPA therapy) may benefit patients by slowing down 
the progression of the disease and increasing the threshold to neuronal death.   
1.4.4 Stroke 
Stroke refers to a disturbance in neurological function caused by an interruption to the blood 
supply to a particular vascular territory within the brain (102). It can be broadly divided into 
two subtypes: haemorrhagic and ischaemic, accounting for 15% and 85% of strokes 
respectively (103). Haemorrhagic strokes occur secondary to haemorrhages within the brain 
parenchyma, and will not be discussed further, as they are not within the remit of this research. 
Ischaemic stroke occurs when the blood supply to an area of the brain is interrupted due to 
vascular occlusion of blood vessels (95).  
Meta-analyses have shown that several polymorphisms associated with hyperhomocysteinuria 
significantly increased the risk of developing an ischaemic stroke (104) and also increase the 
17 
 
risk of recurrent stroke (72). Longitudinal data has revealed that levels of HCy in patients who 
went on to have ischaemic strokes were elevated both before and after the event, revealing that 
hHCy is a prospective risk factor for ischaemic stroke. It remains unclear whether a correlation 
between HCy levels and severity of stroke symptoms exists (77, 78). However, it has been 
demonstrated that patients with higher HCy concentrations had a higher mortality 2 years after 
their stroke (107). Increased activation of NMDA receptors after an ischaemic stroke in rats 
contributes to neuronal cell death and results in increased oxidative damage (98, 102) which 
will be discussed in more detail  in section 1.4.7. As the NMDA receptor is also activated by 
HCy, this suggests that HCy could exacerbate post-stroke damage (108). However, trials using 
NMDA receptor antagonists have been unsuccessful to date in reducing symptoms post 
ischaemic stroke, this is postulated to be in part due to a short therapeutic window for 
intervention. It is thought that these have been unsuccessful to date as ischaemic injury occurs 
immediately after the stroke occurs, therefore intervention with NMDA receptor antagonists 
would be effective if administered prior to the stroke. As a result it is unlikely that NMDA 
receptor antagonists would be likely to effect outcome however may be effective in the 
treatment of a second event, although ongoing research for variations of current NMDA 
channel blockers is in progress (82). 
In addition to HCy, excitatory amino acids (EAA) have been implicated in the pathogenesis of 
ischaemic stroke. Elevated levels of glutamate and glycine in particular are shown in ischaemic 
stroke, and are correlated with the severity of the ischaemic infarct in mice (81). As will be 
discussed later in section 1.5.3, HCy and glycine are partial agonists of the NMDA receptor, 
HCy binds at the glycine binding site of the NMDA receptor and during ischaemia, both can 
enhance NMDA receptor activity and therefore exacerbate the disease process of an ischaemic 
stroke once it has begun. During the acute phase of an ischaemic stroke, the level of glycine 
increases rapidly and remains high for a sustained period, with glycine levels continually rising 
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in ongoing ischaemia (110). Therefore, research is currently underway into the therapeutic 
potential of  NMDA receptor glycine binding site antagonists rather than glutamate binding 
site antagonists (111). HCy is a partial agonist of the glycine binding site in addition to being 
an agonist at the glutamate binding site (112). As levels of glycine are elevated during a stroke, 
an additional increase in HCy during stroke has the potential to exacerbate the stroke severity 
in terms of neuronal cell death. Thus after an ischaemic stroke, if HCy binds the glutamate site 
and glycine binds the glycine site this can trigger excitotoxicity at lower levels of HCy (113). 
Together these findings reveal that the complex interplay of HCy with the NMDA receptor 
warrants further investigation to fully elucidate the best therapeutic strategies for intervention 
in stroke patients presenting with confounding hyperhomocysteinemia.  
1.5 MECHANISMS OF HOMOCYSTEINE TOXICITY 
1.5.1 Overview of toxicity 
In addition to being a risk factor for the initial onset of neurodegeneration, elevated levels of 
HCy may accelerate the rate of degenerative decline (114). There is an established link between 
elevated HCy levels and reduced cognitive function (115), atrophy of AD-linked brain regions 
(116) and mild cognitive impairment (MCI) which can progress to dementia within 4-6 years 
in around 42% of patients (117). There are many proposed mechanisms by which HCy may be 
neurotoxic, these include: direct activation of NMDA receptors and downstream signalling, 
calcium mishandling (86), oxidative stress and damage (87), impaired methylation (76) and 
inflammatory processes (88).  
Many of the existing studies in relation to the neurotoxic effects of HCy have limitations. 
Specifically, the use of supraphysiological doses of HCy to obtain a neurotoxic effect raise 
questions as to the relevance of the results. For instance 1mM and 5mM were used to induce 
cell death in cerebellar granule cells and up to 25mM PC12 cells (89,90), with those linked to 
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homocysteinuria rather than hyperhomocysteinemia used in cerebellar granule neurons (123) 
and hippocampal and cortical neurons (113,114). Nonetheless, toxic responses to 25µM HCy 
have been reported in cerebellar purkinje neurons (124) suggesting that physiologically valid 
models of HCy-linked neurodegeneration can be established.  
In vivo rodent models of elevated HCy generally take one of two forms: 1) a genetic model of 
chronically elevated HCy or 2) induction through diet (93, 94). These may offer a more valid 
insight into the maladaptive effects of HCy on the brain but also have limitations in the number 
of techniques that can be applied in a whole organism situation. Whilst the advantage of 
studying the whole organism as one entity is appealing, genetically modified models of 
chronically elevated HCy have the disadvantage that there are several resultant defects, such 
as increased CVD that can reduce the lifespan of the model and make experimentation 
challenging. Following dietary induction of hyperhomocysteinemia it can be difficult to 
determine and control the circulating levels of HCy in the model organism as a proportion will 
be excreted or converted- often unpredictably. In both cases, monitoring of the exact 
concentration of HCy can be problematic.  
1.5.2 Homocysteine thiolactone 
HCy thiolactone (HCy-T) is a reactive thioester that is generated as a result of elevated HCy in 
an error-editing reaction in methanol tRNA synthase (127). Unlike HCy, HCy-T is cyclic in 
structure. It reacts with amino groups of lysine residues resulting in the addition of peptide 
bound HCy groups (homocysteinylation) (96) and by increasing oxidative stress (129). A 
diagnosis of T2DM results in a 65% increase in the risk of developing AD, and HCy-T can 
inhibit insulin receptor signalling, as discussed in section 1.2.2. HCy-T causes an increase in 
ROS generation which inhibits phosphorylation of insulin receptor tyrosine kinase, and 
therefore PI3K and glycogen synthase kinase (GSK3β) thus disturbing insulin signalling. This 
may be of relevance to the current study as there is a clearly established link between elevated 
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HCy, Alzheimer’s disease and T2DM (130). HCy-T has been shown to induce apoptosis in 
several cell types; in pancreatic β cells, exposure to HCy-T resulted in signs of early apoptosis 
after 18 hours (99). Rat H19-7 hippocampal cells exhibit reduced proliferation in a reduced 
folate environment, with enhanced apoptosis and alterations to vascular transport, cell polarity 
and synaptic plasticity also seen (132). These are related to homocysteinylation of key neuronal 
proteins because of reduced homocysteine-thiolactonase (the enzyme that hydrolyses HCy-T 
to HCy) activity (100). Homocysteinylation of the 42 amino acid form of the Aβ peptide that 
is linked to AD increases neurotoxicity by stabilising soluble oligomeric forms of the peptide, 
enhancing its propensity to aggregate (134). However, the finding that the activity of 
homocysteine thiolactonase is reduced in AD patients (133), implies that homocysteinylation 
of neural proteins can contribute to alterations of differentiation, vesicular transport, and 
plasticity in neuronal cells in vivo (132). Final evidence for a potential role for HCy-T in AD 
comes from the observation that mutations in Paroxonase 1 (PON1) lead to enhanced cell and 
tissue damage by HCy, as this enzyme is crucial for inactivating HCy-T, further linking HCy-
T to HCy-mediated cell damage (135). This occurs because PON1 is able to reduce oxidative 
stress and hydrolyse HCy-T, this ability to neutralise oxidative stress and reduce HCy-T means 
that the process of homocysteinylation is no longer possible (136). 
1.5.3 Homocysteine directly activates the NMDA receptor  
The NMDA receptor is the main excitatory system in the nervous system (137). The main 
physiological agonists of the receptor are glutamate and co-agonists for the receptor are glycine 
and D-serine (138). Activation of the NMDA receptor is required for optimal neuronal function 
and plays an important role in learning and memory (139). However, excessive or insufficient 
activation can activate cell death pathways due to an increase in intracellular calcium and the 
generation of reactive oxygen species (ROS), this can be in the form of apoptosis or necrosis 
(140). The receptor itself is comprised of four subunits. Each receptor is a complex of two 
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GluNR1 subunits and a combination of GluNR2 and GluNR3 subunits (141). The subunit 
composition is an important determinant of the function of the NMDA receptor and is thought 
to depend on anatomical location within the brain. For example, the predominant form of the 
receptor in the hippocampus and cortex contains GluN2A and GluNR2B subunits (142,143).  
Direct activation of synaptic NMDA receptors is required for neuroprotection (144), this occurs 
by the activation of PI3K and Akt to switch off cell death signalling and by the activation of 
CREB to increase pro-survival signalling (136). However, activation of extrasynaptic receptors 
can induce cell death pathways as these are activated by lower stimuli, therefore overactivation 
is more likely (144). Furthermore, extrasynaptic activation causes inhibition of CREB and 
activation of cell death signalling via FOXO. Another potential explanation for the divergent 
cell viability response to receptor activation is that the synaptic and extrasynaptic receptors 
may be comprised of distinct subunit combinations, underpinning their differing physiological 
function. Synaptic receptors predominantly contain two GluNR1 subunits and two NR2B 
subunits whereas extrasynaptic predominantly contain predominantly GluN2A subunits (145). 
The extrasynaptic receptors require a reduced stimulus to mediate a response and can be 
activated by low tonic levels of NMDA, whereas the synaptic receptors require a greater and 
more direct activation (146). The composition of NMDA receptor subunits also varies with 
anatomical localisation. In rodents GluN2A/B containing receptors are predominantly 
expressed in the forebrain whereas GluNR2C are predominantly expressed in the cerebellum 
(111).  
HCy has been shown to directly activate the metabotropic group subtype of glutamate 
receptors, included mGlu1 and mGlu5 and AMPA/kainate receptors (69). 24 hours after a 30 
minute exposure to 20mM HCy, primary cerebellar granule cells exhibited a 60% reduction in 
cell viability, and this was ameliorated by the co-application of channel blockers antagonists 
of mGlu1, mGlu6 (96).   
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It is believed that HCy toxicity is primarily mediated by the NMDA receptor (148–152), as 
HCy is an agonist at the glutamate binding site of the NMDA receptor and a partial agonist at 
the glycine site (112). Calcium imaging and patch clamp recordings have revealed that the 
ability of HCy to illicit a response at the NMDA receptor was approximately 30% less than 
that of NMDA itself (112). However, this may have been a result of its competing antagonistic 
actions at the glycine binding site. In retinal ganglion cells, increasing the concentration of 
glycine from 1µM to 50µM and co-application of HCy was as effective as NMDA at evoking 
currents in whole cell patch clamp experiments (149). Furthermore, this depolarisation was 
sufficient to remove the magnesium block, the resultant increase in neuronal calcium influx 
matched application of NMDA when HCy was administered in the presence of excess glycine 
in cortical neurons (112). This reinforced the hypothesis that the antagonist actions of HCy at 
the glycine co-agonist site were the cause of its apparent reduced potency in comparison to 
NMDA. In support of this, when NMDA receptor channel blockers were applied, there was no 
longer a reduction in cell viability in response to HCy (112). Thus HCy-mediated cell death 
can be blocked with competitive and non-competitive antagonists of the NMDA receptor. Non-
competitive NMDA receptor antagonist, Mk801 causes a full block of the receptor in a use 
dependant manner, this drug only work when the channel is opened through depolarisation. 
Competitive antagonists D-AP5 complete for the glutamate binding site of the NMDA receptor 
and memantine which is a low affinity and voltage dependant antagonist (112). Indeed, 
blockade of the receptor with Mk801 in rat cerebellar granule cells was sufficient to ameliorate 
cell death induced by HCy and resultant calcium influxes associated with NMDA receptor 
activation  (113), revealing that this receptor is central to HCy-mediated neurotoxicity.   
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1.5.4 Homocysteine preferentially activates GluN2A subunits: implications for 
downstream signalling 
When HCy binds the NMDA receptor it predominantly does so at the glutamate binding site, 
but the resultant downstream signalling is distinct from that triggered by glutamate (153). HCy 
preferentially activates the GluN2A-containing extrasynaptic receptors whereas glutamate 
excitotoxicity is primarily mediated via the GluN2B subunit (151). HCy has been shown to 
activate the ERK/MAPK signalling pathway which is an integral component to determining 
the fate of the cell. The magnitude and duration of the signal determines whether pro-cell 
survival or cell death signals are initiated, (figure 1.2). Whilst HCy and glutamate activate the 
same downstream signalling pathways, HCy-mediated phosphorylation of ERK elicits an 
immediate response which reduces to baseline then increases again reaching a maximal level 
after 6 hours (151,154). Glutamate, however, only causes an increase in phosphorylation of 
ERK for 2.5 minutes and this effect is not sustained (151,154). The sustained activation of ERK 
mediated by HCy renders ERK phosphorylation to trigger cell death rather than cell survival 
pathways (151).  
As a result of phosphorylation of ERK, cAMP response element binding (CREB), a key cell 
survival transcription factor is activated leading to the promotion of cell survival pathways. In 
contrast, the sustained ERK phosphorylation in response to HCy elicits only transient CREB 
activation, as a negative feedback mechanism results in dephosphorylation of CREB, thereby 
shutting off cell survival signals (155). This effect can be eliminated by that addition of ERK 
blockers, further reinforcing the hypothesis that HCy-mediated sustained ERK activation is 
central to HCy-mediated cell death.  
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Figure 1.2 Signalling pathways activated by NMDA receptor activation via Glutamate or 
Homocysteine 
 
Figure 1.2 shows the downstream signalling that occurs upon activation of the NMDA receptor when glutamate 
is bound as compared to when HCy is bound. When glutamate binds this causes an increase in calcium influx into 
the cells, followed by phosphorylation of ERK and p38, within 2 to 5 minutes. However, when HCy binds this 
phosphorylation occurs within the first 5 minutes and is maintained for a period of 5-6 hours. Ca2+ = calcium, 
CREB = cAMP response element binding, ERK 1/2 = Extracellular Signal-regulated Kinase-1/2.  
1.5.5 Homocysteine increases levels of intracellular calcium 
Glutamate excitotoxicity causes a rise in intracellular calcium through activation of the NMDA 
receptor (156). Using fluorescent dyes such as Fluo-3 (which binds to calcium), it has been 
shown that HCy also causes a dose-dependent increase in intracellular calcium levels (86), 
which can be enhanced by co-application of glycine (104). It is clear that HCy-mediated 
calcium increases are dependent on HCy activity at NMDA receptors and metabotropic 
glutamate receptors, as they can be blocked by either the addition of non-competitive NMDA 
receptor antagonists (149), or the competitive NMDA receptor antagonist D-2-amino-5-
phosphonopentanoate (AP5) (157). Blockade of the metabotropic glutamate receptors prevents 
25 
 
intracellular calcium increase in response to HCy (158) and calcium transients in both neuronal 
and cardiovascular tissue (157,159). Ultimately, in neurons, increases in intracellular calcium 
can lead to increases in oxidative damage, which leads to cell death (160). However, blockade 
of the NMDA receptor does not fully ameliorate the generation of ROS (86). Furthermore, in 
cerebellar granule neurons, HCy application did not result in an increased uptake of calcium 
(150). Therefore, it can be concluded that HCy can increase intracellular calcium levels in most 
neuronal cell types, which can be ablated by the application of antagonists of NMDA receptors, 
but there are other mechanisms of ROS generation and HCy toxicity that require elucidation 
by further research.  
1.5.6 Nitric oxide in neuronal function 
Nitric oxide (NO) is a key neuromodulator and in the periphery acts as a non-adrenergic and 
non-cholinergic transmitter and has effects such as vasodilation and muscle relaxation (161). 
Nitric oxide is generated by nitric oxide synthase (NOS) of which there are 3 forms: neuronal 
NOS (nNOS),  endothelial NOS (eNOS) and inducible NOS (iNOS) (162). In the brain NO has 
many important functions: for example, it plays an important role in long term potentiation 
(LTP) and therefore is important in synaptic plasticity (163). An increase in NMDA receptor 
activation leads to an increase in intracellular calcium and a subsequent increase in NOS 
activity and NO release, which then upregulates cGMP to aid glutamate release (161), leading 
to further NMDA receptor activation. NOS is commonly found in close proximity to the 
NMDA receptor in neurons at the post synaptic density (PSD) (134). Depending on the 
conditions present, NO can either be neuroprotective or neurotoxic. When there is excessive 
glutamate activation or mitochondrial dysfunction superoxide is generated which reacts with 
NO to form the potent oxidant peroxynitrite (149). NO is also capable of nitrosylating proteins 
such as PKC, leading to dysfunction and NO has also been linked to damaging DNA which 
leads to poly ADP ribose polymerase (PARP) activation (165). Furthermore, NO can bind with 
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complex 1 and 2 of the mitochondrial electron transport chain, inhibiting it (166), thus NO 
mediates many potentially damaging cellular pathways.  
HCy application results in an increase in NO and scavenging NO in neurons can prevent cell 
death induced by HCy (149) . There appears to be a significant overlap in the way that NO and 
HCy induce neuronal cell death, and thus it has also been suggested that inhibition of NO can 
ameliorate the effects of HCy toxicity (129, 130). HCy inhibits dimethylaminohydrolase 
(DDAH) thus modulating the activity of asymmetrical dimethyl arginine (ADMA), which is 
an endogenous inhibitor of eNOS. DDAH degrades and inhibits ADMA to form l-citruline and 
methylamine (161,167). Thus, when HCy post-translationally inhibits DDAH, this enzyme can 
no longer block the activity of ADMA and eNOS activity is increased and as such HCy 
modulates NO, but in an indirect manner. This effect is independent of NMDA receptor 
activation (12,169). In addition, HCy increases the expression of iNOS and can therefore 
increase NO release and nitrosylative stress and ROS (170). This has negative effects on the 
vasculature and blood brain barrier, which is exposed to oxidative damage as a result. iNOS is 
also widely expressed in neurons, astrocytes and glia (171–173) in addition to the endothelial 
cells of the blood brain barrier and thus HCy-mediated iNOS activation can directly upregulate 
nitrosylative stress and ROS expression within the central nervous system. 
It is well established that NO can modify tyrosine residues on proteins (nitrotyrosinylation) 
which can be used as a biomarker of NO activity within cells (136). In cerebral microvascular 
endothelial cells, HCy signals via mGlu5 to activate iNOS leading to increased bioavailability 
of intracellular NO and accumulation of nitrosylatively-modified tyrosine residues (3-
nitrotyrosine (3-NT))(159). 3-NT elevation is observed in a number of neurodegenerative 
conditions such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis 
(174–176). In addition a positive correlation has been exhibited between plasma HCy and 3-
NT-modified proteins in schizophrenia (177). Thus HCy-mediated NO release can increase the 
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expression of a biomarker associated with neurodegeneration indicating that this pathway 
warrants fuller investigation in models of neurodegeneration. 
In addition to modification of tyrosine residues, NO can interact with cysteine through a 
process known as cysteine S-nitrosylation. NO acts directly act on the NMDA receptor via S-
nitrosylation (135), to reduce excitotoxicity, with one study isolating a key region (cysteine 
399) of the GluN2A subunit which is S-nitrosylated and this causes a reduction in the resultant 
calcium influx (178). This implies that since HCy preferentially activates the GluN2A subunit, 
NO could potentially inhibit HCy-mediated toxicity at the NMDAR via reducing the 
intracellular calcium. This further underlines the complexity of the data relating to the actions 
of HCy at NMDAR and its effects on NO, and the need, therefore, for further research into 
these highly interconnected pathways.  
Figure 1.3 Activation of nitric oxide and reactive oxygen species upon NMDA receptor 
activation 
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Figure 1.3 shows that the resultant increase in intracellular calcium upon activation of the NMDA receptor causes 
activation of NOS (nNOS, iNOS and eNOS), which in turn causes an increase in NO and therefore an increase in 
peroxynitrite (ONOO). This directly inactivates several complexes of the mitochondrial respiration chain and 
further increases the generation of ROS, which causes further damage to the cell. In addition to activation of the 
NO pathway, calcium itself causes an increase in the generation of ROS as the mitochondria can act to buffer 
excess calcium influx into the cell. NOS = nitric oxide synthase, nNOS = neuronal nitric oxide synthase, iNOS = 
inducible nitric oxide synthase, eNOS = endothelial nitric oxide synthase, ONOO = peroxynitrite, ROS = reactive 
oxygen species. Ca2+ = calcium.  
1.5.7 The role of mitochondria in energy balance 
Mitochondria are the intracellular organelles responsible for the generation, processing and 
supply of energy. They are highly active in cells which have high energy demands, such as 
neurons (179), and are structurally comprised of an inner and outer membrane with 
intramembrane space and matrix.  In the matrix lies the mitochondrial DNA (mtDNA), which 
has the capacity to generate proteins required for the maintenance of the mitochondrial 
machinery (180). The inner membrane contains all of the required components for the electron 
transport chain (ETC) with 5 main components, complexes I-V, which utilise H+ ions to 
generate ATP (181). During ATP generation, H2O is also generated as well as highly reactive 
free radicals, which generate hydrogen peroxide. This can be converted back to water by 
glutathione peroxidase and catalase (181). However, this system has the capacity to generate 
hydroxyl radicals which can cause oxidative damage to DNA, RNA and proteins and cause 
lipid peroxidation as discussed in further detail in section 1.4.11. Furthermore, this means that 
the mtDNA is also susceptible to damage by hydroxyl radicals due to its proximity to the site 
of radical generation which forms the basis of one of main theories of cellular ageing. Further 
research has implicated mitochondrial dysfunction in several neurodegenerative diseases, 
particularly Parkinson’s disease (PD) (182) and Alzheimer’s disease (177).  
For optimal cellular energy requirements to be met, there must be an adequate number of 
mitochondria, and this is achieved by two processes: mitochondrial fission and mitochondrial 
fusion. The mitochondrial outer membrane fuses with that of another mitochondria in the 
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process of fusion which is required for mitochondrial repair (183). Alternatively, the 
mitochondria can undergo fission: the process of splitting one mitochondria into two 
mitochondria to allow the generation of more cellular energy (183). These processes are usually 
in a constant balance with one another and are tightly controlled by an array of fission and 
fusion proteins (183).   
1.5.8 Homocysteine, oxidative stress and mitochondrial dysfunction 
Intracellular calcium levels are tightly regulated as excessive calcium influx can lead to 
subsequent damage to the mitochondria, and the mitochondria can act as a buffer when calcium 
levels are high (137). However, once the buffering capacity has reached maximal levels there 
is resultant increase in ROS generation, oxidative stress and finally cell death (185). When 
extrasynaptic NMDA receptors are activated by chronic glutamate elevation,  high levels of 
calcium influx into the cell and mitochondrial dysfunction is observed (186). Excessive 
calcium has been found in conjunction with mitophagy and mitochondrial loss which has been 
reported in Parkinson’s disease models extensively (187). When the mitochondria are no longer 
able to buffer excess calcium, it effluxes out of the cell bypassing the conventional pathways 
for the excretion of calcium, in a process known as the mitochondria permeability transition 
pore (mPTP) (188). Under conditions of cellular stress, activation of the NMDA receptor can 
cause opening of the mPTP and causes a reduction in ATP generation due to disruption of the 
electron transport chain (189). Even though HCy also signals via the NMDAR, there is little 
evidence to date regarding the actions of HCy on the mitochondria. 
Studies using retinal ganglion cells from cystathionine β synthase (CBS) deficient mice have 
suggested that HCy may alter mitochondrial fusion and fission proteins thereby affecting the 
mitochondrial network (190).  This study showed that HCy increases the levels of 
mitochondrial fission protein Fis1 (190). Similarly, mitochondrial fission genes are upregulated 
in a yeast model of HCy imbalance (177). Thus, HCy may increase mitochondrial number 
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through upregulation of mitochondrial fission. Similarly, it has been reported that activation of 
the NMDA receptor can result in an increase in mitochondrial fission, which is NO-mediated 
through S-nitrosylation and thus activation, of the pro-fission protein DRP1. In circumstances 
where there is a reduction in mitochondrial fusion protein OPA1 in response to oxidative stress, 
there is a downstream upregulation of NMDA receptors (191). Together these data show that 
a vicious cycle exists whereby oxidative stress leads to dysregulation of mitochondrial 
dynamics. This can lead to upregulation of the NMDA receptor which in turn could exacerbate 
oxidative stress via increased intracellular calcium.  
Figure 1.4 Mechanisms of mitochondrial fusion and fission 
 
Figure 1.4 shows the mitochondria are highly dynamic organelles and upon changes in cellular stress and 
requirements the mitochondria can adapt to the surrounding environment. If a mitochondrion becomes damaged, 
the process of mitochondrial fusion may be activated and therefore an undamaged mitochondrion may share its 
components to repair and support, this creates a network of mitochondria with increased mitochondrial mass. If 
the energy demands of the cell increase it is also possible for fission to occur and thereby create more mitochondria 
to support the energy demands of the cell. 
As HCy has a very pronounced effect on the NMDA receptor, it can be postulated that HCy 
would at the least affect the mitochondria indirectly due to cellular influx of calcium. The 
mitochondrial membrane potential in rat cortical neurons has been shown to be impaired in 
response to HCy exposure (185). In cardiac cells, a more in depth analysis of the effects of 
hHCy was achieved by looking at the enzymatic activity of each of the complexes of the 
mitochondrial respiration chain, showing that hHCy caused the activities of complexes III and 
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IV to be reduced (192). This study showed that cardiac cell contractility was reduced, coupled 
to enhanced lipid peroxidation in response to alterations in the activity of these complexes of 
the respiration chain (182)  
Oxidative stress occurs in cells when the balance between generation of reactive oxygen 
species overthrows the cellular capacity to combat ROS (180). Oxidative stress has been 
reported to be present in AD up to 10 years prior to the onset of symptoms (193). The brain 
has high requirements for oxygen and therefore generates high levels of ROS as a by-product 
of normal metabolism (193). HCy is an oxidising agent in its own right but the exact nature of 
how HCy contributes to oxidative stress remains to be determined (77).  
Several studies have examined the role of ROS, RNS and oxidative damage in response to 
elevated HCy, and it is known that HCy can cause oxidative damage to mitochondrial DNA 
(194) and impair mitochondrial function (119). In astrocytes, the mitochondrial membrane 
potential is impaired in response to HCy exposure (195). Furthermore, HCy can induce 
oxidative stress when it is condensed to form cysteine; a precursor of glutathione, which in the 
reduced form, is one of the main antioxidants and is also used as a measure of antioxidant 
capacity in the cell (77). HCy can also cause uracil misincorporations into DNA and can cause 
lipid peroxidation (114). Together these findings suggest that HCy-mediated oxidative damage 
may be a major contributing factor to the pathology of neurodegenerative disease. 
The aims of this thesis are to establish to what extent HCy metabolite, HCy-T contributes to 
neuronal cell death and how the mechanisms of this compare to HCy. The areas of particular 
interest are the effects on the NMDA receptor, this has been well characterised for HCy so 
whether this is the same for HCy-t is important to determine. Then what role oxidative stress 
and mitochondrial dysfunction plays in cell death induced by these metabolites. Finally, to 
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establish a culture system which can support long term application of HCy and metabolites to 
determine the effects of subclinical concentrations of these in culture.  
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CHAPTER 2: MATERIALS AND METHODS  
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2.1.1 MATERIALS 
Unless otherwise stated all chemicals were obtained from Sigma Aldrich, UK and laboratory 
consumables were obtained from VWR, UK.  
2.2.1 Culture of SH-SY5Y Neuroblastoma Cells 
The SH-SY5Y human neuroblastoma cell line was obtained from European Collection of Cell 
Cultures (ECACC).  These cells were originally derived from the SK-N-SH cell line which was 
sub-cloned three times to SH-SY, SH-SY5 and finally to the SH-SY5Y line. The cells were 
obtained from ECACC on dry ice, and upon collection, the cells were warmed to 37ºC in a 
water bath and mixed with 25ml of pre-warmed 10% FCS medium (Dulbecco’s modified eagle 
medium (DMEM) containing 10% v/v foetal calf serum (FCS, Fisher Scientific, UK), 4.5g/l 
D-glucose, 0.584 g/l L-glutamine and 3.7 g/l sodium bicarbonate). Cells were seeded in a T75 
tissue culture flask and placed into a 5% CO2 incubator until confluent. Once confluent, the 
cells were detached from the base of the flask by trypsinisation using 0.001% w/v trypsin 
(Worthington’s, USA) in calcium and magnesium free phosphate buffer solution (PBS) and 
replaced in the incubator until cells had rounded and lifted from the flask surface. The cells 
were then resuspended in pre-warmed 10% FCS medium.  
2.2.2 Cryopreservation of stocks for future use 
Following trypsinisation, a 10μl aliquot of the cell suspension was mixed with 10μl of trypan 
blue dye to assess the viability of the cells prior to cryopreservation and to determine cell 
number. Cells were counted using a haemocytometer to obtain a 1,000,000 cells/ml suspension 
for cryopreservation. If more than 5% of the cells stained blue, indicating a reduction in cell 
viability, they were discarded. The number of cells in four corner squares of the 
haemocytometer containing 16 squares was counted and the average was taken per square. This 
dilution with trypan blue solution was accounted for by doubling the number of cells counted 
per square, and haemocytometer volume and the number of cells per ml was calculated and 
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appropriate dilutions were made. The media containing the cells for cryopreservation were 
transferred to a falcon tube (5ml for T25 flasks and 10ml for T75 flasks) and placed in Boeco 
u-32r centrifuge and centrifuged at 2500RCF for ten minutes at 37°C. All supernatant was 
removed, and the cells were then suspended in a mixture of 90% FCS and 10% dimethyl 
sulfoxide (DMSO) and frozen at -80°C until required. To reanimate following 
cryopreservation, cells were warmed in a water bath for 1 minute and suspended in 20ml pre-
warmed 10% FCS medium and transferred to a T75 flask. All medium was removed from the 
flask and replaced 48 hours later to prevent cell damage from residual DMSO presence.  
2.2.3 Plating cells for experimentation  
The cells were grown at 37°C in a humidified atmosphere of 5% CO2 and 95% air and allowed 
to grow to 70-80% confluence before trypsinising from the culture flask and plating in 
appropriate sized plates or dishes. The cells were left for at least 48 hours to settle prior to 
treatment. To differentiate to a neuronal phenotype, cells were incubated with 1% FCS medium 
(DMEM supplemented with 1% v/v foetal calf serum, 4.5g/l D-glucose, 0.584 g/l L-glutamine 
and 3.7 g/l sodium bicarbonate) containing 10µM retinoic acid (RA) for 5 days with medium 
renewal every 48 hours. This medium was removed, and the cells were maintained in defined 
SR-2 medium (DMEM containing 18µM 5-fluorodeoxyuridine (5-FDU), 2% v/v serum 
replacement-2 (SR2) 4.5g/l D-glucose, 0.584 g/l L-glutamine and 3.7 g/l sodium bicarbonate) 
for at least one week before treatment. The addition of the mitotic inhibitor 5-FDU ensures that 
minimal undifferentiated cells remained in culture by eliminating cells that remain within the 
cell cycle. The media was then replenished every 48 hours. 
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Table 1: Plating densities of the SH-SY5Y neuroblastoma cells utilised in this study 
Dish/Plate Density Coverslip size 
35mm 1.5X105 22mmX22mm 
60mm 5 X105 22mmX22mm 
24 well plate 5X104 13mmX13mm 
96 well plate 1 X104 NA 
 
2.2.4 Measures of cell viability – Lactate Dehydrogenase Assay 
Cell membrane integrity was assessed using a lactate dehydrogenase (LDH) assay which 
measured the release of intracellular LDH from cells whose membrane permeability had been 
compromised (196). At the end of the experiment, an aliquot of the medium for each 
experimental condition was removed and centrifuged at 13,000 rpm to remove cell debris or 
any floating undifferentiated cells. 50μl of the aliquoted media was then added to a 96 well 
plate. LDH mixture (iodonitrotetrazolium chloride 26% w/w, phenozine methosulphate 6.7% 
w/w, and β-nicotinamide adenine dinucleotide hydrate 67% w/w) was added to a buffer 
containing 0.2M tris(hydroxymethyl)aminomethane (tris) and 0.5% v/v lactic acid. 0.1% v/v 
triton X-100 was added to the final solution and once thoroughly dissolved, this mixture was 
added at an equal volume to the media. The reaction was allowed to progress until a red colour 
developed and the absorbance was read at 490nm on BioHit BP plate reader. A blank value 
from media alone which had not been in contact with the cells was obtained. This blank reading 
was subtracted from the readings obtained for the experimental conditions.  
2.2.5 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) is a yellow tetrazole 
which forms purple formazan crystals in the presence of actively respiring cells (197), and is 
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commonly used as an assessment of cell viability. The assay measures mitochondrial activity 
and readings vary according to respiration rate or the activity of NADPH enzymes, which are 
a key component of the conversion. This was considered when interpreting the results of the 
study. 
100ng/ml MTT solution in PBS was added to cells at a 1:1 v/v ratio to give a final concentration 
of 50ng/ml. The cells were then returned to the incubator for 1-4 hours with frequent checks, 
and the reaction was terminated when the formation of the formazan crystals was visible under 
brightfield microscopy. All medium was removed, and the cells and crystals were solubilised 
in 50μl of DMSO (for wells of 96 well plates) or 500μl (for 24 well plates). Once the crystals 
had fully dissolved the plate was then read on the BioHit BP plate reader at 570nm. A selection 
of wells containing only media, and no cells, were measured to determine the background 
(blank)reactivity of the reaction components with the culture media as above and this value 
was subsequently subtracted from the sample values for analysis.  
2.2.6 Crystal violet assay 
Post treatment, the cells were fixed in neutral buffered formalin solution (NBF; 0.4% w/v 
disodium hydrogen phosphate, 0.65% w/v sodium dihydrogen phosphate, 37-40 v/v% 
formaldehyde solution and deionised water) for 15 minutes. This solution was removed, and 
the cells were washed 3 times for 5 minutes in PBS. The PBS was removed and 100µl of 
solution containing 5% v/v from a stock crystal violet acetate solution (0.1% v/v), 5% v/v of 
100% ethanol and 90% v/v deionised water was added to each well including a row of wells 
which had not contained any cells to serve as a blank. This solution was left for 30 minutes to 
allow for the dye to penetrate the cells and gain sufficient staining, then washed for a minimum 
of 5 times in PBS and until no purple dye remained visible in the PBS solution. The PBS was 
then removed and 100μl DMSO added to 96 well plates and 500μl added to 24 well plates to 
dissolve the cells and release the purple dye. The absorbance of the resultant solution was read 
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at 570nm on BioHit BP plate reader. The blank value was subtracted from each treatment group 
and all data normalised to control to estimate of cell number. 
2.2.7 Determination of cell number by DAPI labelling 
Diamino-2-phenylindole (DAPI) is a cell permeable dye used for fluorescent staining of DNA 
and cell nuclei. DAPI fluoresces blue upon binding to the minor groove of double stranded 
DNA. These factors make DAPI an ideal cell dye for cell counting and counterstaining. Cells 
were grown on coverslips (as is detailed in table 1) and after experimentation were fixed in 
NBF for 15 minutes. The cells were then washed three times in PBS for 5 minutes each wash. 
500ng/ml DAPI in PBS was added for 15 minutes. The cells were then mounted in mounting 
medium (1% w/v N-propyl gallate, 80%v/v glycerol and 19% v/v PBS). Images were obtained 
on a Zeiss AxioImager MR2 microscope using either 40X or 63X magnification ex/em360⁄460. 
5-10 images per condition per coverslip were obtained. To prevent observer bias, the images 
were split into folders and renamed by an impartial party. The number of cells in each field of 
view were counted and data inputted into a spreadsheet. The folders were then converted back 
by the impartial party to reveal the conditions. 
2.2.8 Immunocytochemistry 
Cells were treated for the appropriate time then fixed with NBF and washed three times in PBS. 
Nonspecific binding of the secondary antibody was then blocked by the addition of a 10% v/v 
heat inactivated horse serum in PBS for 30 minutes. This was then removed, and the cells were 
washed twice in PBS and once in PBS containing 0.1% v/v tween 20 to permeabilise where 
appropriate. The cells were then incubated in a solution containing the primary antibody diluted 
in PBS (see table 2 for dilutions). This was incubated overnight at 4°C. The next day the 
primary antibody was washed off with PBS, three times for five minutes and a fluorescently 
tagged secondary antibody was added at a 1:200 dilution in PBS containing 0.1% v/v tween 
20. The fluorescent tag was either FITC or Texas red depending upon the research application, 
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and this was incubated for 2 hours in the dark at room temperature. The secondary antibody 
was selected based on the species in which the primary antibody was grown, for example if a 
mouse monoclonal antibody was used as the primary then an appropriate secondary was 
required as the secondary to bind the primary. This was then washed off three times in PBS for 
five minutes and where appropriate, counterstained with DAPI for 15 minutes. The cells were 
then mounted using a mountant containing 1% propyl gallate w/v, 80% glycerol v/v and 19% 
PBS v/v. This was then sealed onto a glass microscope slide using nail polish and the nail 
polish allowed to dry prior to imaging. Images were obtained using the Zeiss AxioImager MR2, 
on either 40X or 63X magnification with 5-10 images per condition per coverslip obtained. 
Where appropriate, the fluorescence intensity was taken from the image using the Zeiss 
software, Zen 2 blue edition, and the relative fluorescence intensity was calculated as per cell. 
This was achieved by taking the sum intensity from the image obtained directly from the Zeiss 
software, the images were then coded as described above and the number of cells staining 
positive for DAPI were counted. If the cells were on the edge of the image, then they were only 
counted if more than 50% of the cell was visible in the image. The sum intensity was then 
divided by the number of cells counted. The mean intensity per cell was then divided by the 
mean intensity per cell in the untreated group and multiplied by 100 to give a change in 
percentage for each treatment group. 
Table 2 
Antibody Concentration 
Mouse α βIII tubulin (genscript) 1:1000 
Mouse α Tyrosine hydroxylase (sigma) 1:500 
Mouse α 4-hydroxynonenol (abcam) 1:500 
Rabbit α Synapsin I (sigma) 1:1000 
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2.2.9 MitoTracker Red Staining 
MitoTracker is a cell permeable rhodamine-based dye which stains mitochondria red in live 
samples. The ability of the MitoTracker to enter the mitochondria is dependent on the 
mitochondrial membrane potential and is a useful tool for examining the effects of treatments 
on the mitochondrial network (198). The method described for examining the network structure 
of the mitochondria is based on 4 criteria (198). The mitochondria were characterised (using 
the criteria of Wappler) (198) as:  
• Normal: i.e. well dispersed and defined throughout the cells 
 
• Rounded: where the mitochondria cluster together and give the appearance of 
clustering or swelling 
 
• Highly interconnected: where they form string-like networks.  
41 
 
 
• Lacking in mitochondrial staining: in this case there is either a loss of mitochondria 
or as this dyes ability to stain mitochondria is dependent on the mitochondrial 
membrane potential, there has been an alteration in the mitochondrial membrane 
potential.  
 
 
Cells for MitoTracker red staining were grown in 24 well plates containing 13mm diameter 
boroscillate glass coverslips. At the end of the culture period cell medium was removed and 
replaced with pre-warmed DMEM containing 100nM of MitoTracker dye and the cells 
returned to the incubator for 45 minutes. The cells were then washed twice in pre-warmed 
medium and then fixed in NBF for 15 minutes and washed 3 times for 5 minutes in PBS. It 
should be noted that MitoTracker staining persists after fixation. The cells were then 
counterstained with DAPI as described above and mounted using mounting medium or 
CitiFlour mountant (VWR). The coverslips were then sealed with nail polish and imaged using 
the Zeiss AxioImager abs/em 581/644 nm 63X magnification with 5-10 images taken per 
coverslip and a minimum of three separate cultures for each condition. The morphology of the 
mitochondrial network was then characterised according to the criteria of Wappler as outlined. 
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The images were then collated and grouped by treatment; the number of cells containing each 
morphology per field of view was then noted. This was presented as a proportion of the total 
number of cells per field of view. This was then averaged by each coverslip imaged then by 
the number of individual coverslips per batch of cells giving the final number of experiments. 
The data was then presented for each treated batch of cells as a comparison and proportion of 
untreated or control cells.  
2.2.10 DAF2-DA staining 
DAF2-DA is a live cell dye that fluoresces green when bound to nitric oxide (NO). After 
entering the cell, the DAF2-DA is transformed to DAF2 by cellular esterases. This is a widely 
used method for measuring NO generation in cells (199). 
Cells were incubated for 15 mins with 1µM DAF2-DA and then fixed in NBF and mounted 
post treatment as described above (section 2.2.8). It should be noted that DAF-2DA staining 
persists following formaldehyde fixation. 5-10 images per coverslip per condition were taken 
from a minimum of 3 cultures established on separate occasions. Images were taken using the 
same exposure time so that alterations in fluorescent intensity could be detected. The images 
were taken at 63X objective on the Zeiss AxioImager at abs/ em 495nm/515nm microscope. 
The images were then collated and grouped by treatment. The sum intensity of each image was 
taken directly from Zeiss software; the number of cells from each image was then counted. The 
total intensity per field of view was then divided by the number of cells to give the average 
intensity per cell. The data for this was then collated by treatment and by experiment. The 
images from cells which had received no treatment were presented as the untreated control and 
all treatments were normalised to untreated control.  
43 
 
2.2.11 Mitochondrial Membrane Potential 
Alterations in the mitochondrial membrane potential can be indicative of cellular wellbeing. It 
has been widely reported that loss of mitochondrial membrane potential is altered in several 
disease states (200,201). Mitochondrial membrane potential was determined using the dye JC1. 
This dye is a cationic carbocyanine dye which can accumulate in the mitochondria. At low 
concentrations the dye exists as a monomer and therefore emits green fluorescence, and under 
these circumstances the mitochondria are depolarised. At high concentrations the dye exists as 
an aggregate and will emit a red fluorescence, under these conditions the mitochondria are 
considered to be hyperpolarised (202). This gives an indication of the mitochondrial membrane 
potential as green emission is indicative of depolarised mitochondrial membrane potential and 
red is indicative of a hyperpolarised mitochondrial membrane, a normal membrane potential is 
approximately -140mV at rest (203).  
A JC1 dye kit for mitochondrial staining was used and the manufactures guidelines were 
followed. Stock solutions of the JC1 dye were prepared in DMSO to be used at a final 
concentration of 5 µM and stored at -20oC until required. 50µl of the stock solution was added 
to 8 ml of deionised water (dH20) and vortexed. 2ml of staining buffer was added and left at 
room temperature for 2 minutes. This solution was then mixed at a 1:1 ratio with pre-warmed 
culture medium and added to the cells which had been seeded onto coverslips in 24 well plates 
and treated for the appropriate time, according to the experiment conducted. The cells were 
then returned to the incubator for 20 minutes and live imaged using the Zeiss AxioImager 
ex/em 514/529 on the rhodamine and FITC channels. 5-10 images were taken at X40 and X63 
for each coverslip for each condition using cultures established on at least 3 separate occasions. 
The total number of cells per field of view was counted, as was the number of cells displaying 
predominantly green fluorescence and the number displaying a mixture of green and red. The 
totals of both red and green cells were divided by the total number of cells. The data for this 
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was then collated by treatment and by experiment. The images from cells which had received 
no treatment were presented as the untreated control and all treatments were presented as a 
proportion of this. This was presented as a proportion of the total number of cells per field of 
view.  
2.2.12 H2DCF-DA 
To detect the generation of reactive oxygen species in live samples the dye H2DCF-DA was 
used. This dye is a cell permeable dye that binds reactive oxygen species and fluoresces green 
(204).  
Cells were grown on boroscillate glass coverslips in 24 well plates and treated as appropriate. 
After treatment 10µM H2DCFDA was added to the culture media and the cells were returned 
to the incubator for 45 minutes. The coverslip was then removed, and the cells were imaged 
live using the Zeiss AxioImager MR2 Ex/Em: 485/520 nm. 10 images were taken on X40 
magnification per coverslip per condition and on cultures established on at least 3 separate 
occasions. For each experiment the exposure time was constant so that any changes in 
fluorescent intensity could be accurately determined.  The images were then collated and 
grouped by treatment. The sum intensity of each image was taken directly from Zeiss software; 
the number of cells from each image was then counted. The total intensity per field of view 
was then divided by the number of cells to give the average intensity per cell. The data for this 
was then collated by treatment and by experiment. The images from cells which had received 
no treatment were presented as the untreated control and all treatments were normalised to 
untreated control.  
2.2.13 Protein extraction 
Cells were grown on either 35mm or 60mm dishes (see table 1 for densities). After treatment, 
all medium was removed from cells and stored at -20oC for future use in LDH assays to 
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determine whether there were any effects on cell viability, which could confound the analysis 
of protein expression. Cells were washed in PBS followed by a 5-minute incubation in 
extraction buffer containing PBS, 0.1% v/v triton X-100 and 1% v/v protease inhibitor cocktail, 
the volume was determined by cell density. Cells were carefully scraped from the bottom of 
the dish with a cell scraper. All solutions were transferred to a 1ml tube and centrifuged at 
13000 RPM for 10 minutes at room temperature. The supernatant was then transferred to a 
fresh tube and saved as the soluble fraction, the pellet also saved as the insoluble fraction. This 
was stored at -80°C and small aliquots of the soluble fraction were saved at -20°C to avoid 
freeze thawing the samples.  
2.2.14 Protein concentration determination 
The concentration of protein in extractions was determined using a Bradford assay. A range of 
concentrations (0.001 – 100mg/ml) of bovine serum albumin were used to produce a standard 
curve. 10µl of the soluble fraction of each protein sample was mixed with 10µl 1M sodium 
hydroxide to solubilise the protein, and 500µl of Bradford reagent (0.025% w/v brilliant blue, 
40% v/v methanol, 7% v/v acetic acid in deionized water) This was then loaded into a 96 well 
plate and read and 570nm on the BioHit BP plate reader and protein concentration was 
determined by comparison with the standard curve. The standards were plotted as a scatter 
graph and a trend line added. The r and x2 were then added and if the x2 was less than 0.94 then 
this was discarded as it was determined that there was an error in the preparation of the 
standards. The absorbance from each of the samples was then calculated based upon the 
standards and this was calculated as per the calculation from the trendline form the Bradford 
assay. This was standardised and diluted as appropriate for western blotting and ELISA. 
2.2.15 Subcellular fractioning 
To examine the effects of homocysteine on mitochondrial proteins for ELISA the mitochondria 
were extracted. This was achieved by a differential centrifugation method by which organelles 
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of the cell can be fractioned out by centrifuging at different speeds and temperatures. An 
alternative mitochondrial extraction kit was initially tested and compared to the centrifugation 
method and a better yield was obtained with this method rather than the kit, and therefore this 
method was used for these experiments. 
The cells were grown on 60mm dishes (see table 1) and treated as appropriate. All cell medium 
was removed from the dishes and cells were suspended in ice cold extraction buffer (0.3 M 
mannitol, 0.1% w/v BSA, 0.2mM EDTA, 10mM HEPES adjust to pH 7.4 with KOH and/or 
HCl followed by addition of 1% v/v protease inhibitor cocktail-l). Cells were scraped off the 
bottom of the culture dish using a cell scraper and transferred to a dounce homogeniser and 
thoroughly homogenised on ice with approximately 15 strokes. The supernatant was 
transferred to a fresh tube and centrifuged at 1300g for 10 minutes at 4°C. The supernatant 
containing cell debris was discarded and the remaining pellet was resuspended in the extraction 
buffer (0.3M mannitol, 0.1% w/v BSA, 0.2mM EDTA, 10mM HEPES adjusted to pH 7.4) 
mixed and centrifuged again at 7000g for 10 minutes. This supernatant was saved as the 
cytosolic fraction and the pellet resuspended in the isolation buffer. This was then centrifuged 
again at 7000g for 10 minutes and the resultant pellet saved as the pure mitochondrial fraction. 
This was aliquoted and stored at -80°C until required.  
To validate the purity of the samples a western blot was used to check the mitochondrial 
fraction for βIII tubulin to determine whether there was any contamination with cytosolic 
fraction.  
2.2.16 Western blot analysis 
Western blot is a commonly used method to detect changes in the protein expression within 
samples. Unlike some other methods of examining changes in protein expression such as 
ELISA, the western blot allows for a detailed output of the molecular weight of these proteins.  
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Protein samples were mixed at 1:5 ratio of protein sample buffer (2% v/w SDS, 20% glycerol 
v/v, 0.4mM Tris (pH8), 0.01% w/v bromophenol blue, 2% β mercaptethanol v/v, 0.075% 
EDTA w/v and deionised water). The sample buffer provided the samples with the weight and 
the charge to allow for free movement through the gel. The samples were then boiled at 96 °C 
for 10 minutes to denature the sample and expose the antibody binding sites. The samples were 
then loaded in a 10% SDS-polyacrylamide gel (NuSep) giving a final protein concentration per 
well of 20µg/µl as determined by the Bradford assay. The gel was then run using 1X running 
buffer (sigma T7777) prepared from a 10X running buffer stock in deionized water for 
electrophoresis, at 150V for 45 minutes with a standard protein ladder in one lane to allow 
determination of molecular weight. Once optimal separation of the ladder had occurred, the gel 
was then removed and placed into a sandwich for transfer. This comprised of 2 sponges, 2 
pieces of electroblotting paper, the gel, a nitrocellulose membrane, 2 pieces of blotting paper 
then another 2 sponges. This was then loaded into a cassette and placed in the x cell blot module 
™ gel rig with the gel facing the positive electrode so the protein transferred from the gel to 
the membrane for subsequent detection. This was run in 1X transfer buffer (sigma T4904) 
prepared from a 10X transfer buffer stock by a 1:10 dilution in Milli Q water containing 20% 
v/v methanol. On occasions where protein detection was weak, a PVDF membrane was used 
instead of the nitrocellulose, as it has a higher affinity for protein binding but must be soaked 
in ethanol prior to use. In all cases a wet transfer was used and ran at a constant 30V and 200mA 
for at least 90 minutes. After transfer, the membrane was removed and the quality of the transfer 
was checked by staining with Ponceau S solution containing 0.33% w/v ponceau S, 0.3% v/v 
acetic acid in deionised water, which will bind proteins on the membrane (199). If samples 
were visible, the dye was washed off with TBS until the membrane was clear. If this was 
unsuccessful, the blot was discarded as this is indicative of either no protein within the samples 
or a poor transfer. If no obvious error had been made, the samples were run again on the SDS 
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gel as described above, the gel was then removed and stained with coomassie blue (0.025% 
w/v brilliant blue, 40% v/v methanol, 7% v/v acetic acid and deionised water) which was left 
until bands appeared on the gel to check the quality of gel running and protein samples. This 
was then destained in 10% v/v acetic acid in deionized water and visualised using a chemidoc 
gel documentation system under the UV illumination for optimal visualisation of protein bands. 
If this showed positive staining after a negative Ponceau S stain this indicates that there was an 
issue with the transfer and if negative or very low, an issue with the samples themselves and 
new were obtained. 
Immunodetection using specific antibodies (see table 3 for concentrations) was achieved by 
leaving the membrane overnight at 4°C in 5% w/v dried milk in TBS +0.1% v/v triton X-100. 
The membrane was then washed 3 times for 5 minutes in TBS containing 0.1% v/v triton X-
100. Primary antibody binding was detected using an appropriate horseradish peroxidase 
(HRP) conjugated secondary antibody at 1:10,000 v/v in TBS-T and visualised using 
chemiluminescence ECL substrate (Pierce) using the GelDoc Imager it2 with Vision Works 
software. The intensity of the bands was determined using Image J software. This intensity was 
then transferred to a Microsoft Excel spreadsheet, data for treatment groups were presented as 
a percentage relative to untreated cell extractions. This was corrected using a western blot for 
the house-keeping protein α-tubulin as a loading control, which was selected as it gave a better 
signal as compared to β-actin and GAPDH is dysregulated in neurodegenerative disorders 
(193). 
  
49 
 
Table 3 
Antibody Concentration 
Mouse α tubulin (sigma) 1:2000 
Rabbit α APP (Genscript) 1:5000 
Rabbit α pTau (ser262) (Genscript) 1:5000 
Mouse α Nitrotyrosine (Santa Cruz) 1:250 
Goat α VDAC (Santa Cruz) 1:1000 
 
2.2.17 Oxyblot 
To determine if the protein samples had been oxidatively modified the oxyblot assay was used 
to determine if carbonyl groups had been incorporated into proteins. This method shows 
whether protein samples have been oxidised by superoxide or other types of free radicals. In 
this assay, the carbonyl groups are derivatised by 2,4-Dinitrophenylhydrazine (DNPH) and 
then detected using DNP antibodies (199).  
Protein samples were chemically denatured by the addition of 12% w/v SDS in deionized water 
for 15 minutes. The samples were then mixed with DNP residues and left for 20 minutes, and 
manufacturer supplied neutralisation buffer was then added to halt the reaction. 1X sample 
buffer was mixed with a mixture of manufacturer supplied standard proteins to serve as a 
molecular weight ladder. The samples are then loaded into a gel at 10µg/µl per well and the 
remainder of the assay was carried out as described for a western blot (see section 2.2.16). The 
primary antibody was added at a concentration of 1:600 and the secondary was added at 1:300. 
The intensity of the bands was determined using Image J software. This intensity was then 
transferred to an excel spreadsheet, data for treatment groups were presented as a percentage 
relative to untreated cell extractions. 
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2.2.18 ELISA 
As a high throughput method of detecting changes in protein samples, ELISA assay coupled to 
a representative western blot was carried out. This was initially optimised to determine the best 
method to be used. 
Parameters trialled to optimise ELISA:  
• Coating Buffer – PBS, commercially prepared coating buffers, range of dilutions for 
sample in PBS 
• Coating Time - 4 hours at room temperature, overnight at room temperature, overnight 
at 4ºC 
• Primary antibody - range of concentrations for all, overnight at 4ºC, 37 ºC, and after 2 
hours and 4 hours room temperature 
• Secondary antibody – 1 hour at room temperature, attempted at a range 
• Substrate – TMB, KPL substrate, volumes 50µl and 100µl 
 
The final working protocol for the indirect ELISA was as follows. Cell lysates diluted to a 
working concentration of 1µg/µl per well in PBS. This was used as a coating buffer to dilute 
the samples as it was found to be more effective that the commercially-produced coating buffer. 
The samples were loaded in duplicate in to an ELISA plate this was then left overnight at 4°C. 
The following day the samples were removed from the wells and 10% v/v horse serum in PBS 
was used to block all nonspecific binding, this was then left for 30 minutes at room temperature 
(on a rocker) and then discarded. The plate was then washed 3 times with PBS for 5 minutes 
and PBS containing primary antibody was added to each well. Details of dilutions and 
antibodies used are in Table 4. On every occasion each sample was also tested using an 
additional ELISA for -tubulin as a loading control to accurately determine total protein 
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concentration. This was left for 2 hours at room temperature, then removed and the plate 
washed 3 times for 5 minutes with PBS prior to a 1-hour incubation in appropriate HRP 
conjugated secondary antibody at 1:10000 for 1 hour. This was then removed, and the plate 
washed 3 times for 5 minutes in PBS prior to detection with substrate. The substrate that was 
used was the 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) (KPL) substrate 
which a highly sensitive ELISA substrate. This is a 2-part kit in which solutions A and B were 
mixed at equal volumes immediately prior to use and 100 µl was added to each well of the 
plate. There were several wells of each plate lacking protein sample to check that the signal 
obtained was not background reactivity. The readings were taken on BioHit BP plate reader, 
the ABTS substrate has peaks at 630 nm which is known to be in flux. Therefore, hydrochloric 
acid was added to produce a stable reaction product, and this was read at 410nm. The data were 
grouped by each batch of cells used, the average of all wells per batch of cells was then 
averaged. The data for this was then collated by treatment and by experiment. The values 
obtained from cells which had received no treatment were presented as the untreated control 
and all treatments were presented as a percentage of this.  
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Table 4 
Antibody Concentration 
Mouse α βIII tubulin (genscript) 1:2000 
Mouse α Tyrosine hydroxylase (sigma) 1:5000 
Mouse α 4-hydroxynonenol (abcam) 1:500 
anti-extracellular signal-regulated kinase-1 1:250 
Mouse α anti-neuronal nitric oxide synthase 
(Santa Cruz) 
1:1000 
Mouse α anti-inducible nitric oxide synthase 
(Santa Cruz) 
1:2000 
Mouse α anti-GluN2A (Santa Cruz) 1:500 
Rabbit α APP (Genscript) 1:2000 
Rabbit α pTau (ser262) (Genscript) 1:1000 
Goat α anti-presenilin 1 (abcam) 1:2000 
Mouse α α-tubulin (sigma) 1:1000 
 
2.2.19 DNA extraction 
Cells were grown on 35mm dishes and at the end of treatment time the cells were lysed in TE 
buffer (10mM Tris base and 0.5M EDTA) containing 20% w/v SDS. Proteinase K solution was 
then added to the sample to cleave peptide bonds adjacent to the carboxylic group of aliphatic 
and aromatic amino acids allowing digestion of the proteins in the sample. The cell lysates 
were incubated in this overnight at room temperature. The next day, 5M NaCl was added at a 
1:1 v/v ratio to salt out the DNA. The supernatant was removed to a fresh tube and centrifuged 
53 
 
at 13000rpm to pellet the DNA. The supernatant was removed and 1:1 v/v ethanol was added 
to wash the pellet, this was centrifuged for 10 minutes at 13,000 RPM and the supernatant was 
discarded. The resultant pellet was washed 3 times in 70% v/v ethanol to remove any residual 
salt and then centrifuged for 10 minutes at 13,000 RPM. The supernatant was again discarded, 
and the pellet allowed to air-dry for 30 minutes. The pellet was then resuspended in TE buffer 
and this was aliquoted and stored at -80°C. 
2.2.20 DNA methylation detection 
To investigate the epigenetic changes with age in culture a global DNA methylation kit (MDQ1 
Part 2- 96RXN) was used to measure DNA methylation. DNA samples were diluted in the 
manufacturer’s DNA binding solution and added to an ELISA plate to allow for binding. The 
plate was incubated at 37°C for 1 hour to maximise DNA binding. Several wells had just DNA 
binding solution alone to serve as a blank. After the DNA was bound, the manufacturer 
supplied blocking solution was added and the plate was returned to 37°C for a further 30 
minutes. This was removed, and the plate washed 3 times for 5 minutes in PBS. The capture 
antibody for detection of methylated DNA was added at 1:1000 diluted in the supplied wash 
solution at 50µl per well, this was incubated at room temperature for 1 hour. This was then 
washed 3 times for 5 minutes and the detection antibody was added at 1:1000 diluted in wash 
solution. This was then washed again as above and 100µl of detection solution was added to 
each well and left for 1-10 minutes, once a sufficient change from blue to a yellow colour had 
developed, 50µl of stop solution was then added to each well and this was read at 410nm on 
BioHit BP plate reader. The blank was subtracted from each of the values and the absorbance 
was represented as compared to 2 week samples. 
2.2.21 Statistics 
All data was obtained from at least 3 different cultures established on 3 separate occasions. 
Where possible in cell viability assays and any other assay conducted in a 96 well plate the 
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blank data was subtracted from the absorbance values in each case. All data was collated and 
any data points which were more than 3 standard deviations away from the mean were excluded 
as statistical outliers. For plate reader-derived data, any data points that had an absorbance 
above 1 were also eliminated as this is beyond the limit of linear detection of the instrument 
and therefore cannot be considered an accurate reading. Normal distribution was determined 
by plotting the residuals of ANOVA and subjecting the data to Korsakov Smirnoff test of 
normality as there were no more than 30 data points in any experiment. If the data was not 
normal, then the data was transformed using SQRT and log10 transformation as recommended 
for relative data. The data was then analysed with a one-way ANOVA with Tukey post hoc 
test. Alternatively, in cases where there was only 2 data points being compared a student’s t-
test was used. When data was not normal, and this was not achieved through transformations, 
the data was analysed using non-parametric methods. In all cases a P value of less than 0.05 
was considered significant.   
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CHAPTER 3: ESTABLISHING A NOVEL METHOD FOR THE LONG-TERM 
CULTURE OF SH-SY5Y NEURONAL CELLS EXHIBITING BIOMARKERS OF 
AGEING  
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3.1 Introduction 
One of the most commonly used in vitro models for neurodegeneration research is the 
neuroblastoma cell line SH-SY5Y (205). These cells are frequently used undifferentiated as 
they generate a high volume of data rapidly, with a doubling time of 48 hours (206). However, 
it is often appropriate when using this cell line to differentiate the cells to a more representative 
neuronal model (205). Although there are advantages to using undifferentiated SH-SY5Y cells, 
they do not possess the ability to fire action potentials, nor do the cells express an extensive 
array of neuronal markers or possess long neuronal processes. Differentiation of neuroblastoma 
cells can be achieved with several different differentiation agents such as retinoic acid (207), 
phorbol esters (208) or staurosporine (209). Different agents can be used depending on the 
resultant preferred phenotype, either cholinergic or dopaminergic. The dopaminergic 
phenotype makes this system ideal for PD research. For AD research, these cells and can be 
transfected with APP leading to endogenous overexpression of amyloid beta (210). In these 
experiments, SH-SY5Y cells were differentiated with retinoic acid, followed by the addition 
of a mitotic inhibitor, 5-fluorodeoxyuridine (5-FDU), which is discussed in more detail in 
section 2.2.3. 
The use of undifferentiated cell lines for neuroscientific research pose several issues: prior to 
differentiation these cell lines often lack several receptors, either in expression or functionality, 
that would be required for the basic properties of a neuron such as the expression of the NMDA 
receptor (211). Whilst primary cultures were once the method of choice in this area, there is 
increasingly a call to minimise the use of animals in research (212). Furthermore, it can be 
difficult to obtain sufficient tissue from primary cultures for robust biochemical analysis. SH-
SY5Y cells were derived from a bone marrow biopsy of a 4 year old girl and are present in two 
forms: the S-phase, which are free floating and are not subject to differentiation, and the N-
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phase, which are adherent cells, and which can be readily differentiated with a number of 
compounds as outlined above and discussed in detail below (206,213) 
Whilst many protocols exist for differentiation of SH-SY5Y cells to a neuronal phenotype, 
undifferentiated fibroblast-like cells can remain within the culture (see image 3.1). 
Furthermore, S-phase cells can continue to divide and be present undifferentiated in the 
cultures after differentiation protocols, making the analysis of compounds which are known to 
act on neurons problematic (206). Successful differentiation to a neuronal culture requires large 
amounts of maintenance, or alternatively a complex and expensive perfusion pump system, or 
the addition of neurotrophic factors (205,214,215). Thus, there are a number of different 
differentiation agents which have been reported to give rise to neuronal differentiated SH-
SY5Y cultures characterised by the expression of neuron-specific markers such as NeuN (216) 
and βIII Tubulin (216). Phorbol esters such as 12-0-tetradecanoyl-phorbol-13-acetate (TPA) at 
80nM (217), are commonly used for research for neurons of the adrenergic phenotype (218). 
Such esters are now more often used in conjunction with retinoic acid (RA), and the 
concentration most commonly used is 10μM (218–220), but the use of RA concentrations as 
high as 75-100μM has been reported (207). Differentiating with RA for 5 days, followed by 5 
days of 50ng/ml brain-derived neurotropic factor (BDNF) gives rise to an SH-SY5Y culture 
with longer neuronal processes and cellular connections when compared to RA alone (221). 
Other growth factors such as nerve growth factor (NGF) (222) are less commonly used in SH-
SY5Y cells as they do not promote as extensive neurite outgrowth as RA (223). However, 
exogenous growth factors upregulate pathways pertaining to cell survival in addition to 
neuronal differentiation, which may restrict the use of these cells for viability screening (224–
226). A fully differentiated cell culture may be obtained with RA alone followed by the 
application of mitotic inhibitors 10mM 5-Fluorodeoxyuridine (FdUr), 10mM uridine (Ur) and 
1mM cytosine arabinoside (araC) (216). Using a perfusion pump system, the cells thrived for 
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three weeks in culture and showed more phenotypic markers of a neuronal culture including 
the presence of synapses, as compared to differentiation induced using a cocktail of growth 
factors such as NGF and BDNF (214).  
The aim was to develop a method that would not only differentiate SH-SY5Y to a neuronal 
phenotype capable of forming a functional neuronal network, but also which could be used to 
provide a simple in vitro model of cellular ageing. One of the most widely investigated theories 
of ageing centres on the accumulation of oxidative damage with age which has deleterious 
effects on cellular function (227,228).  
To build on the previous work done by Constantinescu et al. (216) cells were differentiated 
with RA before, then added a mitotic inhibitor to the culture, 5FDU, to eliminate any cells that 
remained in the cell cycle following differentiation. The culture medium was optimised for 
long term growth, analysing the differential effects of using a chemically-defined serum free 
supplement (SR-2), comparing it to serum-containing and non-supplemented media. These 
studies revealed a novel and effective way to achieve high purity neuronal cultures, which after 
4 weeks in culture expressed biomarkers of ageing. 
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3.2. Results 
3.2.1 Optimisation of SH-SY5Y cell differentiation and maintenance 
The initial phase of this study aimed to determine which culture medium promoted the most 
robust survival of RA-differentiated SH-SY5Y cells over time in culture. Initial experiments 
had determined that 5 days of 10µM RA treatment is best for SH-SY5Y neuronal 
differentiation. The next stage was to optimise the culture medium. Therefore, cells were grown 
without serum supplementation, in DMEM supplemented with 1% v/v FCS or in DMEM 
supplemented with 2% v/v SR-2. 1% v/v FCS was chosen as this is the serum concentration 
used during RA differentiation (229) and 2% v/v SR-2 was selected in accordance with the 
manufacturer’s recommendations.  
Phase contrast photomicrographs reveal that a robust neuronal phenotype is triggered by this 
differentiation protocol. Undifferentiated cells (Figure 3.1a) show a flattened morphology with 
few or short processes. Following 5 days of treatment with 10M retinoic acid (Figure 3.1a) in 
most cells the soma is rounded, and neurites have been extended from the cells. Following a 
further week’s treatment with 18M 5-FDU very few undifferentiated cells remain, and an 
extensive neurite network covers much of the culture dish, as neurite length was not a priority 
in this study this was not quantified here (Figure 3.1a). There are marked differences in the 
viability of these cells with each of the culture media (Figure 3.1). Very few cells remain in the 
serum free cultures 4 weeks after RA-differentiation (Figure 3.1c) compared to those in which 
the DMEM had been supplemented with either 1% v/v FCS or 2% v/v SR-2 (Figure 3.1c). 
Collating the data from 5 experiments, it was noted that very few, or in some cases, no cells 
survived with serum free medium on all occasions, with most or even all cells dying in 1% v/v 
FCS medium on 2 of 5 occasions. In contrast, less extensive cell death was visually apparent 
in the 2% v/v SR-2 supplemented cultures.  
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Figure 3.1 Phase contrast images of cell differentiation parameters  
a 
 
b 
 
c 
 
Figure 3.1 depicts phase contrast micrographs of the phases of cell development over time within our culture 
system, phase contrast images taken on a Nikon camera at X40 magnification in 3.1a and 3.1c. Figure 3.1a depicts 
the development of the cells from undifferentiated with an arrow depicting undifferentiated epithelial like cell, 
then treated with 10µM retinoic acid with an arrow depicting a cell which has become rounded and has undergone 
the differentiation process. Once treated for a week with mitotic inhibitor, the cells are shown again. Once the 
cells were differentiated with retinoic acid for 5 days they were transferred to media containing no serum (serum-
free, 1 % serum (1% FCS) and a serum replacement (Serum replacement 2). The cells in the serum-free condition 
diminished over time whereas the serum replacement thrived at 4 weeks. Figure 3.1c shows the cells at 4 weeks 
in serum free, 1% and serum replacement 2 with few cells remaining in the serum free condition, cells in 1% FCS 
and SR2 are still thriving. FCS = foetal calf serum, SR2 = serum replacement 2 
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3.2.2 Differentiated SH-SY5Y cells are viable in culture for 4 weeks  
To further determine whether differentiated SH-SY5Y cells could survive in long term culture 
without neurotrophins, and in the absence of a peristaltic pump, cultures of RA-differentiated 
cells were followed for up to 4 weeks after differentiation. These experiments aimed to quantify 
when, or if, the cells were dying and how the number of cells in the culture varied with time 
after RA differentiation. Only cells maintained in 2% SR-2 were followed for the remainder of 
experiments as they demonstrated highest levels of cell survival as documented from the phase 
contrast data. Therefore, in addition to the phase contrast micrographs (Figure 3.1), cultures 
maintained with 2% v/v SR-2 were assessed using lactate dehydrogenase (LDH) assay to 
determine membrane integrity as this is an indicator of cell death (230) and, DAPI imaging to 
determine nuclear number per field of view as an estimate of cell number (Figure 3.2a,b). The 
LDH data shows that the absorbance values fall from 0.223 ± 0.018 two weeks after RA 
differentiation to 0.176 ± 0.016 4 weeks after retinoic acid differentiation (P=0.003, n=6; 
Figure 3.2a). This indicates that there was less cell death occurring at 4 weeks rather than at 2 
weeks. This could be due to a loss of cells prior to 4 weeks therefore the absolute release of 
LDH could fall irrespective of the proportion of cells releasing this enzyme. It was therefore 
essential to couple this data to a measure of absolute cell number. To confirm the finding of the 
LDH experiments, the number of cells per field of view was established by analysing slides 
that had been stained with the nuclear dye DAPI for other imaging procedures (Figure 3.2). No 
significant reduction in cell number over time was detected (9.94 ± 2.66 cells per field of view 
T=2 weeks post differentiation; 6.36 ± 2.56 cells per field of view, 4 weeks post differentiation 
(P=0.76, n=7; Figure 3.2 b, c); Taken together this shows that there is no significant difference 
in the number of cells between 2 weeks and 4 week cultures. Indeed, the LDH data presents 
evidence of a reduction in dying neurons between 2 and 4 weeks. The likelihood of cells that 
remain in the cell cycle being present in the cultures will decrease with time. Thus, could be 
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attributed to a larger number of cells may be dying in the earlier stages of culture due to the 
presence of the mitotic inhibitor.  
Figure 3.2 Confirmation of cell viability between 2 and 4 weeks post differentiation 
 a       b 
 
Figure 3.2 bar charts demonstrating that cells remain viable between 2 and 4 weeks in culture. Using LDH assay 
(a) there was a significant reduction in LDH release between 2 and 4 weeks (P=0.003, n=6; Figure 3.2a) although 
no significant differences in cell number were detected using DAPI counts of cell nuclei (P=0.076, n=7; Figure 
3.2b, c). LDH = lactate dehydrogenase, DAPI = 4',6-diamidino-2-phenylindole 
 
3.2.3 SH-SY5Y cells differentiated by this novel protocol express neuronal 
markers  
To show that these cells had indeed taken on a neuronal phenotype after exposure to RA 
(216,229), the cells were fixed and stained in their undifferentiated state or 2 weeks after RA-
differentiation for the neuronal marker, β III tubulin. βIII tubulin is the primary component on 
microtubules, and this isoform is almost exclusively found in neurons (231). This was further 
supported by looking for changes in protein expression between undifferentiated and cells 2 
weeks post-differentiation by using an ELISA assay for β III tubulin and tau (Figure 3.3). The 
immunocytochemistry showed prominent staining in differentiated cells as compared to the 
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undifferentiated population (Figure 3.3a) and this staining appears to localise to extended 
neuronal process. In confirmation of this, the ELISA showed a 39.03 ± 18.6% increase in β III 
tubulin in cells 2 weeks post-differentiation compared to undifferentiated cells (P=0.002, n=5; 
Figure 3.3b). An ELISA for tau was also performed as an additional neuronal marker and here 
a 91.2 ± 43.3% increase in expression is observed in 2 week differentiated cells compared to 
the undifferentiated population (P=0.012, n=5; Figure 3.3c). This shows that the protocol 
developed here results in cells which have characteristic markers of a neuronal phenotype. 
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Figure 3.3 Monitoring of changes in neuronal marker expression: Tau and  III tubulin 
a 
 
Blue = DAPI, Green = BIII tubulin 
b       c 
 
Figure 3.3 demonstrates that there is an increase in the expression of neuron-specific βIII tubulin post-
differentiation as determined by an increase in βIII tubulin immunostaining (a) and this was supported by a βIII 
ELISA, showing an increase to 139.0 ± 18.6% relative to undifferentiated cells in 2-week post-differentiation 
cells (P=0.002, n=5; Figure 3.3b). An ELISA for tau was also used to support the presence of other neuronal 
markers which showed an increase in tau expression to 191.2 ± 43.3% in 2 week differentiated cells relative to 
undifferentiated cells, (P=0.012, n=5; Figure 3.3c).  
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3.2.4 Differentiation with retinoic acid followed by mitotic inhibitions using 5-
FDU produces SH-SY5Y cells of a dopaminergic phenotype 
To determine whether these cells were differentiating to a dopaminergic phenotype as reported 
in the literature (232), the expression of tyrosine hydroxylase, the rate limiting enzyme in 
dopamine biosynthesis (233), was determined using immunocytochemistry on fixed cells and 
ELISA on protein extracts. Immunocytochemical staining demonstrated prominent 
immunoreactivity for TH in 2 week post-differentiation cells, with an absence of this 
dopaminergic biomarker in undifferentiated cells (Figure 3.4a). In support of this, there was 
54+ 25.8% increase in the expression of tyrosine hydroxylase (TH) (P=0.035, n=4; Figure 
3.4b) between undifferentiated cultures and 2-week post-differentiation neurons as determined 
using ELISA assay (Figure 3.4b).  
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Figure 3.4 Once differentiated, SH-SY5Y cells express markers of dopaminergic neurons 
a 
 
b 
 
Figure 3.4 Using immunocytochemistry and ELISA, the expression of TH, a marker of dopamine biosynthesis 
was examined. There was an increase in TH expression observed in the ICC (Figure 3A) and this was backed up 
by an ELISA assay demonstrating a significant increase in TH expression between undifferentiated and 
differentiated cells by 154.0 ± 25.8% (P=0.035, n=4; Figure 3.4b). TH = tyrosine hydroxylase, ICC = 
immunocytochemistry, ELISA = Enzyme linked immunosorbent assay. 
3.2.5 SH-SY5Y cells differentiated using this novel protocol form synapses and 
exhibit electrophysiological activity 
One of the defining features of a neuronal population is the ability to form synaptic connections 
and a functional neuronal network (234). Therefore, it was important to establish the presence 
of synapses in the differentiated cultures and furthermore, it was important to determine that 
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any synapses present were functional. The data shown in figure 3.5a and 3.5b were from 
experiments conducted in collaboration with Dr GB Miles, University of St Andrews. These 
figures detail representative electrophysiological patch clamp recordings from the cells at 2 
weeks post-differentiation. The inward sodium current was measured which gave a potential 
of -60mV, this is typical of normal neurons (235), furthermore the cells were capable of 
forming spontaneous action potentials as can be seen in figure 3.5a-b. Immunocytochemical 
staining for the synaptic marker, synapsin, was used to determine whether synapses were 
present. The images here show widespread synaptic staining using this marker which was not 
observed in the absence of primary antibody (Figure3.5c). Together these data show that by 2 
weeks post differentiation these cells are forming functional synaptic connections with one 
another. 
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Figure 3.5 Using this differentiation protocol, these cells display several key neuronal features  
a      b 
    
 
c 
 
Blue = DAPI, Green = Synapsin 
Figure 3.5 demonstrates that from as early as 2weeks post removal of retinoic acid, these cells exhibit synapses 
and a sodium current of -60mV which is in keeping with a typical neuron (a). Furthermore, spontaneous action 
potentials were generated from these cells, further supporting neuronal physiology (b). Robust immunoreactivity 
for synapsin is also apparent on these cells (c).   
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3.2.6 Cells prepared using this protocol show accumulations of oxidative damage 
to lipids with time in culture 
A key feature of neuronal cell ageing is the accumulation of oxidative damage to DNA, RNA 
proteins and lipids (236). Although there is no definitive limits in place for cell damage which 
would define a cell as aged, the progressive accumulation of oxidative damage with time is 
proposed as a valid in vitro model as it replicates the in vivo build-up of oxidatively damaged 
cellular components (237). To determine whether any alterations in oxidative damage to lipids 
occurs with time in culture, immunocytochemistry (ICC) was used to detect 4-hydroxynonenol 
(HNE) (Figure 3.6). Formation of HNE results from oxidation of phospholipids containing ω-
6 polyunsaturated fatty acyl chains and therefore HNE presence is a widely used as a marker 
of oxidatively damaged lipids (238). The intensity of the cellular staining from ICC showed an 
increase in positive staining between 2 and 4 weeks (Figure 3.6a). The staining appeared to 
localise to the cell membranes and was also apparent along neuronal processes. Although 
immunoreactivity was observed 2 weeks post retinoic acid differentiation there was a 
substantial increase in the staining intensity by 4 weeks post differentiation. This data was 
supported by an HNE ELISA wherein there was a 49.9 ± 23.1% increase in HNE levels 
(P=0.003, n=5; Figure 3.6b) between 2 and 4 weeks post retinoic acid differentiation. Together 
these data show that with time in culture, SH-SY5Y cells differentiated and maintained by this 
novel protocol show accumulating HNE levels which is a well-established biomarker of lipid 
peroxidation. 
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Figure 3.6 Cells accumulate lipid peroxidation after 4 weeks in culture 
a 
 
b      c 
 
Figure 3.6 shows that in cultures stained 2 and 4 weeks, after retinoic acid differentiation an increase in positive 
HNE staining was observed. This was supported by an ELISA showing an increase in HNE expression between 
the 2 time points by 49.9 ± 23.1% (P=0.003, n=5; Figure 3.6b). Furthermore, in cells cultured for 2 and 4 weeks 
there was a 45.3% ±16.3% increase in DNA methylation between the 2 time points (P=0.05 n=3; Figure 3.6c). 
HNE = 4-hydroxy-2-nonenal, ELISA = enzyme-linked immunosorbent assay. 
3.2.7 In this culture system, SH-SY5Y cells exhibit an increase in ROS generation 
over time and reduction of mitochondrial activity  
 It is well established that an accumulation of oxidative damage and an increase in ROS 
generation is observed in neuronal ageing (239). To determine whether there was a modulation 
of ROS generation between 2 and at 4 week post differentiation in this culture system, the cells 
were imaged using the live cell dye H2- DCFDA. This dye binds ROS in live cells and 
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fluoresces green upon binding. Therefore, fluorescence intensity will reveal the relative amount 
of ROS in each condition. There was a very clear difference in the levels of ROS detected in 2 
weeks and 4 week post-differentiation cultures (Figure 3.7a) with a marked increase in intensity 
by 4 weeks. Quantification of signal intensity through image analysis shows that there is a 
highly significant increase in the generation of ROS with time in culture from 164055 ± 42348 
a.u. per cells at 2 weeks to 862539 ± 299320 a.u. per cell at 4 weeks post differentiation 
(P=0.000, n=8; Figure 3.8b).  
As mitochondria are the major site of ROS generation (240), an MTT assay was used as a 
measure of mitochondrial activity 2 and 4 weeks post differentiation. This reaction measures a 
reduction of MTT believed to be due the activity (at least in part) of succinate-dehydrogenase 
(240).  There is a reduction in mitochondrial activity which is not due to cell loss (see figure 
3.2). Thus, the level of MTT reduction 4 weeks post differentiation was only 37.7 ± 4.1% 
(P=0.000, n=3; Figure 3.8c) of that observed 2 weeks post differentiation. This implies that 
mitochondrial function is declining over time and as such may explain the increased level of 
ROS produced.   
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Figure 3.7 Impact of time in culture on markers of oxidative stress 
a 
 
b       c 
 
Figure 3.7a shows cells at 2 and at 4 weeks which had been imaged using the live cell dye, DCF-DA; this is 
represented in graphical form in panel c as arbitrary units (au). Panel c shows an increase in ROS with age 
(P=0.000, n=8; Figure 3.7a). Oxidative stress is a known marker shows a significant reduction in mitochondrial 
activity (P=0.000, n=3; Figure 3.7c). DCF-DA = 2',7' –dichlorofluorescin diacetate, ROS = reactive oxygen 
species 
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3.3 Discussion 
The neuroblastoma cell line SH-SY5Y is a commonly used cell line in neurodegenerative 
research, as it expresses a neuronal phenotype and endogenously expresses the genes APP, tau 
and PS1, which are linked to familial Alzheimer’s disease (241,242). Furthermore, these cells 
can be differentiated to express an adrenergic, cholinergic or dopaminergic phenotype by using 
differentiating agents such as growth factors, phorbol esters and staurosporine (219,243). RA 
induced differentiation is by far the most well categorised protocol for differentiation and gives 
rise to a dopaminergic phenotype (167). Frequently RA is used in conjunction with growth 
factors  to promote upregulation of gene expression of neuronal markers and promotes neurite 
outgrowth (221). By using RA as a differentiating agent and a simple protocol post-
differentiation, we have established that the human neuroblastoma cell line SH-SY5Y 
expresses key neuronal markers and is physiologically similar to neurons. Furthermore, it was 
possible to use this protocol to model cell ageing in culture (as defined by the accumulation of 
oxidative biomarkers) within 4 weeks.  
Other systems for using this cell line for long term culture have included using growth factors 
such as NGF and BDNF (221) and complex systems for maintaining the cell line (159). 
Although maintenance of growth factors in culture would be highly advantageous, the expense 
of setting up such a system would be significant. In lieu of growth factor supplementation, the 
perfusion pump system offers a unique alternative that would be an initially costly venture and 
furthermore, for communal work areas this may not be suitable. With regular and consistent 
medium changes, and careful handling, this study has demonstrated that it is possible to 
maintain these cells for at least 4 weeks on glass coverslips and within nunc coated dishes (both 
24 and 96 well).  
These results show that the most effective medium for maintaining SH-SY5Y cells in culture 
for 4 weeks is using chemically-defined medium. A commercially produced serum replacement 
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formulation, SR2, was assessed which has the advantage of giving rise to more consistency. 
SH-SY5Y cells have the potential to be maintained for longer than the 4 weeks, and this was 
investigated here: on two occasions cells were maintained for 6 weeks. However, the cells were 
lost in the fixation step, therefore further steps would have to be taken to ensure the coverslip 
was coated- in these experiments coating with poly lysine was sufficient. Subsequent coating 
with laminin, fibronectin or matrigel may enhance cell adhesion. In prostate cancer cells,  
fibronectin, poly-L-lysine and poly-L-ornithine enhanced cell adhesion, however, laminin and 
collagen type IV did not promote cell adhesion and promoted cell aggregation (244). Therefore, 
a robust evaluation of cell adhesion matrices would be warranted if it was necessary to maintain 
the cultures for more than 4 weeks.  
Using this protocol, it was shown that these cells express the neuronal markers β III tubulin, 
tau and tyrosine hydroxylase post-differentiation thus showing that these are dopaminergic 
neurons in culture. Furthermore, what has never been shown in these differentiated cultures 
until now is the presence of functional synapses. Herein is demonstrated positive 
immunoreactivity for the presynaptic marker, synapsin I, and this is supported with 
electrophysiological recordings showing that these cells are capable of firing spontaneous 
action potentials and that they have a sodium current typical of neurons. This could have been 
further examined using FM4-64 to determine actively firing neurons by cell staining as the dye 
is taken up by synaptic vesicles during neurotransmitter release and reuptake, furthermore a 
post-synaptic marker could have been examined. This protocol for neuronal differentiation is 
valuable as it gives rise to markers which are associated with neuronal ageing but does not 
result in excess cell death making study of cellular damage possible without specialist 
equipment.   
Current theories of ageing suggest that as neurons age, they accumulate damage through 
generation of oxidative stress and therefore accumulate oxidative damage to DNA, RNA, lipids 
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and proteins (236). Studying ageing presents many challenges and predominantly, models are 
time consuming include longitudinal human studies, rodent and avian models (245). Using the 
method developed in this study, it will be possible to study the underlying mechanisms of 
cellular ageing and to examine potential pharmacological means of deterring the deleterious 
effects of ageing over a short time (i.e. 4 weeks) using human derived cells in vitro. In this 
study, these cells begin to show signs of oxidative damage to lipids as well as an increase in 
the generation of ROS. These are signs that are characteristic of ageing. This phenotype may 
be indicative of an impairment of the cellular capacity to deal with the increase in the generation 
of ROS and therefore it is possible that the antioxidant capacity of the cell may be reduced 
(228,246). Furthermore, this study has shown that there is reduction in mitochondrial activity 
without a concurrent reduction in cell number which may represent a loss of mitochondria or 
may suggest that the mitochondria are ageing, and that the accumulation of damage therein has 
reduced their functional capacity. Therefore, it would be interesting in the future to further 
examine the effects of ageing on the mitochondria and mitochondrial DNA.   
In conclusion, this chapter established a novel method of culturing functional neuronal cells 
from the SH-SY5Y cell line which can rapidly represent an ageing phenotype. This will be an 
invaluable resource for future research on ageing.  
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CHAPTER 4: HOMOCYSTEINE THIOLACTONE AS A NEUROTOXIN  
77 
 
4.1 Introduction 
HCy has been widely implicated in a plethora of cardiovascular and neurodegenerative 
disorders (15,107,247–250). In addition to excretion from the body, homocysteine has several 
other fates which are not conducive to optimal health (251). Further to HCy itself, there are 
many other derivatives which may be toxic in their own right. One such derivative is HCy-T, 
which is generated in cells by an error editing reaction by methionyl tRNA synthase enzyme 
(252). HCy-T is a highly reactive cyclic compound and has the capability to bind lysine 
residues on proteins and incorporate HCy in forming N-homocysteineylated proteins, thereby 
impairing structure and function (252). HCy-T can be converted back to homocysteine in a 
hydrolytic pathway by bleomycin hydrolase (127). 
There is little data to date on the cellular effects of HCy-T. However it is frequently used to 
induce seizures in rodents (253–255) and has been implicated in cardiovascular disease 
(129,249). There are currently two proposed mechanisms of action for these seizure effects 
namely that HCy-T modulates the nitric oxide system, and in particular inhibits the actions of 
iNOS (254); or that it acts on the GABAergic system, which has also been shown with HCy 
(255,256). The GABAergic system is the main inhibitory system in the nervous system and has 
been strongly linked with seizures (257). Some of the toxic actions mediated my HCy may be 
ameliorated by blockade of the GABA-A receptor with the use of muscinol (258). When 
muscinol was added in conjunction with HCy, there was a reduction in ROS generation and a 
suppression of phosphorylated ERK (258). These features have also been associated with the 
blockade of the NMDA receptor but as these systems are interconnected, there may be some 
crossover or additive effects of HCy actions at the NMDA and GABA receptors, this may 
provide some insight into the actions of HCy-T. In addition HCy-T has been show to induce 
degeneration of retinal cells (259), this was attributed to an increase in homocysteinylation 
when concentrations of up to 200µM were introduced. 
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The proportion of HCy converted to HCy-T is approximately 60% (260), and there is the 
potential for cells to convert HCy back to methionine or to cysteine as part of the remethylation 
or transsulferation pathways respectively (Figure 1.1). However, the breakdown of HCy-T is 
much more complex, and therefore although HCy-T may be less abundant than HCy, it has the 
potential to remain intact for much longer (260). Furthermore, HCy-T has been linked to 
protein aggregation, which is a common factor in the development of almost all 
neurodegenerative diseases and in normal ageing (261).  
HCy is an agonist at the NMDA receptor at the glutamate binding site and a partial agonist at 
the glycine binding site (112) and toxicity mediated by HCy can be prevented by the addition 
of NMDA receptor channel blockers (155,262–264). The aim of these experiments was to 
explore whether HCy-T was neurotoxic and whether it exerted any neurotoxic responses 
through activation of the NMDA receptor. 
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4.2 Results  
4.2.1 Neither homocysteine nor homocysteine thiolactone are cytotoxic to 
undifferentiated SH-SY5Y cells 
It has previously been reported that undifferentiated SH-SY5Y cells only express the GluN1 
subunit of the NMDA receptor (256). Therefore, if HCy or HCy-T require activity of the 
GluN2A subunit to mediate a cytotoxic response, as reported previously for HCy (155), neither 
reagent should be neurotoxic to SH-SY5Y cells in their undifferentiated state. Therefore, 
undifferentiated SH-SY5Y cells were treated with a range of concentrations of HCy from 50-
200M (figure 4.1a and c) or 50-200M HCy-T (figure 4.1b and d) for 120 hours. The toxicity 
of HCy and HCy-T was determined by MTT and LDH assays. There was no significant 
reduction in cell number even at the highest concentration tested, 200µM HCy with 91.5 ± 
2.6% mitochondrial activity relative to untreated control as determined by MTT assay (P 
=0.622, n=3; Figure 4.1a). This was supported by a LDH assay which showed, at the same 
concentration 85.5 ± 9.0 LDH release relative to untreated control (P =0.070, n=3; Figure 4.1c). 
MTT assay revealed that 200µM HCy-T resulted in 93.0 ± 3.2% relative to untreated control 
(P =0.347, n=3; Figure 4.1b). This was supported by LDH assay with 92.7 ± 11.0% LDH 
release relative to untreated control (P=0.452, n=3; Figure 4.1d).  
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Figure 4.1 Neither homocysteine nor homocysteine thiolactone are cytotoxic to 
undifferentiated SH-SY5Y cells 
a       b      
 
c       d 
 
Figure 4.1 Bar charts demonstrating the dose response of undifferentiated SH-SY5Y cells to HCy and HCy-T 
from 50 to 200 µM, this was determined by MTT and LDH assays. There was no significant reduction in cell 
number even at the highest concentration tested, 200µM HCy with 91.5 ± 2.6% (P =0.136, n=3; Figure 4.1a), 
MTT relative to untreated control, this was supported by an LDH assay which showed the same concentration 
85.5 ± 9.0 (P =0.088, n=3; Figure 4.1c). MTT assay revealed that 200µM HCy-T with 93.0 ± 3.2% (P =0.331, 
n=3; Figure 4.1b) relative to untreated control, this was supported by LDH assay with 92.7 ± 11.0% (P=0.053, 
n=3; Figure 4.1d). MTT assay = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium, LDH = lactate 
dehydrogenase, HCy = homocysteine, HCy-T = homocysteine thiolactone.  
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4.2.2 Retinoic acid differentiation upregulates expression of GluN2A 
One possible explanation for the lack of cytotoxic response to either HCy or HCy-T in 
undifferentiated SH-SY5Y cells is that these cells lack the GluN2A subunit reported to 
mediated their neurotoxicity (155). Furthermore, to determine whether differentiated SH-
SY5Y cells are a useful model of HCy neurotoxicity and signalling it was necessary to 
determine whether GluN2A was expressed following retinoic acid differentiation. The 
literature reports both the absence (256) and presence of GluN2A post differentiation (256) and 
therefore re-evaluation was deemed necessary. Therefore, both undifferentiated and retinoic 
acid differentiated SH-SY5Y cells were used to determine the expression of GluN2A. An 
ELISA assay was used to determine the level of GluN2A expression in undifferentiated and 
differentiated SH-SY5Y cells and here a 32.4 ± 20.6% (P=0.036, n=4; Figure 4.2b) increase 
following differentiation was recorded.   
Figure 4.2 Expression of GluN2A increases following retinoic acid differentiation after 5 days 
a        
 
 
Figure 4.3: This figure shows that there is an increase in the expression in GluN2A in differentiated SH-SY5Y 
cells compared to undifferentiated cells. This was determined ELISA where there was a 32.4 ± 20.6% increase 
(P=0.036, n=4; Figure 4.2b) in GluN2A expression (STATS). ELISA = enzyme linked immunosorbent assay. 
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4.2.3 Both homocysteine and homocysteine thiolactone are neurotoxic to 
differentiated SH-SY5Y cells 
Having established that retinoic acid-induced differentiation upregulates the expression of the 
GluN2A subunit of the NMDA receptor previously reported to be integral to HCy-mediated 
toxicity (155), dose responses to both HCy and HCy-T were established. Cell viability was 
determined using a combination of both CV assay and LDH assay to determine cell number 
and membrane permeability, respectively. After 120 hours treatment with HCy, a significant 
reduction in cell number was observed at 100 and 200µM HCy showing a reduction of 71.5 ± 
4.2% (P = 0.010 n=8; Figure 4.3a) and 63.2 ± 4.4% (P = 0.001, n=8; Figure 4.3a). After 120 
hours in culture, there was no significant decrease in viability at any concentration below this 
as determined by either CV (Figure 4.3a) or LDH with 100 and 200µM HCy showing an 
increase in LDH release of 124.0 ± 7.9% (P = 0.045, n=6; Figure 4.3b) and 131.0 ± 4.6% (P = 
0.008, n=6; Figure 4.3b) respectively. After 120 hours exposure to 100µM HCy-T, in 
comparison to the untreated control, only 65.2 ± 10.4% of cells remained in the culture as 
determined by CV assay (P=0.007; n=8; Figure 4.3c). Accordingly, a significant increase in 
LDH release was detected in 100µM HCy-T treated cultures 118.1 ± 5.1% (P=0.002, n=23; 
Figure 4.3d). Together these data reveal that differentiated SH-SY5Y cells are vulnerable to 
both HCy and HCy-T and this contrasts with the findings for this cell line in its undifferentiated 
state.  
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Figure 4.3 Both homocysteine and homocysteine thiolactone are neurotoxic to differentiated 
SH-SY5Y cells 
a      b 
 
c      d    
 
Figure 4.3: Differentiated SH-SY5Y cells treated for 5 days with HCy (a-b) or HCy-T (c-d), were assayed for 
viability in response to a range of concentrations of each metabolite by CV (a, c) or LDH (b, d) assay. For HCy 
after 120 hours a significant reduction in cell number was observed at 100 and 200µM HCy showing a reduction 
of 71.5 ± 4.2% (P = 0.001 n=8; Figure 4.3a) and 63.2 ± 4.4% (P = 0.0004, n=8; Figure 4.3c) HCy-T, after 120 
hours in culture, there was no significant decrease in viability any concentration below this as determined by either 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
Control 50µM
HCy
100µM
HCy
200µM
HCy
P
er
ce
n
ta
g
e 
ce
ll
 n
u
m
b
er
:u
n
tr
ea
te
d
 
co
n
tr
o
l
0.0
20.0
40.0
60.0
80.0
100.0
120.0
Control 50µM
HCy-T
75µM
HCy-T
100µM
HCy-T
P
er
ce
n
ta
g
e 
ce
ll
 n
u
m
b
er
:u
n
tr
ea
te
d
 c
o
n
tr
o
l
**
0
20
40
60
80
100
120
140
160
Control 50µM
HCy
100µM
HCy
200µM
HCy
L
D
H
 r
el
ea
se
:u
n
tr
ea
te
d
 c
o
n
tr
o
l
* **
0
20
40
60
80
100
120
140
Control 50µM
HCy-T
75µM
HCy-T
100µM
HCy-T
L
D
H
 r
el
ea
se
:u
n
tr
ea
te
d
 c
o
n
tr
o
l
**
*** 
*** 
84 
 
CV or LDH with 100 and 200µM HCy showing an increase in LDH release of 124.0 ± 7.9% (P = 0.045, n=6; 
Figure 4.3b) and 131.0 ± 4.6% (P = 0.008, n=6; Figure 4.3b) HCy. However, after 120 hours exposure to 100µM 
HCy-T, in comparison to the untreated control only 65.2 + 10.4% of cells remained in the culture as determined 
by CV assay (P = 0.007; n=8; Figure 4.3c). Accordingly, a significant increase in LDH release was detected in 
100mM HCy-T treated cultures 118.1 + 5.1% (P = 0.002; n=23; Figure 4.3d). HCy = homocysteine, HCy-T = 
homocysteine thiolactone, LDH = lactate dehydrogenase, CV assay = crystal violet assay.  
4.2.4 Homocysteine thiolactone toxicity is ameliorated by blockade of the NMDA 
receptor with Mk801 
It is well documented that HCy is neurotoxic by acting on the glutamate binding site of the 
NMDA receptor and is also a partial agonist at the glycine binding site of the receptor (112). 
Many studies have shown that blockade of the NMDA receptor in a competitive and non-
competitive manner is sufficient to ameliorate HCy-mediated cell loss (112). As HCy-T 
induces seizures in rodents that are linked to NMDAR over-activation, the possibility that HCy-
T neurotoxicity is mediated via NMDAR was investigated (265). Therefore, retinoic acid 
differentiated SH-SY5Y cells were incubated with either 50 or 100M HCy-T (Figure 4.3) 
alone or in combination of 0.2µM non-competitive NMDAR antagonist Mk801, although this 
blocker is only affective upon activation of the receptor (149). In confirmation of the previous 
findings there was no decrease in SH-SY5Y viability with 50M HCy-T (Figure 4.4b). As 
above there was a significant decrease in cell number relative to control after 120h incubation 
with 100M HCy-T 21.2 ± 3.4% (P=0.014, n=6; Figure 4.4b), but very little difference 
detected following co-administration of MK801 19.7 + 7% decrease in survival relative to 
control although the latter was no longer statistically significantly different to control 
(P=0.295, n=6; Figure 4.4b, d). The data derived from LDH assay clearly showed that HCy-T 
increases membrane permeability with a 21.7 ± 4.6% increase relative to the untreated control 
after 120h (P=0.000, n=14; Figure 4.4d).  However, in the presence of Mk801, only a 13.1 ± 
3.3% increase in LDH was detected which was not different to control (P=0.122, n=14; Figure 
4.4d). Taken together these data imply that HCy-T toxicity is indeed mediated via the NMDAR. 
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The same experiments were conducted using HCy at a range of concentrations to 100µM HCy 
with co-application of 2µM Mk801 to ensure that HCy could be blocked with Mk801 as has 
been shown from other groups. No significant results were obtained with CV assay with 
100µM reduction to 75.4 ± 13.4% (P=0.312, n=4; Figure 4.4a) this was a result to issues with 
the assay as an original n=11 was conducted but had to be excluded as they did not meet the 
criteria of 20% cell death with toxin alone. Using LDH it was not possible to support previous 
results and it was shown that application of 100µM HCy caused a 124.0 ± 7.9% increase in 
LDH (P=0.045, n=6; Figure 4.4c), there was no significant decrease when 2µM Mk801 was 
co-applied 124.9 ± 5.6% (P=0.057, n=6; Figure 4.4c) but the data for Mk801 administration 
was not significantly different to control viability.  
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Figure 4.4 Homocysteine thiolactone cell death may partially be ameliorated with Mk801 
a      b  
 
c      d 
 
Figure 4.4 As above there was a significant decrease in cell number relative to control after 120h incubation with 
100µM HCy-T 21.2 ± 3.4% (P=0.014, n=6; Figure 4.4b). Co-administration of MK801 caused a 19.7 + 7% 
decrease in survival relative to control (P=0.275, n=6; Figure 4.4b, d). The LDH assay showed that HCy-T 
increases membrane permeability with a 21.7 ± 4.6% increase relative to the untreated control after 120h 
(P=0.009, n=14; Figure 4.4d).  However, in the presence of Mk801, a 13.1 ± 3.3% increase in LDH was detected 
which was different to control (P=0.033, n=14; Figure 4.4d). Using 100µM HCy with co-application of 2µM 
Mk801 there was no significant results with CV assay 75.4 ± 13.4% (P=0.193, n=4; Figure 4.4a) Using LDH it 
was shown that 100µM HCy caused a 124.0 ± 7.9% increase in LDH (P=0.04, n=6; Figure 4.4c), there was no 
significant increase when 2µM Mk801 was co-applied 124.9 ± 5.6% (P=0.057, n=6; Figure 4.4c). HCy = 
homocysteine, HCy-T = homocysteine thiolactone, LDH = lactate dehydrogenase, CV assay = crystal violet assay. 
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4.2.5 Homocysteine thiolactone toxicity is ameliorated by blockade of the NMDA 
receptor with D-L APV 
Retinoic acid differentiated SH-SY5Y cells were incubated with either 50 or 100M HCy-T 
(refer to figure 4.3) alone or in combination of 200µM competitive NMDAR antagonist, D-L 
APV (187). As above there was a significant decrease in cell number relative to control after 
120h incubation with 200M HCy (68.9 ± 7.4%, P=0.412, n=2; Figure 4.4a), but very little 
difference detected following co-administration of APV 69.3 + 1.7% decrease in survival 
relative to control although the latter was no longer statistically significantly different to control 
(P=0.101, n=2; Figure 4.4a). The data derived from LDH assay clearly showed that HCy 
increases membrane permeability with a 114.0 ± 1.0% increase relative to the untreated control 
after 120h (P=0.006, n=4; Figure 4.5c).  However, when APV was co-administered with HCy, 
none of the concentrations were significantly increased compared to untreated control with 
200µM showing an increase to 116.3 ± 2.6% increase in LDH (P=0.067, n=4; Figure 4.5c). In 
confirmation of the previous findings there was no decrease in SH-SY5Y viability with 50M 
HCy-T (Figure 4.4b, d). As above there was a significant decrease in cell number relative to 
control after 120h incubation with 200M HCy-T 70.4 ± 3.3%, (P=0.014, n=5; Figure 4.4b), 
but very little difference detected following co-administration of APV 92.8 + 11.3% decrease 
in survival relative to control although the latter was no longer statistically significantly 
different to control (P=1.000, n=5; Figure 4.4b). The data derived from LDH assay clearly 
showed no significant increase relative to the untreated control after 120h (P=0.298, n=8; 
Figure 4.5d).  Together the data demonstrate that the HCy or HCy-T treated cultures did not 
significantly differ from those co-treated with 200µM D-L APV.  
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Figure 4.5 Cell death is not ameliorated with D-L APV 
a       b 
 
 
c       d  
 
Figure 4.5 shows a significant decrease in cell number relative to control after 120h incubation with 200M HCy 
68.9 ± 7.4% (P=0.412, n=2; Figure 4.5a) but very little difference detected following co-administration of APV 
69.3 + 1.7% decrease in survival relative to control; Figure 4.5a although the latter was no longer statistically 
significantly different to control (P=0.101, n=2; Figure 4.5a). Figure 4.5c showed that HCy increases membrane 
permeability with a 114.0 ± 1.0% increase relative to the untreated control after 120h (P=0.006, n=4; Figure 4.5c).  
However, in the presence of 200µM APV there were no significant differences in any condition, with 200µM 
showing an increase to 116.3 ± 2.6% increase in LDH (P=0.067, n=4; Figure 4.5c). In confirmation of the previous 
findings there was no decrease in SH-SY5Y viability with 50M HCy-T Figure 4.4b, d. As above there was a 
significant decrease in cell number relative to control after 120h incubation with 200M HCy-T 70.4 ± 3.3% 
(P=0.014, n=5; Figure 4.4b) but very little difference detected following co-administration of APV 92.8 + 11.3% 
decrease in survival relative to control although the latter was no longer statistically significantly different to 
control (P=1.000, n=5; Figure 4.4b). The data derived from LDH assay clearly showed no significant increase 
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relative to the untreated control after 120h (P=0.298, n=8; Figure 4.5d). HCy = homocysteine, HCy-T = 
homocysteine thiolactone, LDH = lactate dehydrogenase, CV assay = crystal violet assay.   
4.2.6 Homocysteine thiolactone and homocysteine toxicity is not potentiated by 
co-administration of NMDA receptor co-agonist glycine 
As HCy is a partial antagonist of the NMDAR through its actions on the glycine binding site 
of the receptor, it has previously been documented that co-administration of glycine with HCy 
potentiates its neurotoxicity as glycine out-competes HCy for access to the co-agonist site 
(112). Differentiated SH-SY5Y cells were cultured with a range of concentrations from 0 to 
100µM HCy together with 100µM glycine (Figure 4.6a-d). There was a significant decrease in 
cell number relative to control after 120h incubation with 100M HCy (72.9 ± 1.6% P=0.006, 
n=8; Figure 4.6a), following co-administration of glycine, 100µM showed no further reduction 
to 60.1 ± 7.7 (P=0.145, n=4; Figure 4.6a). The data derived from LDH assay clearly showed 
that 200M HCy increases membrane permeability to 121.8 ± 3.9% relative to the untreated 
control after 120h (P=0.039, n=4; Figure 4.5c).  When co-applied with glycine, no 
concentrations were significantly increased compared to untreated control with 200µM HCy 
with 100µM glycine showing an increase to 134.0 ± 6.1% increase in LDH was detected 
(P=0.140, n=4; Figure 4.5c). There was a significant decrease in cell number relative to control 
after 120h incubation with 100M HCy-T 65.2 ± 10.4%, (P=0.603, n=8; Figure 4.4b), but very 
little difference detected following co-administration of glycine 54.8 + 13.4% decrease in 
survival relative to control (P=0.023, n=4; Figure 4.4b). The data derived from LDH assay 
clearly showed no significant increase relative to the untreated control after with concentrations 
up to 100µM HCy-T at 120h to 116.8 ± 7.3% (P=0.509, n=3; Figure 4.5d). However, when 
100µM glycine was added in conjunction there was no significant increase in lactate 
dehydrogenase released at any concentration to 122.7 ± 10.2% (P=0.899, n=3; Figure 4.5d). 
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Taken together, glycine has not been shown to potentiate both HCy and HCy-T toxicity as 
determined by CV and LDH assays.   
Figure 4.6 Homocysteine thiolactone and homocysteine toxicity is not potentiated by co-
administration of NMDA receptor co-agonist glycine 
a       b 
   
c       d 
 
Figure 4.6 5 shows a significant decrease in cell number relative to control after 120h incubation with 100M 
HCy 63.2 ± 4.4% (P=0.006, n=8; Figure 4.6a) co-application of glycine showed no significant reduction to 60.1 
± 7.7 (P=0.145, n=4; Figure 4.6a). The data derived from LDH assay clearly showed that 200µM HCy increases 
membrane permeability to 121.8 ± 3.9% increase relative to the untreated control after 120h (P=0.039, n=4; 
Figure 4.5c).  However, in the presence of glycine, co-administration of no concentrations of HCy were 
significantly increases compared to untreated control with all concentrations tested showing an increase to 134.0 
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± 6.1% increase in LDH was detected which was not different to control (P=0.140, n=4; Figure 4.5c). 100M 
HCy-T showed a reduction in cell number to 65.2 ± 10.4%, (P=0.603, n=8; Figure 4.4b), but very little difference 
detected following co-administration of glycine 54.8 + 13.4% decrease in survival relative to control (P=0.509, 
n=4; Figure 4.4b). The data derived from LDH assay clearly showed no significant increase relative to the 
untreated control after with concentrations up to 100µM HCy-T at 120h to 116.8 ± 7.3% (P=0.518, n=3; Figure 
4.5d). However, when 100µM glycine was added in conjunction there was no significant increase in lactate 
dehydrogenase released at any concentration of HCy-T to 122.7 ± 10.2% (P=0.899, n=3; Figure 4.5d) HCy = 
Homocysteine, HCy-T = homocysteine thiolactone, CV=crystal violet assay, LDH = lactate dehydrogenase.   
4.2.7 Homocysteine thiolactone toxicity is not potentiated by co-administration of 
NMDA receptor co-agonist D-serine 
As it was shown that glycine potentiated HCy and HCy-T toxicity, it was important to 
determine if other agonists of the NMDA receptor had the same effect. Therefore, to further 
substantiate whether the NMDAR was central to HCy-T-mediated neurotoxicity, differentiated 
SH-SY5Y cells were cultured with a range of concentrations of from 0 to 200µM HCy or HCy-
T together with 10µM D-serine (266) (Figure 4.7a-d). There was a significant decrease in cell 
number relative to control after 120h incubation with all concentrations up to 200M HCy 63.2 
± 4.4% (P=0.001, n=8; Figure 4.7a), but no difference could be determined following co-
administration of D-serine 59.8 + 15.6% (P=0.092, n=4; Figure 4.7a). The data derived from 
LDH assays showed a significant increase with 200µM HCy in LDH to 115.1 ± 18.5% 
(P=0.033, n=4; Figure 4.7c). There was again no difference with co-administration of D-serine 
at any of the concentrations of HCy tested, with 200µM HCy showing no significant difference 
(P=0.380, n=2; Figure 4.7c). There was no significant decrease in cell number relative to 
control after 120h incubation with 100M HCy-T (65.2 ± 10.4%, (P=0.603, n=8; Figure 4.7b), 
and no difference detected following co-administration of D-serine 57.4 + 14.7% (P=0.382, 
n=4; Figure 4.7b). The data derived from LDH assay clearly showed no significant increase 
relative to the untreated control after with concentrations up to 100µM HCy-T at 120h to 107.7 
± 10.2% (P=0.819, n=4; Figure 4.5d). However, when 10µM D-serine was added in 
conjunction there was still no significant increase in lactate dehydrogenase released at any 
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concentration of HCy-T (P=0.380, n=4; Figure 4.5d). Therefore, application of D-serine does 
not exacerbate cell death induced by either HCy or HCy-T. 
Figure 4.7 Homocysteine thiolactone and homocysteine toxicity is not potentiated by co-
administration of NMDA receptor co-agonist D-serine 
 
  
Figure 4.7 shows a significant decrease in cell number relative to control after 120h incubation with 200µM HCy 
63.2 ± 4.4% (P=0.001, n=8; Figure 4.6a) co-application of co-administration of D-serine 59.8 + 15.6% (P=0.092, 
n=4; Figure 4.7a). The data derived from LDH assays showed a significant increase with 200µM HCy in LDH to 
115.1 ± 18.5% (P=0.033, n=4; Figure 4.7c). There was still no difference with co-administration of any of the 
concentrations of HCy showing 128.4 ± 21.4% increase in LDH (P=0.380, n=2; Figure 4.7c). There was a 
significant decrease in cell number relative to control after 120h incubation with 100µM HCy-T (65.2 ± 10.4%, 
(P=0.603, n=8; Figure 4.7b), but very little difference detected following co-administration of D-serine 57.4 + 
14.7% (P=0.382, n=4; Figure 4.7b). The data derived from LDH assay clearly showed no significant increase 
relative to the untreated control after with concentrations up to 100µM HCy-T at 120h to 107.7 ± 10.2% (P=0.819, 
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n=4; Figure 4.5d). However, when 10µM D-serine was added in conjunction there was still no significant increase 
in lactate dehydrogenase released at any concentration of HCy-T to 123.4 ± 13.5% (P=0.380, n=4; Figure 4.5d). 
HCy = homocysteine, HCy-T = homocysteine thiolactone, LDH = lactate dehydrogenase, CV assay = crystal 
violet assay. 
4.2.8 Homocysteine thiolactone alters downstream signalling of NMDA receptor 
Although HCy has been shown to act at the glutamate binding site of the NMDA receptor 
(112), the downstream signalling activated is ultimately different from glutamate per se. Under 
excitotoxic conditions when glutamate binds the NMDA receptor, it causes a transient 
phosphorylation of extracellular (ERK) within 2.5 minutes of application. When HCy is added, 
the phosphorylation of ERK in the first few minutes is mimicked however there is a subsequent 
increase in pERK 2-6 hours post application which is not seen when glutamate is added (151). 
To determine whether HCy-T altered the same downstream signalling as that seen with HCy, 
ELISA was used to determine the levels of phosphorylated ERK from protein extracted at a 
range of timepoints. The results showed a 138.9% ± 6.3% (P=0.001, n=13; Figure 4.8a) 
increase in phosphorylated ERK after 2.5 minutes. This returned to the same as control 
conditions between 2.5 to 5 minutes and continued to increase again at 6 hours with a 
significant increase of 237.1% ± 29.8% at 6 hours post treatment (P=0.005, n=13; Figure 4.8a). 
This is a similar pattern to that observed by other authors with HCy though not with glutamate 
(153).  
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Figure 4.8 Homocysteine thiolactone induces ERK activation both transiently and chronically 
  
 
Figure 4.6 showed an ELISA depicting the timecourse of ERK activation. This showed an increase at 2.5 minutes 
to 138.9% ± 6.3% (P=0.001, n=13; Figure 4.8) which is indicative of a transient ERK activation, similar to that 
seen in HCy. This returned to the same as control conditions between 5 minutes and began to increase again at 2 
hours with a significant increase of 237.1% ± 29.8% (P=0.005, n=13; Figure 4.8) at 6 hours post treatment. ERK 
= Extracellular Signal-regulated Kinase-1, HCy = homocysteine.  
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4.3 Discussion 
HCy exerts neurotoxicity via binding and activation of the NMDA receptor and is a partial 
antagonist at the glycine binding site. Using the cell differentiation protocol as outlined in 
chapter 3, the results have shown that HCy is neurotoxic at the NMDA receptor as previously 
shown by other authors, in other cell types (121,150,267,268). Initial experiments focussed on 
the use of undifferentiated SH-SY5Y cells, however cell death was not observed. As in other 
cell types, such as HT22 cells, many neuronal features are not expressed. Initial experiments 
focussed on the GluN2A receptor subunit of the NMDA receptor as this has been shown to be 
the receptor HCy exerts actions upon, GluNR2B containing subunits are predominantly 
glutamate activated and therefore not examined in this experiment (155). Using ELISA, the 
GluN2A subunit is shown to be upregulated upon differentiation in keeping with other cell 
types (211). Although this is unlikely to be the only factor impairing HCy toxicity to 
undifferentiated cells. Compared to neurons, neuroblastoma cell lines can be difficult to induce 
cell death in, it is therefore unsurprising that upon differentiation, the cells become more 
sensitive to stress. Furthermore, differentiation prior to HCy application made this more 
representative of elevated HCy in the brain.  
HCy-T is most commonly researched due to its ability to cause homocysteinylation and exert 
toxicity in the CNS via its effects within the vasculature (255). It was important to first 
determine at what concentration HCy and HCy-T were toxic within these cells, both HCy and 
HCy-T were neurotoxic at 100µM. When using higher concentrations of HCy-T, cell viability 
assay was not possible due to high variability. As mentioned before, D-L HCy and HCy-T were 
used, the dose expressed is half that stated as only the L-isoform of HCy is toxic, thus toxicity 
was observed at 50µM. This is the concentration at the upper range of being a risk factor for 
CVD and classified as mild to moderate hyperhomocysteinemia (269) To determine if HCy-T 
was neurotoxic via the same or distinct mechanisms as HCy, a selection of experiments 
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previously conducted using HCy were repeated. These included using Mk801 and APV which 
have shown that blockade of the receptor reduces cell death induced by HCy (142, 256, 263). 
This was done for HCy to show that these results are in keeping with the literature, HCy-T was 
tested as this has not been shown before in neurons. The addition of NMDA receptor channel 
blocker reduces the seizure incidence in rats who had been exposed to HCy-T (265). 
Furthermore, blocking NMDA receptors in vascular tissue reduces the toxic effects of HCy 
(271). It was therefore likely that this would be the case within neurons. Figure 4.4 and 4.5 
show the effects of both HCy and HCy-T in the presence of Mk801 and the competitive 
antagonist APV, all conditions showed a significant increase in cell death as determined by 
LDH and CV with HCy and HCy-T alone. This was not the case with the addition of Mk801 
with both HCy and HCy-T and APV only effective in blockade of HCy toxicity. Therefore, 
HCy has a more potent action upon the NMDA receptor than HCy-T in this cell type, glycine 
had no additive effect. However, blockade of the receptor itself does not conclusively indicate 
that HCy-T binds the receptor. With both HCy and HCy-T, the reduction in cell death was 
modest by comparison to the experiments that had been replicated, however several of these 
had used much higher concentrations of HCy (96).  
A subsequent method used to determine that HCy neurotoxicity involves NMDA receptors is 
the addition of glycine. As HCy is a partial agonist at the glycine binding site of the NMDA 
receptor, when glycine levels are elevated, HCy becomes neurotoxic at much lower 
concentrations as it can no longer act as an antagonist at the glycine binding site (112). 
Therefore, experiments using an excess of glycine were repeated in the differentiated SH-
SY5Y cells with both HCy and HCy-T. With both metabolites, there was an exacerbation of 
neuronal cell death however, this was more marked with HCy treated cultures. This further 
implicates HCy-T acting at the same sites as HCy, however this was only supported in the LDH 
assay at low concentration HCy-T. D-serine acts as a co-agonist at the glycine binding site of 
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the NMDA receptor, therefore it is possible this may have also enhanced neurotoxicity induced 
by HCy and HCy-T, as was achieved with the application of glycine. However, no significant 
differences were observed in any condition. The final area to be examined was the downstream 
signalling upon activation of the NMDA receptor. Upon application of HCy, there was an 
increase in the levels of phosphorylated ERK, this occurred in a different time frame to that 
observed upon glutamate binding (figure 1.2). When glutamate binds the NMDA receptor, 
there is a transient phosphorylation of ERK between 2 and 5 minutes which returns to baseline 
HCy causes the same transient increase which returns the baseline then increases again after a 
period of 6 hours (153). As this required almost 100 protein samples, only HCy-T was 
examined, the same timeframe of ERK phosphorylation was observed.  
Taken together, this strongly suggests that HCy-T does have neurotoxic properties that mimic 
NMDA receptor, although this is not as potent as HCy itself. This could be a result of the 
difference in structure compared to HCy as HCy-T is cyclic. Alternatively, HCy-T may 
modulate NOS activity, thereby enhancing the sensitivity of the NMDA receptor to further 
stimulation as will be discussed in more detail in chapter 5. HCy-T is also known to increase 
ROS generation and oxidative stress, blockage of the NMDA receptor can reduce cell stress 
therefore these results may be a generic reduction in ROS by blocking the NMDA receptor and 
not necessarily related to any interaction between the two.  
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CHAPTER 5: EFFECTS OF HOMOCYSTEINE AND HOMOCYSTEINE-
THIOLACTONE ON OXIDATIVE AND NITROSYLATIVE STRESS  
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5.1 Introduction 
Mitochondrial abnormalities are present in age-related diseases; such as AD,  prior to symptom 
onset (198). The mitochondria are the powerhouse of the cell and are responsible for energy 
generation in the form of ATP (272). The mitochondria are also the main contributor to the 
generation of reactive oxygen species (ROS), a by-product in the generation of ATP (273). 
ROS is responsible for causing cellular damage to DNA, RNA and proteins (274). The cells 
have the capacity to deal with ROS generation and the associated cellular damage, through 
their own antioxidant capacities. However, if there is an imbalance between the generation and 
removal of these toxic species, cellular damage will occur (275).The mitochondria are highly 
dynamic organelles and may be recruited to any area of the cell, as required for cellular 
processes (184). Furthermore, the mitochondria can undergo the processes of fusion and fission 
for the generation of new mitochondria or under conditions of stress (276). These processes 
are regulated by several proteins such as Mfn1 and fis1 which are regulated by several genes 
(277). 
Under conditions where cellular stress has been induced by treating with neurotoxins, the 
mitochondria can undergo excessive fusion or fission. This impairs the function of the 
mitochondria as a network and can impair the cells ability to generate energy which ultimately 
leads to cell death. Furthermore, when the cells are under stress, it has been shown in cells that 
there is an increase in the generation of ROS and subsequent oxidative damage. The 
mitochondria have a gradient to allow the transition of ions through the membrane, in an 
excitotoxic event, which disrupts the mitochondrial membrane potential and therefore the 
overall function of the mitochondria (278). There has been little research to date about the 
effect of HCy or HCy-T on mitochondrial kinetics. 
In addition to mitochondrial dysfunction, NO is a gaseous modulator within the CNS and the 
vasculature (163), and is generated by nitric oxide synthases (NOS); enzymes categorised by 
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anatomical location and named for the properties that they possess. These are as follows: 
endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS) (164). There is 
some research suggesting that there may be an entity known as mitochondrial NOS, but this is 
disputed, and some authors believe that this may in fact be a variation of another NOS isoform 
(270, 272). This debate results from the action the NO has within the mitochondria to disrupt 
mitochondrial respiration, it has been found in some preparations that the mitochondria may 
be capable of generating NO. If this is the case that would require NOS to be present within 
the mitochondria however, none of the NOS isoforms contain a sequence to cross into the 
mitochondria, suggesting an entity to be known as mitochondrial NOS. However, this has not 
been found using western blot analysis or sequencing.  eNOS is predominantly found within 
the vasculature, and is responsible for the induction of vasodilation (161), it is not widely 
expressed within the CNS in comparison to nNOS and iNOS and was therefore not examined 
by this study. iNOS is activated in a calcium dependent manner and predominantly occurs 
within the nervous system (170). The final generator of NO: nNOS, is calcium independent 
(268), and the effect of elevated HCy on iNOS and nNOS were examined as part of the current 
study. 
NO has several actions in the brain, one of which is to modulate NMDA receptor activity. NOS 
enzymes can be activated in response NMDA activation, thus resulting in an increase in NO 
generation (280). HCy is also reported to alter NO signalling and NO can cause an increase in 
the generation of ROS from the mitochondria and therefore indirectly increase oxidative stress 
and oxidative damage (281). This may in part be mediated by activation of the NMDA receptor, 
which can both affect NOS signalling and mitochondrial wellbeing by modulating the influx 
of calcium post activation (279). The effect that HCy has on NO generation has been 
extensively studied with respect to CVD (282–284).   
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Scavenging NO from cells which had been treated with HCy has proven effective in preventing 
neuronal cell death (285), thereby indicating a possible role of HCy in NO generation. 
Furthermore, HCy-T is known to generate high levels of peroxynitrite through PON1 activation 
(135), therefore it was important to determine if scavenging peroxynitrite would ameliorate the 
deleterious effects of HCy-T. This study aims to assess whether HCy-T also modulates NO 
signalling, and if it causes the same effects as reported with HCy within differentiated SH-
SY5Y cells, and furthermore, whether HCy influences NOS expression. The categorisation of 
the mitochondrial network dynamics is based on a paper by Wappler and colleagues, and 
defines the mitochondria as highly interconnected, rounded, normal or poorly labelled and 
therefore this was adopted for categorisation within these experiments (198). 
As both nitrosylative and oxidative stress have been implicated in HCy-induced cellular 
damage it was important to determine if, in SH-SY5Y cells, HCy and HCy-T caused an 
increase in NO and ROS generation. The potential role of RNS and ROS in HCy and HCy-T-
mediated cell death was explored by pharmacological modulation of NO and ROS levels. As 
changes to expression of NOS isoforms could underpin the previously reported NO-mediated 
cell death in response to HCy, the levels of nNOS and iNOS were analysed in HCy and HCy-
T-treated neurons. Finally, as mitochondrial dynamics are robustly altered under conditions of 
cellular stress, the effects of HCy and HCy-T on mitochondrial networks was examined. 
Together these experiments aimed to determine whether HCy and HCy-T mediate changes in 
the generation of NO or ROS and whether their known deleterious effects involved changes in 
the mitochondrial network.    
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5.2 Results 
5.2.1 Neither metabolite (homocysteine or homocysteine thiolactone) modulates 
the expression of neuronal NOS or inducible NOS 
It has previously been reported that HCy-T toxicity is increased by inhibition of iNOS (286), 
and that NO plays a crucial role in HCy-mediated neuronal death. Therefore, to determine if 
either metabolite altered iNOS or nNOS expression ELISA was used, it was determined that 
there was no significant effect of the application of 100M HCy-T on nNOS expression, 83.6 
± 41.1% relative to untreated control (P=0.470, n=3; Figure 5.1a), and there was also no effect 
of HCy-T on iNOS 123.3 ± 47.6% expression relative to untreated control (P=0.650, n=3; 
Figure 5.1b). Additionally, there was no significant effect of the application of 100M HCy on 
nNOS expression, 82.2 ± 41.1% relative to untreated control (P=0.470, n=3; Figure 5.1a) or 
on iNOS 97.7 ± 47.6% relative to untreated control (P=0.650, n=3; Figure 5.1b). Thus, the 
reported NO-mediated effects of HCy and HCy-T are not underpinned by changes in the 
expression of either nNOS or iNOS protein.  
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Figure 5.1 Effects of homocysteine or homocysteine thiolactone on expression of neuronal 
NOS and inducible NOS 
a       b     
    
 
Figure 5.1a shows the effects of the application of 100µM HCy and HCy-T on the expression of nNOS1 enzyme 
found within neuronal tissue. eNOS was not examined as this is not a predominant form in neuronal tissue. This 
shows there was no significant effect with the application of HCy 82.2 ± % (n=3 P=0.) or HCy-T on nNOS 
expression, 83.6 ± 41.1% (P=0.470, n=3; Figure 5.1a). Figure 5.1b shows there was no effect of HCy on iNOS 
97.7 ± % (P=0., n=3; Figure 5.1b) There was also no effect of HCy-T on iNOS 123.3 ± 47.6%, (P=0.650, n=3; 
Figure 5.1b). HCy= homocysteine, HCy-T = homocysteine thiolactone, NOS = nitric oxide synthase, nNOS = 
neuronal nitric oxide synthase, iNOS = inducible nitric oxide synthase. 
5.2.2 Homocysteine and homocysteine thiolactone do not increase nitric oxide 
generation in SH-SY5Y cells 
To determine if HCy or HCy-T altered the generation of NO either acutely (after 3 hours 
incubation) or chronically (after 48 hours incubation), a cell-permeable dye used to detect NO 
generation, 4,5-Diaminofluorescein diacetate (DAF2-DA; 1M), and the relative fluorescence 
intensity per cell was measured. An intermediate (24 hour) time point was also investigated. 
Thus, cells were treated with two concentrations of HCy or HCy-T, 100 and 200µM, for 3, 24 
and 48 hours. DAF-2DA was added to the cells for 15 minutes at the end of the treatment time 
to determine if the treatments had altered the rate of NO generation. There was no significant 
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change in NO levels following 3 hours of HCy treatment (178.1 ± 59.7% for 100µM relative 
to untreated control (P=0.484, n=5; Figure 5.2a-b) and 179.8 ± 53.3% (P=0.469, n=5; Figure 
5.2a, b) for 200µM. Similarly, there was no significant change observed at 24 hours, with 
100µM giving 94.0 ± 22.5% (P=0.964, n=5; Figure 5.2a, b) and 200M showing 146.2 ± 35.7, 
P=0.617, n=5; Figure5.2a, b). Similar data was obtained after 48 hours incubation, with 100µM 
giving 126.5 ± 30.0% (P=0.918, n=5; Figure 5.2a, b), and 200M showing 182.8 ± 61.3% 
(P=0.371, n=5; Figure 5.2a, b).  HCy-T also did not modulate NO generation with 116.2 ± 
12.5% of control levels observed after 3 hours application of 100µM HCy-T (P=0.889, n=6; 
Figure 5.2a-b) and 179.8 ± 53.3% of control levels observed after 3 hours application of 200µM 
(P=0.295, n=6; Figure 5.3a-b). Again, no significant difference was observed after 24 hours 
with 100µM giving 147.2 ± 27.3% of control levels (P=0.429, n=6 Figure 5.2a-b), and 200µM 
showing 152.0 ± 38.1% of control levels (P=0.429, n=5; Figure 5.2a-b). Finally, at 48 hours 
no significant difference was detected at 100 µM (P=0.755, n=5; Figure 5.2a-b) or 200 µM 
(P=0.565, n=5; Figure 5.2a -b).  The data from these experiments was highly variable therefore 
these experiments was repeated several times. Thus, despite a robust analysis of approximately 
5 coverslips per condition on each occasion and 5-6 biological repeats, there was no statistically 
significant difference in the levels of NO generation in these cells in response to 100 or 200M 
of either HCy or HCy-T.   
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Figure 5.2 Effects of homocysteine on nitric oxide generation 
a 
 
 
b
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Figure 5.2a shows the effect on increase concentration of HCy of 0, 100 and 200µM respectively at 3 hours and 
at 24 hours and 48 hours. The generation of NO as determined by the dye, DAF2-DA, these are the images 
obtained. When quantified as average fluorescence per cell this was plotted as figure 5.2b this showed no change, 
178.1 ± 59.7% for 100µM (P=0.484, n=5; Figure 5.2b) and 179.8 ± 53.3% (P=0.469, n=5; Figure 5.2b) for 
200µM at 3 hours post application. No change was observed at 24 hours with 100µM giving 94.0 ± 22.5% 
(P=0.964, n=5; Figure 5.2b) at 24 hours. 200µM at 48 hours giving an increase of 182.8 ± 61.3% (P=0.371, n=5; 
Figure 5.2b). However, despite an almost 2-fold increase no significant results were obtained (n=5). HCy = 
homocysteine, NO = nitric oxide, DAF2-DA = 4,5-Diaminofluorescein diacetate. 
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Figure 5.3 Effects of homocysteine thiolactone on nitric oxide generation 
a 
 
 
b 
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Figure 5.3a shows images obtained from a time course and dose response for the generation of NO as determined 
by the dye, DAF2-DA. When plotted as average fluorescence per cell, this showed no change of 116.2 ± 12.5% 
for 100µM HCy-T (P=0.889, n=6; Figure 5.3b) and 179.8 ± 53.3% for 200µM (P=0.295, n=6; Figure 5.3b) at 3 
hours post application. This showed an increase at 24 hours with 100µM giving 147.2 ± 27.3% (P=0.429, n=5; 
Figure 5.3b), matched with 200µM. This increase was maintained with both concentrations; at 48 hours no 
significant result was obtained at 100 µM (P=0.755, n=5; Figure 5.3b) and 200 µM (P=0.565, n=5; Figure 5.3b). 
HCy-T = homocysteine thiolactone, NO = nitric oxide, DAF2-DA = 4,5-Diaminofluorescein diacetate. 
5.2.4 Scavenging nitric oxide and peroxynitrite does not ameliorate cell death 
caused by homocysteine and homocysteine thiolactone in SH-SY5Y cells 
It has previously been reported that NO mediates the neurotoxic effects of HCy (285), although 
the role of NO in HCy-T-mediated neurotoxicity remains to be determined. The data presented 
above elucidates that neither HCy nor HCy-T upregulate NO generation (Figures 5.2-5.3). 
Furthermore, neither of these two compounds modulate the expression of the NO generating 
enzymes iNOS and nNOS (Figure 5.1). Nonetheless the possibility that HCy and/or HCy-T 
modulate viability by interacting with NO at the level present within these cells remains. 
Although there is no increase in NO generation, there is NO present within these cells that may 
be being harnessed to mediate cell death. Therefore, the effects of pharmacological modulators 
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of NO and its metabolite peroxynitrite on HCy and HCy-T-mediated neurotoxicity was 
determined. 
SH-SY5Y cells were treated with known toxic doses of 100µM HCy or HCy-T (Chapter 3, 
Figure 3.2), with the addition of 100µM of the nitric oxide scavenger 2-4-carboxyphenyl-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (CPTIO) (285) or 10µM of the peroxynitrite 
scavenger manganese (III) tetrakis (4-benzoic acid) porphyrin chloride (MnTbap) (285). The 
CV assay was used to determine cell viability by measuring the number of adherent cells after 
5 days treatment with HCy or HCy-T in the presence of peroxynitrite and NO scavengers 
respectively. The addition of CPTIO or MnTbap alone had a large effect on cell number within 
these cultures in some experiments, although this was very variable (Figure 5.4b).  
In the NO scavenging experiments, 100M HCy alone resulted in a reduction in cell number 
to 53.7 ± 3.6% of control survival (P=0.062 n=6; Figure 5.4a) and when NO was scavenged 
with CPTIO in HCy-treated cultures this resulted in a reduction in cell number of 34.7 ± 1.3% 
(P=0.017, n=6; Figure5.4a). When peroxynitrite was scavenged in the absence of HCy there 
was again a variable effect on cell number. In these experiments, 100M HCy alone resulted 
in a reduction in cell number to 65.5 ± 13.7% of control survival (P=0.688, n=6; Figure 5.4b). 
Co-application of MnTbap resulted in 85.5 ± 38.3% viability (P=0.883, n=6; Figure 5.4b). For 
HCy-T, cell number fell to 60.4 ± 6.2% (P=0.821, n=6; Figure 5.4a), and 53.3 ± 25% 
(P=0.748, n=6; Figure 5.4a) respectively. This increased to 97.9 ± 43.3% with NO scavenger 
(P=1.000, n=6; Figure5.4a) and with peroxynitrite scavenger this resulted in 68.8 ± 20.3% 
(P=0.999, n=6; Figure 5.4b). This could not be supported by LDH assays as there was a 
problem with the components of the assay and the samples had to be discarded. Furthermore, 
due to the variation in scavenger alone with both drugs, no conclusive result could be obtained. 
Together the data obtained does not support a role for NO signalling mediating the downstream 
effects of HCy or HCy-T in SH-SY5Y cells. However, there does appear to be a variable effect 
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of scavenging endogenous NO or ONOO. in untreated SH-SY5Y that may be confounding the 
data.  
  
111 
 
Figure 5.4 Effects of scavenging nitric oxide or peroxynitrite on either homocysteine or 
homocysteine thiolactone treatment 
a        
 
b 
 
Figure 5.4 HCy alone resulted in a reduction in cell number as determined by CV assay of 53.7 ± 3.6% and 65.5 
± 13.7%, (P=0.688, n=6; Figure 5.4b), and when NO was scavenged with CPTIO this resulted in a reduction in 
cell number of 34.7 ± 1.3% (P=0671, n=6; Figure5.4a) and with MnTbap reduction this was 85.5 ± 38.3% viability 
(P=0.883, n=6; Figure 5.4b). For HCy-T, cell number fell to 60.4 ± 6.2% (P=0.821, n=6; Figure 5.4a), and 53.3 
± 25% (P=0.748, n=6; Figure 5.4a). This was ameliorated to 97.9 ± 43.3% with NO scavenger (P=1.000, n=6; 
Figure5.4a) and with peroxynitrite scavenger this resulted in 68.8 ± 20.3% (P=0.999, n=6; Figure 5.4b). HCy = 
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homocysteine CV = crystal violet, NO = nitric oxide, CPTIO = 2-4-carboxyphenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide, MnTbap = manganese (III) tetrakis (4-benzoic acid) porphyrin chloride, 
HCy-T = homocysteine thiolactone, LDH = lactate dehydrogenase. 
5.2.5 Homocysteine thiolactone increases reactive oxygen species generation  
Despite the negative data obtained for NO generation, the potential for other ROS rather than 
NO to mediate the deleterious effects of HCy and/or HCy-T remains. Therefore, the generation 
of total reactive oxygen species was determined after 48 hours incubation with 100µM of either 
metabolite using the dye H2-DCFDA. This is a cell-permeable live cell dye which fluoresces 
green upon binding to ROS. Because both HCy and HCy-T are likely to interact with the cell 
via the NMDAR, the NMDAR blocker Mk801 (2µM) was also analysed in these experiments, 
both alone and in combination with HCy or HCy-T (100M). Due to the complexities of live-
cell imaging, a single concentration of HCy or HCy-T was analysed and 100M was selected 
as it exhibits neurotoxicity (Chapter 3, figure 3.2) yet is within the potential physiological 
range. In these experiments there was a striking effect of Mk801-mediated blockade of the 
NMDAR. This treatment increased the level of ROS detected from 2356216 ± 490382a.u. in 
untreated control to 5141105 ± 1244191a.u. in Mk801-treated cells (P=0.001, n=3; Figure 5.5 
a-c).  This is in keeping with previous studies showing increased ROS generation following 
Mk801 administration in the rat retrosplenial/posterior cingulate cortex in vivo (287).  
Intriguingly, 100M HCy did not modulate ROS levels in these cells; 3637922a.u. ± 797758 
compared to 2356216 ± 490382a.u. in untreated control (P=0.320, n=3; Figure 5.5b), but it did 
negate the increase in ROS mediated by Mk801. Thus, cells co-treated with HCy and Mk801 
exhibited 3334510 ± 498468a.u. average intensity which, in contrast to the findings for Mk801 
alone. The result for the HCy and Mk801 co-treated cultures was not statistically significantly 
different to untreated control (P=0.992, n=3; Figure 5.5b).  
In contrast, HCy-T which showed a significant increase in fluorescence to 4790103± 849961 
a.u. compared to the untreated control reading of 2356216 ± 490382a.u. (P=0.003, n=3; Figure 
113 
 
5.5 a, c).  This was unchanged in the presence of Mk801 where fluorescence intensity was 
4536405 ± 1337647a.u. (P=0.023, n=3; Figure 5.5a, c). These data highlight some very 
important differences between HCy and HCy-T in these cells. Whilst HCy does not increase 
ROS generation after 48 hours in culture HCy-T does. There is a striking increase in ROS 
generation when Mk801 is added to SH-SY5Y cultures that is ameliorated by the presence of 
HCy but not HCy-T. This finding makes a crucial step towards our understanding of how these 
metabolites mediate their neurotoxicity and how we can best counteract it.  
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Figure 5.5 Effects of homocysteine, homocysteine thiolactone and Mk801 on reactive oxygen 
species generation in SH-SY5Y cells 
a 
     
b      c 
Figure 5.5a shows the increase in average fluorescence intensity emitted per cell upon the addition of the dye, 
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DCFDA, which gives an approximation of ROS generation by the cells with each treatment. When quantified as 
average fluorescence per cell this was plotted as figure 5.5b for HCy and Figure5.5c for HCy-T. This showed an 
increase from 2356216 ± 490382 in untreated control to 5141105 ± 1244191 in Mk801 alone (P=0.001, n=3; 
Figure 5.5b). No significant result was observed with HCy alone with an increase to 3637922 ± 797758 (P=0.320, 
n=3; Figure 5.5b). The same was not observed for Figure5.5c HCy-T which showed an increase in fluorescence 
to 4790103 ± 849961 (P=0.003, n=3; Figure 5.5c) this was unchanged in the presence of Mk801 where 
fluorescence intensity was increased to 4536405 ± 1337647 (P=0.023, n=3; Figure 5.5c). DCFDA = 2',7' –
dichlorofluorescin diacetate, ROS = reactive oxygen species, HCy = homocysteine, HCy-T = homocysteine 
thiolactone. 
5.2.6 Differential effects of homocysteine and homocysteine thiolactone in 
mitochondrial network morphology 
The data presented in section 5.2.5 reveal a key difference between HCy and HCy-T with 
respect to ROS generation. As mitochondria are the major source of intracellular ROS, a fuller 
understanding of the effects of HCy and HCy-T on the mitochondrial network may elucidate 
some of the mechanisms underpinning this exciting finding. Therefore, to determine if HCy or 
HCy-T alter mitochondrial network dynamics preceding the observed increase in ROS 
generation, cells were stained after 24 hours with MitoTracker dye to specifically image 
mitochondria. This live cell dye was applied at 100nM as describe in chapter 2 at the end of 
the culture period, then the cells were fixed, fields of view were imaged with cell number 
counted, and the mitochondria characterised. As can be seen in the images obtained, HCy 
increased the number of cells with predominantly rounded mitochondria (as analysed by the 
criteria of Wappler (198)) at 24 hours showing predominantly  rounded mitochondria compared 
to untreated control. In contrast, 24 hours treatment with 100M HCy-T resulted in a marked 
increase in cells with predominantly highly interconnected mitochondria (Figure 5.6a, c).  
To determine whether this change in mitochondrial network morphology was enhanced with 
longer term exposure to HCy or HCy-T (both at 100M), analysis was repeated at 120 hours, 
which was the end point of the viability experiment reported in chapter 3 Figure 3.3. After 120 
hours exposure to 100µM HCy showed no significant change in any morphology category, 
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compared to untreated controls (n=3; Figure 5.6b, d). There was a significant reduction in the 
number of normal mitochondria when treated with HCy-T from 76.7 ± 8.6% to 24.8 ± 2.9% 
(P=0.033, n= 3; Figure 5.6d). The enhanced number of cells with predominantly highly 
interconnected mitochondria was maintained in 100µM HCy-T-treated cultures with 47.9% ± 
6.7% showing this morphology compared to 3.7 ± 1.2% of untreated control cells (P=0.039, 
n=3; Figure 5.6d).   
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Figure 5.6 Effects of homocysteine and homocysteine thiolactone on mitochondrial 
morphology 
a 
 
b 
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Figure 5.6a-b shows HCy increased the number of cells with predominantly rounded mitochondria at 24 hours 
with 15.1 ± 5.6% of cells in control culture showing predominantly rounded mitochondria. In contrast, 24 hours 
treated with 100µM HCy-T resulted in an increase in cells with predominantly highly interconnected mitochondria 
(Figure 5.6a) However there was no significant changes in any group as compared to untreated control. After 120 
hours exposure to 100µM HCy showed no significant change in any morphology category, compared to untreated 
controls (n=3; Figure 5.6b, d). There was a significant reduction in the number of normal mitochondria when 
treated with HCy-T from 76.7 ± 8.6% to 24.8 ± 2.9% (P=0.033, n= 3; Figure 5.6d). The enhanced number of cells 
with predominantly highly interconnected mitochondria was maintained in 100µM HCy-T-treated cultures with 
47.9% ± 6.7% showing this morphology compared to 3.7 ± 1.2% of untreated control cells (P=0.039, n=3; Figure 
5.6d).  HCy = homocysteine, HCy-T = homocysteine thiolactone. 
5.2.7 There was a reduction in the mitochondrial membrane potential with acute 
application of homocysteine or homocysteine thiolactone but not chronic 
application 
Given the striking effects on the morphology of the mitochondrial network, it was important to 
determine whether HCy or HCy-T were affecting mitochondrial membrane potential as a 
measure of mitochondrial wellbeing. This was determined using the JC-1 dye to stain the 
mitochondria. This dye penetrates the cell and it accumulates in healthy mitochondria where 
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(due to high mitochondrial membrane potential) the dye aggregates yielding a red to orange 
coloured emission. In contrast when mitochondrial membrane potential is reduced, JC-1 is 
predominantly a monomer that yields green fluorescence. The acute effects of HCy and HCy-
T (100M) were examined by imaging cells 45 minutes after co-administration of JC-1 and 
either HCy or HCy-T. The rationale for this is that membrane depolarization events tend to be 
rapid and therefore it was hypothesised that this may precede the changes in mitochondrial 
network morphology. 10 images were obtained per experiment and counted, and the cells were 
characterised as either all green, mainly mixed or all red. As can be seen there is a reduction in 
the presence of red stained mitochondria, therefore a reduction in mitochondrial membrane 
potential, after this acute treatment. 100µM HCy showed a reduction to 80.1 ± 2.6% of 
predominantly red cells compared to untreated control (P=0.018, n=3; Figure 5.6c), and 
100µM HCy-T showed a reduction to 73.7 ± 3.6% (P=0.000, n=3; Figure 5.6c). Thus, both 
metabolites significantly decrease mitochondrial membrane potential rapidly after 
administration.  
Decreased mitochondrial membrane potential has previously been associated with enhanced 
ROS generation (288). This experiment was repeated after 48 hours of treatment with HCy or 
HCy-T (100M), the time point at which differential effects of these metabolites on ROS 
generation was detected (Figure 5.5).  The image analysis data revealed no significant 
differences in mitochondrial membrane potential after 48 hours (Figure 5.6 b-d) implying that 
the effects of the metabolites on this parameter are acute rather than sustained.  
  
120 
 
Figure 5.7 Effects of homocysteine and homocysteine thiolactone on mitochondrial membrane 
potential 
a 
 
 
b 
 
c      d 
 
Figure 5.7a-b shows representative images of cells which has been treated with 100µM HCy and HCy and 
immediately stained with the live cell dye, JC-1. The total number of cells in the field of view were counted and 
presented as a proportion of mixed red and green cells vs completely green, in each condition, the percentage of 
red containing cells within the field of view was plotted. This indicates a change in mitochondrial membrane 
potential. This was plotted as figure 5.7b for immediate staining (0 hours) and Figure5.6c for 48 hour treatment 
then stained. This showed a reduction in cells containing red stained mitochondria with 100µM HCy at 80.1% ± 
0
20
40
60
80
100
120
Control 100µM
HCy
100µM
HCy-T
P
er
ce
n
ta
g
e 
o
f 
ce
ll
s 
co
n
ta
in
in
g
 r
ed
 
st
ai
n
ed
 m
it
o
ch
o
n
d
ri
a 
at
 0
h
0
10
20
30
40
50
60
70
80
90
100
Control 100µM
HCy
100µM
HCy-T
P
er
ce
n
ta
g
e 
o
f 
ce
ll
s 
co
n
ta
in
in
g
 r
ed
 
st
ai
n
ed
 m
it
o
ch
o
n
d
ri
a 
at
 4
8
h
* 
*** 
121 
 
2.6% (P=0.018, n= 5; Figure 5.7d). 100µM HCy-T with a reduction to 73.7 ± 3.6% (P=0.000, n=5; Figure 5.7c). 
There were no significant results at 48 hours. JC-1 = 2',7' (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolocarbo-cyanine iodide), HCy = homocysteine, HCy-T = homocysteine thiolactone. 
5.2.8 Effects of mitochondrial reactive oxygen species scavenging with 
MitoTempo on cell viability in response to homocysteine or homocysteine 
thiolactone 
As stated above, one of the major sites of ROS generation is the mitochondrion. The data 
presented in this chapter has demonstrated an acute effect of either HCy or HCy-T (100M) in 
reducing mitochondrial membrane potential. Thereafter these metabolites have differential 
effects on mitochondrial network morphology with HCy inducing an increase in rounded 
mitochondria and HCy-T inducing a highly interconnected network. Moreover, HCy-T 
increases the generation of ROS in these cells but not in a time frame that aligns with the 
changes observed in mitochondrial membrane potential. Therefore, it is essential to establish 
whether mitochondrial ROS generation is contributing to HCy and/or HCy-T neurotoxicity. In 
these experiments cells were treated with 100µM HCy or HCy-T and 5nM of MitoTempo (288) 
for 120 hours, a mitochondrial specific antioxidant which scavenges mitochondrial superoxide 
(281). If cell death was predominantly a direct result of mitochondrial oxidative damage, then 
it is likely an amelioration of cell death induced by these toxins would be observed in the 
presence of MitoTempo.  Cell viability was analysed by a combination of CV and LDH assay. 
The presence of MitoTempo alone had no effect on cell viability (P=0.727, n=4; Figure 5.8a). 
100µM HCy did not significantly reduce viability in these experiments although there was a 
reduction in cell number detected with crystal violet to 80.6 ± 13.5% (P=0.341, n=4; Figure 
5.8a) and no difference was noted with the addition of MitoTempo (72.1 ± 14.9% viability 
relative to untreated control, P= 0.072, n=4; Figure 5.8a). Similarly, the reduction in viability 
with HCy-T was detected by CV was not significant in these experiments 74.2 ± 18.6% (P= 
0.111, n=4; Figure 5.8a). However, when co-applied with MitoTempo this was increased to 
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100.6 ± 3.5% (P= 1.000, n=4; Figure 5.8a) making the cultures indistinguishable from the 
untreated control. A similar trend was observed LDH assay however again, no significant 
results were obtained. Thus, there was a trend towards amelioration of HCy-T but not HCy-
mediated cell loss with MitoTempo, as this is a mitochondrial specific antioxidant this suggests 
that HCy-T is likely affecting the mitochondria more than HCy. However, the lack of a 
significant toxicity in this experiment means that this cannot be definitively concluded.  
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Figure 5.8 Effects of MitoTempo on SH-SY5Y viability in response to homocysteine or 
homocysteine thiolactone 
a        
 
b        
  
Figure 5.8 shows No change in any group with too much variation in MitoTempo alone to continue experiments. 
The results from Figure5.7a and Figure5.7b showed that the presence of MitoTempo alone had no effect on cell 
viability, 100.0 ±0.0 % to 86.9 ± 16.8% (P=0.727, n=4; Figure 5.8a). When treated with 100µM HCy, the 
approximate cell number dropped to 80.6 ± 13.5% (P=0.341, n=4; Figure 5.8a) this was exacerbated with the 
addition of MitoTempo 72.1 ± 14.9%. (P= 0.072, n=4; Figure 5.8a). The same control for both untreated and 
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number to 74.2 ± 18.6% (P= 0.111, n=4; Figure 5.8b) when co-applied with MitoTempo this was increased to 
100.6 ± 3.5% (P= 1.000, n=4; Figure 5.8b). This was supported by LDH assay however again, no significant 
results were obtained. ROS = reactive oxygen species, HCy = homocysteine, HCy-T = homocysteine thiolactone, 
LDH = lactate dehydrogenase.  
5.2.9 Glutathione prevented homocysteine thiolactone induced cell death but not 
homocysteine 
As HCy-T significantly enhanced the generation of ROS it seemed likely oxidative stress may 
play a role in cell death induced by these metabolites. The data from experiments negating 
solely mitochondrial ROS were inconclusive. However, one other way to determine whether 
oxidative stress played a role was to scavenge ROS using a cellular antioxidant rather than a 
mitochondrial-specific one, and using CV and LDH assays, determine if cell death is 
ameliorated. The following experiment looked at the effects of incubation of the cells with the 
same treatment as above, but with 250µM glutathione (290) added as an antioxidant. This is a 
more generic antioxidant and has been shown to protect cellular components from oxidative 
damage. The CV assay conducted after 120 hours of treatment (Figure 5.9a) showed that there 
was no difference in the number of adherent cells with HCy compared to HCy with glutathione 
62.4 ± 13.8% cells in cultures treated with HCy compared to 61.8 ± 42.3% cells treated with 
HCy and glutathione (P=1.000, n=4; Figure 5.9a). For HCy-T there was a marked decrease in 
cell number to 68.5 ± 5.4% of untreated control cultures. There was an increase to 98.8 ± 28.3% 
in cultures co-treated with glutathione although this did not approach significance (P=0.256, 
n=4; Figure 5.9a). Looking specifically at membrane rupture, there was a significant increase 
with HCy (100M) to 127.3 ± 13.9% of control levels (Figure 5.9b) which was ameliorated by 
co-administration of 250M glutathione to 94.2 ± 8.8% (P=0.001, n=5; Figure 5.9b). 
Similarly, with HCy-T a significant increase compared to untreated control culture 118.4 ± 
16.9% (P=0.040, n=5; Figure 5.9b) which was reduced in the presence of glutathione to be 
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statistically indistinguishable to control. Thus, a general cellular antioxidant appears to 
ameliorate cell death induced by HCy and HCy-T.  
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Figure 5.9 Effects of glutathione on neurotoxicity via homocysteine and homocysteine 
thiolactone  
a        
 
b 
 
Figure 5.9 shows that there may not be any significant change in approximate cell number as determined by the 
CV assay with HCy and only 100 µM HCy-T (P=0.008, n=5; Figure 5.9a), this was not supported by the LDH 
assay which showed HCy toxicity could be ameliorated by the addition of glutathione 127.3 ± 13.9% to 94.2 ± 
8.8 (P=0.001, n=5; Figure 5.9b). HCy-T showed an increase in LDH release as determined by the LDH assay. 
This showed an increase from 118.4 ± 16.9% (P=0.040, n=5; Figure 5.9b). In the presence of glutathione as well 
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this was 114.5 ± 8.6%. CV = crystal violet, HCy = homocysteine, HCy-T = homocysteine thiolactone, LDH = 
lactate dehydrogenase. 
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5.3 Discussion 
It has previously been shown in other cell types that HCy causes an increase in the generation 
of NO and ONOO. To determine if HCy-T would have the same effect, and whether these 
changes were mediated by alterations in NOS enzyme expression or activity, it was important 
to determine if either metabolite change of the expression of the predominant NOS isoforms 
found in the brain. However, no significant effects of HCy or HCy-T were observed on iNOS 
or nNOS. This implies that HCy does not modulate neuronal NOS expression levels, at least 
with respect to nNOS and iNOS which were evaluated here. It has previously been shown that 
HCy upregulates the expression of iNOS in vascular endothelial cells (291). In contrast in 
macrophages, HCy increases the activity of C5MTase and thus the level of iNOS gene DNA 
methylation, resulting in a decrease of iNOS expression (292), thus the effects of HCy on iNOS 
expression vary with cell type. Although iNOS is expressed in neurons and in differentiated 
SH-SY5Y cells as demonstrated here (Figure 5.1), it is predominantly expressed in glial cells 
(292). Whilst this was beyond the scope of this project, future studies should focus on whether 
HCy modulates iNOS expression in the support cell populations of the CNS which may 
elucidate further crucial clues to its CNS actions. HCy is not known to dynamically modulate 
nNOS expression and no evidence for this was found in this study. Homocysteine thiolactone 
has not been shown to modulate NOS expression per se. However, other components of the 
NO generation pathway, such as the enzyme dimethylargininase are susceptible to 
downregulation through homocysteinylation of the enzyme (292). As HCy, and even more 
potently HCy-T, have been implicated in protein modification in this way, this suggests that 
investigation into post-translational homocysteinylation of components of the NO system 
warrants future investigation to fully understand the role of HCY and/ or HCy-T in its 
regulation. 
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Previous studies have demonstrated an increase in NO generation in response to HCy (293).  
Therefore, the NO live cell dye DAF-DA was used and pharmacological methods of NO and 
ONOO- modulation to elucidate the role of NO in SH-SY5Y neuronal cells. Neither of these 
methods yielded significant results. However, in primary sensory neurons there is also no 
increase in NO observed following HCy administration (285), therefore my data is in 
accordance with this finding. There are a number of potential reasons why NO and ONOO 
scavenging did not ameliorate HCy or HCy-T-mediated toxicity including the relatively low 
levels of HCy and HCy-T used in these studies in comparison to that used by other authors 
(285). As my studies aimed to keep levels of these neurotoxins as close as possible to that 
observed in patients with hyperhomocysteinemia, these differences may be of high importance. 
Thus, the effective concentration of physiologically active HCy or HCy-T in my studies was 
50M as compared to 125M in the primary sensory neurons mentioned above. Levels of 
125M are only observed in homocysteinuria and the downstream signalling triggered by HCy/ 
HCy-T in such patients may be very different from individuals with non-symptomatic elevated 
HCy. It is the latter group that have a prospective risk of AD and that are central to this study. 
Therefore, one could hypothesise that NO and ONOO may be important in the cell death which 
is part of the cognitive impairment observed in individuals with homocysteinuria, but that the 
role of these RNS in converting moderately elevated HCy in individuals at risk of 
neurodegeneration to neurotoxicity remains unproven.  
Studies on the effects of HCy on mitochondria within neuronal cells have been very sparse to 
date and due to the ease of use of the SH-SY5Y system, it has been possible to examine this in 
depth. It was initially important to determine if these metabolites effected the generation of 
ROS within these cultures. Therefore, cells were treated with a known toxic dose of HCy and 
HCy-T (100 M; effective concentration 50 M as D-L isoform was used) and used the live 
cell dye, DCF-DA, after a period of several days. A significant increase in ROS generation was 
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observed after 48 hours exposure HCy-T but not HCy. This immediately demonstrated a 
marked difference between HCy and HCy-T in their effects on oxidative stress. An interesting 
aside finding from these experiments was the effect of blocking the NMDA receptors using 
Mk801 on ROS generation, which markedly enhanced the generation of ROS in SH-SY5Y 
neurons. The intension of this set of experiments was to determine if the activation of the 
NMDA receptor was the initiating factor in the generation of ROS and therefore any observed 
effects on the mitochondria. There have been previous reports of ROS upregulation following 
Mk801 administration (24) and the current studies results are in keeping with this. However, it 
is also interesting to note that HCy, but not HCy-T significantly reduced Mk801-mediated ROS 
generation to control levels (Figure 5.5b-c). One plausible explanation for this is that because 
HCy is well established to interact with the NMDAR (112), it is interfering with the binding, 
and antagonism of the receptor, mediated by Mk801 alone. In contrast, HCy-T is not. This 
could imply that HCy-T does not mediate its ROS-generating effects by NMDAR. Thus, the 
presence of NMDAR antagonist does not therefore interfere with its ability to upregulate ROS 
generation. What is interesting is that whether it is Mk801 or HCy-T that is inducing oxidative 
stress, the levels produced are similar, perhaps because the levels may have reached the 
maximum detection limit of the system, thus no additive effects are observed. Alternatively, 
both Mk801 and HCy-T may interact with the same binding site on the NMDAR to induce the 
same response.  
Oxidative stress and oxidative damage are often attributed to the mitochondria, the powerhouse 
of the cell and the main contributor to increases in ROS. Wappler and colleagues had shown 
that following oxygen-glucose deprivation, the dynamics of the mitochondrial network was 
disrupted to deal with stress and the mitochondria undergo fusion and fission to deal with the 
stress. Images were defined as normal, well defined mitochondria; rounded which was 
postulated to be excessive fusion; highly interconnected which they defined as a lack of fission 
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where the mitochondria appear to form strings; and the final characterisation was poorly 
labelled, this is where there do not appear to be mitochondria present. After 0 or 48 hours HCy 
application resulted in predominantly rounded mitochondria, a result which was more 
prominent at 48 hours.  HCy-T application, in contrast, induced more highly interconnected 
mitochondrial networks. Again, this highlights a key difference between the two metabolites 
in how they affect the mitochondria.  
As alterations to the mitochondrial network have been closely linked to mitochondrial 
dysfunction, the mitochondrial membrane potential was measured following application of 
HCy and HCy-T, both acutely and after 48 hours incubation. There was an acute effect on the 
mitochondrial membrane potential at where both metabolites resulted in a reduction in the 
mitochondrial membrane potential, but this was not maintained at 48 hours. It is well 
established that dysfunctional mitochondria are removed from the cell by mitochondrial 
autophagy (294). Therefore, my findings raise the possibility that both HCy and HCy-T initially 
induce mitochondrial dysfunction and that these mitochondrial are removed from the 
mitochondrial pool by mitophagy as part of a defence mechanism by the cell (294). This would 
result in a ‘survivor’ population of mitochondria at the 48 hour time point that show greater 
resilience to HCy and HCy-T. To test this hypothesis a number of experiments would be needed 
including time course analysis of mtDNA by qPCR load to determine mitochondrial number 
within the cells (198) or citrate synthase activity assay for mitochondrial mass (295). This could 
be coupled to electron microscopy analysis of mitochondria to identify mitophagy (295). This 
finding is also intriguing as the increase in ROS mediated by HCy-T was observed markedly 
at 48 hours.  As mitochondrial membrane potential decreases are associated with ROS 
generation (288) we would hypothesise that if the main source of HCy-T-triggered ROS was 
mitochondrial the decrease in mitochondrial membrane potential would still be apparent after 
48 hours in these cultures. Further to this, pharmacological methods were used to determine if 
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mitochondria-specific antioxidant, MitoTempo could ameliorate the cell death induced by HCy 
or HCy-T. Intriguingly this reagent did not significantly protect against HCy mediated cell 
death although there was a non-significant increase in survival in HCy-T/ MitoTempo co-
treated cultures. For the general antioxidant glutathione, LDH assay revealed that both HCy 
and HCy induced cell death could be ameliorated, however, this could not be supported by CV 
assay. It has been shown that cytosolic sources can also generate ROS in addition to the 
mitochondria (296). Therefore, the potential for mitochondrial-independent sources in these 
cells warrants future analysis. 
Taken together it can be concluded that using physiological levels of HCy or HCy-T (effective 
concentration 50M), NO and ONOO signalling are not required to mediate a neurotoxic 
response. Thus, in contrast to experiments conducted that are more pertinent to 
homocysteinuria (296), nitrosylative stress is not central to HCy-mediated toxicity in SH-
SY5Y cells at concentrations seen in hyperhomocysteinemia. A role for ROS is strongly 
alluded to for HCy-T as there is a marked increase in ROS generation and this can be 
ameliorated with glutathione and potentially MitoTEMPO. For HCy, the data is less clear, but 
the neuroprotective actions of glutathione imply a role for ROS. A fuller time course may reveal 
an increase in ROS mediated by HCy that was not revealed in these experiments. These data 
present, for the first time, a clear indication that there are marked differences in the cellular 
effects of HCy and HCy-T in regulating mitochondrial network and ROS generation.  
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CHAPTER 6: CHRONIC EFFECTS OF HOMOCYSTEINE, HOMOCYSTEINE-
THIOLACTONE AND HOMOCYSTEIC ACID USING A LONG TERM CULTURE 
SYSTEM  
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6.1 Introduction 
Longitudinal experiments have shown that elevated levels of HCy increase the risk of the 
development of many diseases, such as CVD (297) and neurodegenerative diseases 
(84,248,298). Long term folate deprivation in rodent models has given rise to MCI (299) and 
impaired LTP (86). However, the contribution of HCy to these impairments is still very much 
elusive. In cell culture  examining HCy, supraphysiological concentrations of 1M and above, 
are applied for acute periods up to 6 days (155,157,300). However, in addition to the acute 
mechanisms of cell damage induced by HCy outlined in chapters 4 and 5, it was important to 
determine if cell damage was induced by HCy, HCy-T and homocysteic acid at physiological 
levels with chronic application. This was important to determine as high acute doses of these 
metabolites are not necessarily representative of what would be observed in most of the 
population with moderately elevated HCy. Additionally, the mechanisms underpinning cellular 
toxicity induced by HCy at acute high doses may not be the same as chronic, moderate 
concentrations.  
In addition to HCy and HCy-T, homocysteic acid (HCA) was investigated in this chapter. HCy 
can auto-oxidize to produce HCA (301).  HCA induces intraneuronal accumulation of 
neurotoxic Aβ1-42 in vitro (301). In addition, studies of both AD patients and 3xTg-AD model 
mice (expressing three dementia-related transgenes, namely APPSWE, PS1M146V, and 
tauP301L) corroborate these observations. High HCA concentrations are detected in both AD 
patients and 3xTG-AD mice compared to age-matched controls (301). Together these findings 
suggest that HCA may play an important role in AD. 
As elevated HCy has been implicated in the development of neurodegenerative diseases 
(84,248,298) and HCy lowering strategies in elderly people has proved effective at reducing 
MCI (90), it was therefore important to determine what damage is elicited by moderate, 
representative doses of HCy and metabolites in a cell culture system. In ageing and 
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neurodegenerative diseases, several damaging effects and features are apparent, which may 
also be examined within a culture system, these include an increase in oxidative stress and 
oxidative damage (228). Additionally, most neurodegenerative diseases display some form of 
protein aggregation, in AD this is predominantly amyloid plaques (302) and in PD this is 
synuclein (303).  
Therefore, this chapter aimed to expand on the chapter 3, developing a culture system to study 
ageing, and examine what effect a neurotoxin may have on the ageing cells. As shown in earlier 
chapters, this culture system illustrates that these fully differentiated cells show signs of cell 
loss, oxidative damage and increase in oxidative stress markers such as HNE, all key features 
of neuronal cell ageing as described in section 3.2.7. Therefore, HCy and metabolites were 
applied at concentrations of 50 and 100µM, these were chosen as 100µM has previously shown 
some toxicity within 5 days however 50µM has not (section 4.2.3). As 100µM was not enough 
to cause more than 20% cell death over a period of 5 days, it was presumed that this 
concentration would be appropriate for this study.  
This chapter aims to elucidate whether chronic administration of physiological levels of HCy, 
HCy-T and HCA (50M) would be damaging to ageing SH-SY5Y cells in vitro and by also 
working with a concentration of these metabolites known to induce rapid neurotoxicity 
(100M), a comparison of toxic and sub-toxic concentrations can be made. Specifically, the 
extent to which HCy and metabolites affected oxidative stress and damage in the culture system 
outlined in chapter 3 will be determined. For instance, there is an enhancement of ROS 
generation with age using this culture (section 3.2.9), this chapter aims to determine if HCy 
and metabolites hasten the expression and accumulation of ageing markers. Furthermore, the 
increase in oxidative stress and oxidative damage in this culture over a period of 4 weeks made 
it possible to determine to what extent HCy exacerbated cell damage at lower concentrations 
than those used in chapter 4 and 5. Finally, the expression of biomarkers linked to AD 
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(specifically APP, PS1 and p-tau) were investigated using this system. It should be noted that 
as D-L HCy, HCy-T or HCA was used, that 50µM HCy is the equivalent upper dose considered 
to be a risk factor for CVD (304).   
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6.2 Results 
6.2.1 A reduction in cell viability was observed after 2 and 4 weeks with 
homocysteine, homocysteic acid and homocysteine thiolactone 
As very few publications in the literature have reported HCy-mediated apoptosis at 
physiologically relevant concentrations, one of the most important aspects of this chapter was 
to determine what effect sub-toxic doses of these metabolites had on cell viability in a model 
of cellular ageing. Therefore, cells were treated with each of the metabolites and cell viability 
determined with phase contrast micrographs and LDH assays at 4 weeks. There was an 
exacerbation of cell death at 2 and 4 weeks in the presence of HCy with an increase in LDH 
release (142.2 ± 26.9% P=0.030, n=5; Figure 6.1c) but not HCy-T (153.2 ± 59.1% P=0.164, 
n=5; Figure 6.1c) or HCA 155.5 ± 97.9% (P=0.573, n=5; Figure 6.1c) as determined by the 
LDH assay. However, when examined the phase contrast micrographs, HCy and HCy-T have 
the most pronounced reduction in cell number as these had images taken which were not 
exposed to a staining procedure. This could not be determined by CV as in previous chapters, 
as the cells became detached during the staining process. However, taken together the phase 
contrast images show markedly reduced cell number with HCy, HCy-T and HCA. LDH assay 
detects only the enzyme released in the previous 12 hours of culture, therefore the time points 
tested here only represent short snap shots of the dynamics of the extended culture period. 
Nonetheless, significant cell death was observed after treating with 100M HCy at 4 weeks 
showing that cell death is ongoing in these cultures. The timing of death in HCy-T and HCA 
is not established using these 2 time points.  
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Figure 6.1: Viability of SH-SY5Y cells in response to 50 and 100µM homocysteine following 
2 or 4 weeks administration 
a 
 
 
b 
 
 
c 
 
Figure 6.1 shows phase contrast micrographs of cells treated 100µM HCy, HCy-T and HCA. The images show a 
reduction in cell number with 2 weeks application (Figure 6.1a), very few cells at 4 weeks were remaining (Figure 
6.1b). Figure 6.1c shows the LDH release after 4 weeks treatment with 50 and 100µM HCy this showed a dose 
dependant increase in LDH release to 142.2 ± 26.9% (P=0.030, n=5; Figure 6.1c). 50 and 100µM HCy-T showed 
no significant increase in LDH release to 153.2 ± 59.1% (P=0.164, n=5; Figure 6.1c) the same was observed with 
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HCA, no significant increase in LDH release to 155.5 ± 97.9% (P=0.573, n=5; Figure 6.1c). HCy = homocysteine, 
HCy-T = homocysteine thiolactone, HCA = homocysteic acid, LDH = lactate dehydrogenase 
6.2.2 After 4 weeks, cells treated with 100µM homocysteic acid had increased 
reactive oxygen species generation 
Oxidative stress is a feature of ageing and neurodegenerative diseases and is apparent prior to 
onset of symptoms. It was therefore important to determine if this was observed after 2 and 4 
weeks in culture. Thus, cells were treated for 2 weeks with either HCy, HCy-T or HCA (50 or 
100M) and then stained with the dye DCF-DA, which fluoresces green in the presence of 
ROS. To determine if there was an increase in the generation of ROS as compared to untreated 
control cells, this was analysed using the average fluorescence per cell in 5 images per slide, 
each slide was generated from cells of different cultures. None of the treatments resulted in an 
increase in ROS generation at 2 weeks and, at the 4 week time point, only 100µM HCA resulted 
in a significant increase in ROS generation from 3688003 ± 713922.1a.u. in untreated control 
cells to 18417321 ± 4724582 in 100M HCA-treated cultures, (P=0.001, n=20 Figure 6.4b). 
These data demonstrated an interesting dynamic of ROS generation with levels similar to those 
in control untreated cultures after 2 weeks incubation and a highly significant increase in HCA-
treated cultures after 4 weeks demonstrating differential time dependant effects of these 
metabolites on ROS generation. This could be in part due to the acidity of HCA as compared 
to HCy and HCy-T. 
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Figure 6.2 shows reactive oxygen species generation as determined by DCF-DA at 2 and 4 
weeks  
a 
 
b 
 
c 
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Figure 6.2a-b shows the changes in ROS generation in response to 50 and 100µM HCy, HCy-T and HCA at 2 
weeks. No treatment was any different to the untreated control. Figure 6.2c-d shows the change in ROS generation 
at 4 weeks, the only treatment that was increased as compared to the untreated control was 100µM HCA. This 
showed an increase from 3688003 ± 713922.1 to 18417321 ± 4724582 (P=0.001 n=20; Figure 6.2b). HCy = 
homocysteine, ROS = reactive oxygen species, HCy-T = homocysteine thiolactone, HCA = homocysteic acid. 
6.2.3 Homocysteine, homocysteine thiolactone or homocysteic acid do not 
modulate the expression of the AD-linked biomarker, APP 
To determine if the expression of biomarkers associated with age-linked neurodegeneration 
were modulated within this system, the expression of APP by ELISA was determined. This 
was achieved by growing cells for 2 weeks with the addition of 50 and 100µM HCy, HCy-T 
or HCA and the protein extracted thereafter for analysis. The aim was also to determine this at 
4 weeks however not enough protein could be obtained. There was no significant change 
observed for any metabolite at any concentration, such that 100µM HCy (Figure 6.3a) HCy 
caused an increase in APP expression relative to untreated controls of 117.7 ± 6.7%, (P=0.428, 
n=6; Figure 6.3b) for 100µM HCy-T this was 130.9 ± 22.4% (P=0.530, n=6; Figure 6.3c) and 
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for HCA 150.1 ± 33.1% (P=0.204, n=6; Figure 6.3c). Thus, chronic administration of HCy, 
HCy-T or HCA to SH-SY5Y cells does not modulate APP expression.  
Figure 6.3 There is no difference in expression of APP expression at 2 weeks in the presence 
of 100µM homocysteine, homocysteine thiolactone or homocysteic acid 
a      b 
 
c      d   
 
Figure 6.3 shows that there was no change in the expression of APP with 100µM HCy APP 117.7 ± 6.7%, 
(P=0.428, n=6; Figure 6.3a). Additionally, there was no change with 100µM HCy-T 130.9 ± 22.4% (P=0.530, 
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n=6; Figure 6.3b) or HCA, 150.1 ± 33.1%, (P=0.204, n=6; Figure 6.3c). HCy = homocysteine, HCy-T = 
homocysteine thiolactone, HCA – homocysteic acid, APP = amyloid precursor protein 
6.2.4 Chronic administration of homocysteine, homocysteine thiolactone or 
homocysteic acid does not modulate the expression of p-tau 
Using the same protein extracts as in 6.2.3 above, the levels of p-tau (phosphor-threonine 181) 
were determined by ELISA because pTau 181 is widely accepted as an AD biomarker and is 
known to be elevated in mild to moderate AD (305). There was no significant change observed 
for any metabolite at any concentration, thus for 100µM HCy (Figure 6.4a) p-tau levels were 
122.0 ± 9.1%, (P= 0.232, n=6; Figure 6.4b) relative to untreated control cultures, for 100µM 
HCy-T p-tau expression was 140.5 ± 21.2% (P=0.281, n=6; Figure 6.4b) and for HCA 156.7 
± 32.2% (P=0.120, n=6; Figure 6.4c). Thus, chronic administration of HCy, HCy-T or HCA 
to SH-SY5Y cells does not modulate p-tau expression. 
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Figure 6.4 There is no difference in expression of p-tau after 2 weeks in the presence of 100µM 
homocysteine, homocysteine thiolactone or homocysteic acid  
a       b 
 
c       d 
   
Figure 6.4 shows no change in p-tau with any metabolite examined. P-tau expression with 100µM HCy was 122.0 
± 9.1% (P= 0.232, n=6; Figure 6.4a) with HCy-T this was 140.5 ± 21.2% (P=0.281, n=6; Figure 6.4b) and HCA 
showed 156.7 ± 32.2% (P=0.120, n=6; Figure 6.4c). HCy = homocysteine, HCy-T = homocysteine thiolactone, 
HCA – homocysteic acid, pTau = phosphoTau 
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6.2.5 There is no difference in expression of PS1 expression at 2 weeks in the 
presence of 100µM homocysteine, homocysteine thiolactone or homocysteic acid 
The final biomarker selected was PS1, this was selected as it is one of the main enzymes 
associated with cleaving APP to form the toxic form Amyloid β 1-42, and again this was 
examined by ELISA. This was achieved by growing cells for 2 weeks with the addition of 50 
and 100µM HCy and the protein extracted for analysis. ELISA was done using an antibody 
against PS1 and α-Tubulin as a loading control. There was no significant change observed any 
metabolite at any concentration, thus for 100µM HCy PS1 levels were 128.8 ± 9.8% of the 
untreated control (P=0.144, n=6; Figure 6.5a) for 100µM HCy-T 144.9 ± 27.2%. (P=0.341, 
n=6; Figure 6.5b) and for HCA 163.7 ± 42.1% (P=0.202, n=6; Figure 6.5c). Thus, chronic 
administration of HCy, HCy-T or HCA to SH-SY5Y cells does not modulate PS1 expression. 
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Figure 6.5 There is no difference in expression of Presenilin 1 after 2 weeks in the presence of 
100µM homocysteine, homocysteine thiolactone or homocysteic acid  
a       b 
 
c      d 
 
Figure 6.5 shows no change in PS1 with either concentration of HCy Figure 6.5a, HCy-T Figure6.7b and HCA 
Figure6.7c. There was a tendency towards increase in PS1 expression with 100µM HCy 128.8 ± 9.8% (P=0.144, 
n=6; Figure 6.5a) with HCy-T 144.9 ± 27.2%. (P=0.341, n=6; Figure 6.5b) and HCA 163.7 ± 42.1% (P=0.202, 
n=6; Figure 6.5c). HCy = homocysteine, HCy-T = homocysteine thiolactone, HCA = homocysteic acid, PS1 = 
presenilin 1 
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6.3 Discussion 
These experiments have shown that HCy, HCA and HCy-T are all potentially neurotoxic at 
lower concentrations than is used in most other cell culture toxicity experiments  (306,307), 
over a prolonged period of time in culture. It should be noted that this was apparent using D-L 
HCy, HCA and HCy-T, as in all other experiments discussed previously, only the L-isoform 
of HCy is toxic and can be converted to HCy-T. However, both D and L isoforms of HCy-T 
and HCA have similar properties.  
There is a clear discrepancy between the phase contrast photomicrographs which show marked 
cell death with HCy- T and HCA which was not observed by LDH assay. As these experiments 
were done over a prolonged period of time and the half-life of LDH in culture media is 12 
hours, it is possible that the LDH may have been removed from the culture media through 
repeated media changes and could have been detected at earlier time points. These data suggest 
that for future experiments, serial measurements of LDH should be made and that a lower 
concentration of these metabolites might been worth evaluating.  Other methods of evaluating 
cell number such as determining the number of cells per view in higher power phase contrast 
images, or determining nuclear number using DAPI staining could also be considered. Another 
aspect to be considered was the large variation of the data obtained from these experiments, 
therefore with increased repetitions, statistical significance for other metabolites may have 
been attained. Particularly when looking at HCA, some plates had so few cells remaining at 4 
weeks, the variation was very large and therefore a lower concentration may have been 
required. However, whilst the technical demands of working with these cultures has impeded 
the use of techniques such as crystal violet assay (which rely upon sustained cell attachment 
throughout repeated wash steps in the assay), there is remarkable loss of neurons with relatively 
low levels of HCy, HCy-T and HCA in cells that model the accumulation of an aged phenotype 
in culture (as observed in the photomicrographs). This suggests an enhanced sensitivity to the 
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neurotoxic effects of HCy, HCy-T and HCA and should be further investigated in future with 
more repeat measures, a greater range of empirical techniques and a greater range of metabolite 
concentrations as outlined above.  
When looking at signs of damage within this culture, keeping cells viable was less successful 
than in chapter 3 due to treated cells not adhering to the coverslips for the duration of the 
staining procedure. Repeat staining for oxidative damage to DNA and lipids by OhdG and HNE 
staining respectively was attempted, however this was unsuccessful for all metabolite 
treatments. This may reflect the greater fragility of the metabolite-treated cells compared to the 
untreated ageing cells in chapter 3. It is possible that execution of the staining could be achieved 
by further optimisation of the coating protocol for cell staining. Nonetheless, live cell imaging 
was still possible as there was less manipulation to the cells and therefore it was possible to 
determine the generation of ROS with the application of all metabolites. Unlike in chapter 5 
where there was an increase in ROS generation with HCy-T, this was not apparent with chronic 
application. Here the only increased in ROS was detected with 100µM HCA at 4 weeks. ROS 
generation may be predominantly an acute event, or a smaller, more gradual occurrence with 
the application of these metabolites. Therefore, a fuller time series of imaging may elucidate 
more information on ROS generation per se, and moving forward, the analysis of oxidatively 
damaged cellular components in biochemical rather than immunocytochemical assays may 
prove an easier method of investigating the effects of HCy, HCy-T and HA in cell-based 
models of ageing.  
There was no significant increase in any of the AD-linked biomarkers examined within this 
culture system. However, all concentrations of all metabolites showed a tendency towards an 
increase in the expression of APP, pTau and PS1. Although there were 5 sets of protein 
extracted for this set of experiments, 2 were lost because the extracted sample was too dilute 
to gain information for experimentation. Furthermore, this could only be repeated twice 
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because only a small volume of extract that could be gathered from the remaining samples, this 
was due to the reduction in cell number. To enhance this for future experiments, cells should 
be grown in larger dishes to gather more cells or a coating applied to all dishes to enhance the 
chance of continued cell adhesion. Due to the lack of protein generated, examination of other 
proteins associated with cell ageing could not be conducted. Therefore, this data should be 
viewed as a pilot study of these metabolites and again warrants further repetition, adjusting the 
empirical conditions to improve yield.  
A key feature of neuronal cell ageing, and an initiating factor in the development of 
neurodegenerative disorders, is the reduction in neuronal cell function and synapse loss. 
Therefore, future experiments examining electrophysiological recordings to determine if there 
was a reduction in action potential generation within these cells when treated with all the 
metabolites would be interesting. The presence of synapsin as determined by ELISA or 
immunofluorescence would also be interesting but could not be done as outlined in the reasons 
above. 
To continue these experiments for future research, some optimisation to increase the adherence 
of the cells to the coverslips and the dishes must be carried out. More than half of the cells 
generated for these, and staining experiments, were lost due to cells detaching when all culture 
media was removed for the final experiments. This was not observed to this degree in the 
culture system as outlined in chapter 3 and as per the controls in these experiments, therefore 
it is likely due to the application of the toxic metabolites causing a reduction in adherence 
making experimentation problematic. Therefore, this system may not be effective for the study 
of cell neurotoxins in ageing. However, this system may be effective to look at neuroprotection. 
The addition of these metabolites to this system was too toxic to these cells making consistent 
results difficult to obtain. 
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CONCLUSIONS 
This thesis aimed to examine the role of HCy and metabolites in neuronal cell death and 
establish a culture system that would be capable of supporting long term exposure to HCy and 
metabolites. In results 1 it was shown that using a novel differentiation protocol whilst forgoing 
expensive neurotrophic factors it was possible to maintain SH-SH5Y cells for 1 month. These 
cells remained viable and were identified as functional neurons as they were capable of 
spontaneously firing action potentials and displayed synaptic marker synapsin. For future 
work, further investigation to determine post-synaptic markers such as PSD95 should be 
examined. Additionally, markers for astrocytes and further determination of the culture 
population would have been beneficial. These cells also displayed signs of neuronal ageing in 
the form of oxidative damage to lipids and proteins. Therefore, this protocol gives rise to cells 
which are valuable for neurodegenerative and neuroprotective research, further benefit could 
be gained from transfecting these cells to further study the effects of specific neurodegenerative 
disease. 
The second part of my thesis focussed on determining the mechanism by which HCy and HCy-
T are neurotoxic. This found that unlike HCy, HCy-T toxicity could not be blocked with the 
addition of NMDA receptor antagonists to the same extent as HCy, this may be a result of the 
cyclic structure of HCy-T. However, the pattern of ERK signalling was the same as that of 
HCy, this may be because of the conversion to HCy-T back to HCy. Upon further examination 
in results 3 it is more likely that HCy-T is responsible for the increase in oxidative stress. Whilst 
neither HCy or HCy-T caused any alterations in NO release however this was very variable, 
and a higher throughput measurement of generation may reveal more. However, HCy-T shows 
a large increase in ROS generation and the mitochondria shows abnormal morphology, the 
mitochondria became highly interconnected which implies an impairment in the balance of 
mitochondrial fusion and fission. Furthermore, both metabolites showed both acute and chronic 
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impairment of mitochondrial membrane potential. Attempts were made to extract the 
mitochondria and examine the alterations of mitochondrial fusion and fission proteins such as 
FIS1 and Mfn, not enough was generated from the mitochondrial protein extraction methods 
to complete this.  
The final results section aimed to examine the long term effects of subtoxic concentrations of 
HCy, HCy-T and HCA. However, this was unsuccessful as the cells generated from results 1 
were too delicate for this type of experiment. Whilst widespread cell death was observed from 
phase contrast micrographs, this could not be quantified as the extent of cell death was below 
the limits of detection. Furthermore, determination of the cell stress markers was not successful 
as upon fixation, cells became detached. However, this did indicate that subtoxic 
concentrations of HCy, HCy-T and HCA were more neurotoxic over a period of 2 to 1 month 
and that ageing cells appear more susceptible to insult from these metabolites. As the cell death 
was so severe, the variability obtained from the cell death assays was too much to gain any 
significant results from. Furthermore, protein which was extracted to examine AD markers, 
APP, PS1 and pTau was in varied quantities and therefore results here were too varied to obtain 
significant results from. However, all metabolites appear to increase these markers and possibly 
with more samples this may be an interesting finding. This chapter highlighted that the protocol 
established in results 1 may be more effective for the study of neuroprotective agents than 
neurotoxic as the cells are too delicate for experiments of this nature.  
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